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Abstract
Activation of the Sonic Hedgehog effector Smoothened counteracts L-Dopa induced
dyskinesia by restoring cholinergic interneuron function
By: Lauren Malave
Advisor: Andreas Kottmann
Many types of neurons act as multimodal signaling centers. Yet, we have only limited
insight into the regulation and functional consequences of neuronal co-transmission. For
example, dopamine (DA) neurons, whose degeneration causes motor deficits characteristic of
Parkinson’s Diseases (PD), communicate with all their targets by DA but only a selective subset
of their targets using GABA, Glutamate, and the secreted cell signaling protein Sonic Hedgehog
(Shh). It is unknown whether Levo-dopamine (L-Dopa) induced dyskinesia (LIDs), a severely
debilitating side effect of DA supplementation in PD, might appear because DA neuron targets
are exposed to high DA- but low Shh- signaling in medicated patients. Here I show that restoring
the balance of DA and Shh signaling attenuates LID formation and acute expression in mouse
and macaque models of PD. Cholinergic neurons are responsive to Shh signaling via stimulation
of the Shh effector GPCR smoothened. Using conditional KO mice of pre or postsynaptic Shh
we show that reduced signaling in cholinergic neurons is sufficient and necessary for LID
formation. Conversely, selective expression of a constitutive active form of Smo (SmoM2) in
cholinergic neurons is sufficient to render the sensitized aphakia model resistant to LID. The
relative degree of imbalance of DA and Shh signaling rather than their absolute strength
determines the severity of LID and highlights the bidirectional effect both factors have on LIDs.
Activation of Smo reduces MAP-kinase pathway signaling, a physiological marker of LID,
selectively in CINs of the dorsolateral but not dorsomedial striatum and enhances the neuronal
iv

activity marker p-rpS6240/244 through activation of Smo on CINs. Additionally, semi-chronic,
pulsatile optogenetic stimulation of DA neurons results in LID-like behaviors that can be
attenuated by Smo activation. Together, my data reveal that balanced Shh and DA signaling is a
critical modulator of cholinergic physiology and provide an unexpected link between LID and
DA neuron degeneration. Furthermore, since pulsatile L-Dopa dosing might induce a perversion
in the DA neuron provided teaching signal resulting in acquisition and selection of unpurposeful, abnormal motor programs seen in LIDs, then the novel animal models described here
could be a starting point for in vivo analysis to assess the function and importance of neuronal
co-transmission of Shh signaling.
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1. Chapter 1: Introduction
1.1 Basal ganglia circuitry
Components of the basal ganglia
In order to execute learned motor behavior, the brain coordinates a complex,
heterogeneous network of nuclei known as the basal ganglia (Alexander and Crutcher 1990;
Boraud et al. 2018; Graybiel 1998; Graybiel et al. 1994). This network is composed of the
striatum, subthalamic nucleus (STN), globus pallidus interna (GPi), globus pallidus externa
(GPe), substantia nigra par reticulata (SNr), and substantia nigra pars compacta (SNpc). The
major input processing area of this circuit that is involved in movement command and action
selection is the striatum. The striatum receives information both internally, from nuclei within
the basal ganglia, and externally, from the cortex and thalamus, in a feedback loop manner to
control movement (Albin et al. 1989; Alexander et al. 1986; Parent and Hazrati 1995). One of
the main innervations of the striatum comes from dopaminergic neurons of the midbrain SNpc.
Dopamine (DA) is a key player in neuromodulation with its tonic and phasic firing
abilities providing a reward prediction error signal in reinforcement learning (Apicella et al.
1992; Bayer and Glimcher 2005; Fiorillo et al. 2003; Schultz 1992). In the adult brain, 75% of
dopaminergic input comes from the midbrain (Wallen and Perlmann 2003). A lateral subset of
these midbrain dopaminergic projections from the SNpc mainly target the dorsal striatum and
make up the mesostriatal, or commonly termed nigrostriatal pathway (Haber et al. 2000; Ikemoto
2007; Lammel et al. 2008). Alternatively, there is the mesolimbic pathway that consists of
medial midbrain dopaminergic neurons from the ventral tegmental area (VTA) and projects to
the ventral striatum (Morales and Margolis 2017). Although both areas target the striatum, their
functions are very different. The nigrostriatal pathway is involved in learned movement control,
1

while, the mesolimbic pathway is involved in emotion and mood driven behaviors (Lammel et al.
2008; Morales and Margolis 2017; Poulin et al. 2014). These differences are reflected in the
motor impairment disorder Parkinson’s Disease (PD), which leads to specific degeneration of the
SNpc DA neurons while VTA DA neurons remain intact.
Furthermore, within the dorsal striatum there are different compartments that fulfill
functionally diverse roles in motor command (Graybiel 2008). Although SNpc dopaminergic
neurons have arborous projections throughout, the dorsomedial striatum (DMS) encodes for
early skill acquisition and goal-directed behavior, while the dorsolateral striatum (DLS) encodes
for advanced skill acquisition and habitual behavior (Chatham et al. 2014; Dickinson and
Weiskrantz 1985; McGeorge and Faull 1989; Perrin and Venance 2019; Redgrave et al. 1999).
During procedural learning, there is a shift in activity from the DMS to the DLS when the skill is
learned (Yin et al. 2004; Yin et al. 2005). Differences between the tasks are reflected by distinct
firing patterns of striatal neurons, receptor density gradients, and alterations in cortico-striatal
plasticity via NMDA/AMPA receptor ratios between the DLS and DMS (Chuhma et al. 2014;
Yin et al. 2009). Interestingly, the DLS is the homologous area in humans for the greatest DA
neuron loss in PD (Antonini et al. 1995; Pavese et al. 2011).
The SNpc dopaminergic input to the striatum acts in tandem with glutamatergic input
from cortical and thalamic nuclei to translate thought into context appropriate action (Daw et al.
2005; Hunnicutt et al. 2016; Maia and Frank 2011; Parent and Hazrati 1995). Cortical and
thalamic information streams are integrated onto striatal neurons where DA modulates their
synapse strength (Wickens et al. 2003). Cortical glutamatergic input of the striatum come from
pyramidal projection neurons and are critical for reinforcement learning (Alexander et al. 1986;
Graybiel and Grafton 2015). As mentioned above, DA acts as a neural substrate that translates
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prediction error by encoding differences between the outcome of an action and the expected
result. This allows strengthening of specific synapses based on prior experience and contributes
to reinforcement learning, which streamlines performance (Bi and Poo 1998; Schultz 1992;
Schultz 2006; Schultz 2013; Schultz et al. 1997). The mechanism of DA signaling relies on a
triple coincidence when stimulation of glutamate, postsynaptic depolarization, and binding of
DA occur at the same time to elicit spine growth and plasticity (Yagishita et al. 2014). The
disorganization of this process is observed in PD as akinesia, a symptom that involves slow
movement, and is caused by a constant negative reward predication error as a result of the loss of
DA, and therefore, the loss of this plasticity (Beeler et al. 2012).
Striatal neurons within the basal ganglia
Our capacity to execute context appropriate and well-coordinated movements requires the
dynamic selection and suppression of possible actions. The multifaceted cell types within the
striatum process and integrate incoming signals to produce these controlled movements
(Silberberg and Bolam 2015). A majority of the neuronal population within the striatum is the
projection neurons, making up 95%, and they are anatomically termed medium spiny neurons
(SPN; Figure 1.1). SPNs are separated into two distinct populations, either the direct excitatory
pathway (dSPN) or the indirect inhibitory pathway (iSPN). The dSPN pathway promotes
movement by inhibiting the SNr and the GPi, two main output nuclei of the basal ganglia. In
contrast, the iSPN pathway terminates ongoing movement by stimulating the GPe and the STN
of the basal ganglia to activate the GPi (Sano et al. 2013).
Although separated into two pathways, both classes of SPNs are GABAergic and
synchronize to implement a desired movement following dopaminergic input from the SNpc
(Moss and Bolam 2008). This is accomplished via distinct dopaminergic receptor expression
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profiles between dSPNs and iSPNs. DA released into the striatum binds to D1-like receptors
(including D5) that are predominantly expressed by dSPNs, or to D2-like receptors that are
primarily expressed by iSPNs (Albin et al. 1989; Oorschot 1996; Sano et al. 2013; Tozzi et al.
2011). Continuous binding of D1-like receptors facilitates the induction of Hebbian long-term
potentiation (LTP), while suppressing Hebbian long-term depression (LTD) of the dSPNs. On
the other hand, binding of D2-like receptors suppresses LTP induction, and promotes LTD of the
iSPNs. These Hebbian principles act on cortical glutamatergic inputs, which heavily regulate
dSPN and iSPN activity (Keysers and Perrett 2004; Schultz et al. 1997; Song et al. 2000; Zhai et
al. 2018). Overall, learned motor behavior stems from this complex complementary balance
between the dSPN and iSPN pathways (Figure 1.2).
The remaining 5% of neurons within the striatum are interneurons that project locally to
regulate both classes of SPNs and are either the small GABAergic subtypes or the large aspiny
cholinergic interneurons (CINs; Figure 1.1) (Ibáñez-Sandoval et al. 2015; Kimura et al. 1980;
Tepper et al. 2010). The diverse GABAergic interneurons include fast-spiking GABAergic
interneurons (FSN), calretinin-expressing interneurons, and persistent/low threshold spiking
interneurons which differ in either their binding protein, neuropeptides or enzyme expression,
such as parvalbumin, somatostatin, neuropeptide Y, nitric oxide synthase, or tyrosine
hydroxylase (TH) (Ibáñez-Sandoval et al. 2015; Tepper et al. 2010). The larger CINs produce the
primary internal source of acetylcholine (ACh) and maintain the highest density of ACh and
cholinergic markers in the brain (Kawaguchi et al. 1995; Wilson et al. 1990; Zhou et al. 2002).
CINs act as an inhibitory mechanism of hyperactivity and are thought to contribute to the
cognitive and hypokinetic motor symptoms of PD (Barbeau 1962; Bordia et al. 2016; McGeer et
al. 1961; Tanimura et al. 2018). Although few in numbers, these CINs exert strong control over
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SPNs and are critical for the translation of thought into action by integrating glutamatergic,
GABAergic, and dopaminergic inputs (Chuhma et al. 2014; Surmeier and Graybiel 2012).
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Figure 1.1: Simplified striatal circuitry
SNpc dopaminergic input and cortical glutamatergic input converge onto the striatum to
modulate the control of excitatory SPN (D1) and inhibitory SPN (D2), along with interneurons,
to elicit a motor output. Glut: glutamate; CIN: cholinergic interneuron; FSN: fast spiking
interneuron; SOM: somastatin interneurons; SPN: medium spiny neurons; DAN: dopamine
neurons; SNpc: substantia nigra pars compacta.
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Figure 1.2: Direct and indirect pathway effects on motor output (adapted from (Calabresi
et al. 2014))
In the physiological condition, direct (D1 SPN) and indirect (D2 SPN) pathways coordinate
learned motor behavior. In Parkinson’s Disease, the balance is shifted toward the indirect
pathway and results in motor impairment. During L-Dopa therapy, there is another shift towards
the hypoactivity of the direct pathway leading to dyskinesia. SPN: medium spiny neuron; DA:
dopamine; ACh: acetylcholine; D1R: dopamine 1 receptor; D2R: dopamine 2 receptor; M1R:
muscarinic acetylcholine 1 receptor; M4R: muscarinic acetylcholine 4 receptor.
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1.2 Striatal cholinergic interneurons
Properties of striatal CINs
CINs make up for their small numbers with an extensive arborization throughout the
striatum that overlaps with dopaminergic and glutamatergic terminals and have dense terminal
fields on SPNs (Phelps et al. 1985). Under basal conditions, CINs have a continuous firing
pattern of rhythmic bursts and single spike firing rate of 5 – 10 hz (Aosaki et al. 1995; Raz et al.
1996; Wilson et al. 1990). One main regulatory neurotransmitter of CIN activity comes from
DA. CINs have both D1/5R and D2R that act to increase or attenuate ACh release, respectively
(Acquas and Di Chiara 1999; Stoof et al. 1982; Straub et al. 2014). Pharmacological studies
show that selective D1/D5R agonists increase ACh release, while D1/5R antagonist and D2R
agonist reduce ACh release (Acquas et al. 2001; Damsma et al. 1990). The bidirectional action
DA holds on CINs allows for the fine-tuning of locomotor activity. Specifically, activation of
D2R on CINs produces a “pause” in firing that lasts 60-80ms and further potentiates the DA
signal on other striatal neurons (Kharkwal et al. 2016). Quickly following this “pause”, there is a
“rebound” burst of 200-300ms in firing of CINs to restore striatal balance. The role of burstfiring activity of CINs is (1) to enhance iSPN suppression of movement and (2) reset corticostriatal circuit for selecting appropriate behavior. It was recently discovered that glutamate from
DANs contribute to this “rebound” of burst firing, as well as other factors (Chuhma et al. 2018).
This evidence demonstrates a mechanism by which DA acting on CINs regulates striatal activity,
as well as, the possible importance of other signaling factors working to counteract DA
inhibition on CINs.
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ACh receptors in the striatum
The continuous activity of endogenous ACh from CINs maintains motor control within
the striatum through tonic activation of muscarinic ACh receptors (mAChR) and nicotinic ACh
receptors (nAChR) to regulate dopaminergic, GABAergic, and glutamatergic signaling,
collectively (Quik and Wonnacott 2011). The striatum is densely populated by both mAChR and
nAChR with multiple subtypes. mAChR are G-coupled protein receptors (GCPR) that are slow
acting and have longer modulatory control compared to the ionotropic nAChR, which have a
more rapid time scale. Of the two mAChR classes found in the striatum, Gq-coupled mAChR are
M1R-like and consist of M1, M3 and M5 mAChR, whereas, Gi-coupled mAChR are M2R-like
and consist of M2 and M4 mAChR. M1 and M4 mAChR are expressed by SPNs, M3 and M5
mAChR are on nigrostriatal dopaminergic afferent projections, and M2 and M4 mAChR are on
CINs producing an auto-regulatory role. Specifically, M4 mAChR are found primarily in the
DLS on CINs and dSPNs. CINs increase excitability of iMSNs through M1 mAChR and
decrease excitability of dMSNs through M4 mAChR.
The expression of nAChR are predominately on afferent projection terminals in the
striatum (Quik and Wonnacott 2011). Twelve distinct neuronal nAChR subunits exist that are
classified as either alpha subunits (α2 to α10) or beta subunits (β2 to β 4 (Dani 2015; Zoli et al.
2015)). The alpha subunit has a recognition site for ACh, whereas the beta subunits just promote
the binding of ACh to the alpha subunits. For this reason, most nAChR are heteromeric with both
alpha and beta subunits together. In DA neurons, binding of ACh to presynaptic nAChR has
been shown to facilitate DA release (Drenan et al. 2010; Gotti et al. 2010; Livingstone and
Wonnacott 2009). Glutamate, GABA, and serotonergic neuron terminals all express nAChR
subunits to promote their neurotransmitter release as well (Grilli et al. 2009; Kaiser and
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Wonnacott 2000). The diverse roles of nAChR subunits on different neurotransmitter terminals
in the striatum allow for the precise regulation of motor control from CINs. Interestingly, nAChR
drugs have been found to be neuroprotective against dopaminergic degeneration in the SNpc, as
reflected in a decreased risk of PD development among smokers (Noyce et al. 2012; Quik et al.
2007; Searles Nielsen et al. 2012; Tanner et al. 2002; Wirdefeldt et al. 2011). The abundance of
ACh receptors expressed presynaptically and postsynaptically throughout the striatum points to
the complex and powerful influence CINs exert on motor function.

1.3 Parkinson’s Disease and L-Dopa induced dyskinesia
Parkinson’s Disease (PD)
Motor dysfunctions arise due to the progressive loss of DA neurons in the SNpc and is
the cardinal feature of PD (Ungerstedt 1971). The subsequent decrease in striatal DA
concentration causes an imbalance between the dSPN and iSPN pathways (Figure 1.2) and
results in motor impairments such as bradykinesia, rigidity and slow movement (Dauer and
Przedborski 2003). Parkinsonian symptoms emerge following more than 50% loss of DA
neurons (Kordower et al. 2013; Ungerstedt 1971) and renders the striatum hypersensitive to DA.
As a result, iSPNs become hyperactive and suppress movement, while, dSPNs become
hypoactive leading to non-activation of movement. LTD and LTP are therefore lost in the iSPN
and dSPN pathways, respectively (Albin et al. 1989; Mallet et al. 2006). This shift in balance
favors the iSPN pathway and results in activation of the SNr, which inhibits the thalamocortical
circuit and decreases motor output.
In PD patients, both DA and ACh levels fall, but DA diminishes to a larger extent than
ACh levels (Barbeau 1962; McKinley et al. 2019). This describes the well-established seesaw
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effect of the disequilibrium between DA and ACh with intrinsic cholinergic activity scaling
higher than dopaminergic input, resulting in increased inhibition of movement (Barbeau 1962;
Duvoisin 1967; Quik and Wonnacott 2011). Optogenetic studies show activation of CINs
augments parkinsonian symptoms in mouse models, whereas, inhibition of CINs dampen them
(Kravitz et al. 2010; Threlfell et al. 2010). While anticholinergic drugs are an effective therapy in
alleviating PD symptoms, they cause too many side effects and are used less frequently in the
clinical setting (Maurice et al. 2015). The off-target side effects include cognitive deficits,
confusion, constipation, dry mouth, and urinary issues among others. Interestingly, inhibition of
CINs in normal animals does not alter locomotion, exhibits no effect on MSN excitability, and
has no change in spontaneous or cortically driven activity, suggesting that the role of CIN in
motor function critically depends on the dysfunction of dopaminergic tone.
L-Dopa induced dyskinesia
To date, there are no disease modifying therapies available for reversing or halting the
progression of PD. Instead, symptomatic treatment by DA substitution from Levo-Dopa (LDopa) therapy remains the most efficacious management of PD (Lees 1994). L-Dopa therapy is
seen as the best treatment because of its ability to cross the blood brain barrier and provide the
substrate for DA, fundamentally giving back the neurotransmitter that is lost in PD. However, as
much as L-Dopa is an effective replacement for DA, this therapy exhibits many shortcomings. LDopa therapy ameliorates most but not all symptoms of PD and, worse, induces uncontrollable
L-Dopa induced dyskinesias (LIDs). LIDs are a complicated and debilitating side effect,
prompting hyperkinetic abnormal involuntary movements characterized as chorea/choreoathetoid
or rapid, irregular, unpredictable, non-stereotyped movements (Bastide et al. 2015; Eriksson et
al. 1988; Hechtner et al. 2014; Marsden and Parkes 1977; Quinn et al. 1982). The appearance of
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LID reflects “aberrant reinforcement learning” caused by daily L-Dopa induced DA peaks each
mimicking a positive reward prediction error that occur at ectopic synapses and are uncoupled
from behavioral context (Surmeier et al. 2014; Zhai et al. 2018; Zhuang et al. 2013). The L-Dopa
therapy induced spike of unregulated DA leads to hyperactivity of dSPNs via D1R and increased
inhibition of the iSPNs through excessive D2R activation after repeated exposure and increased
receptor sensitivity. This causes another shift in the balance of the dSPN and iSPN pathways
from dSPNs being hypoactive during PD to hyperactive during LIDs, and vice versa for iSPNs
(Figure 1.2). Importantly, LIDs appears in almost all patients following 5-10 years of chronic LDopa treatment or in advanced stages of PD (Cenci and Lundblad 2006; Fabbrini et al. 2007).
Despite years of research, why and how LIDs form is not understood.
Current LID therapy
Considering the multitude of neurons and neurotransmitters within the striatum, antidyskinetic drug targets have been vast and ineffective. For example, many studies have looked
into targeting postsynaptic modulatory mechanisms such as the opioid, cannabinoid,
glutamatergic, noradrenergic, or serotonergic systems without much success (Espay et al. 2018).
The difficulty is that these drugs must have anti-dyskinetic properties, while not curtailing the
beneficial effects of L-Dopa. The best clinical antidyskinetic drug to date is amantadine, an
NMDA antagonist (Pahwa et al. 2017; Rascol et al. 2015). Although the safety of amantadine
has been considered “acceptable”, there are additional side effects such as confusion,
hallucinations, ankle edema, lethargy, nausea, and vomiting that make it a non-optimal treatment
(Fox et al. 2011). Other advanced therapies have been developed but require invasive
intervention, such as deep brain stimulation, infusion of levodopa-carbidopa intestinal gel, and
continuous subcutaneous apopmorphine infusion (Durif et al. 1994; LaHue et al. 2017; Larson
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2014; Perestelo-Pérez et al. 2014). This list exemplifies many limitations in optimally managing
LID because of the complexity and many off-target responses these therapies produce.

1.4 CIN involvement in LID
Targeting CINs and ACh receptors in LID
Recently, the focus of interest in LID formation has shifted towards the role of CINs
based on several intriguing findings. However, the mechanism(s) of action remain elusive and
contradictory. Deciphering whether increased or decreased cholinergic signaling contributes to
LID formation and expression has been a challenge because there is strong evidence that high
ACh reduces LID as well as low ACh reduces LID. For example, LID expression is attenuated
by (1) administration of chronic nicotine, an agonist of nAChR mediated cholinergic signaling
((Quik et al. 2013; Quik et al. 2013; Quik et al. 2013; Zhang et al. 2013) and clinical trial
NCT00957918), (2) muscarinic agonists through M4R activation on dSPNs (Shen et al. 2015)
and (3) optogenetic “long-duration” stimulation of CINs (Bordia et al. 2016). Whereas, LID
formation is augmented by (1) the ablation of striatal CINs (Won et al. 2014), (2) muscarinic
antagonist, dicyclomine (Ding et al. 2011) (3) inhibition of RGS4 expression (Ko et al. 2014), a
negative modulator of muscarinic feedback regulation of acetylcholine release (Ding et al. 2006),
and (4) optogenetic “short-duration” stimulation of CINs (Bordia et al. 2016). How to reconcile
these divergent results is not readily apparent but two possibilities are discussed most often: a)
chronic nicotine administration could lead to desensitization of endogenous ACh release which
could explain functional outcomes that are also achieved by methods of inhibiting cholinergic
signaling or b) ACh signaling through specific nicotinic receptors attenuates, while ACh
signaling through specific muscarinic receptors facilitates, LID formation (Bordia et al. 2016;
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Quik et al. 2018). Together these findings suggest a critical role of cholinergic activity and tone
in the formation and expression of LIDs.
Molecular targets of CINs in LID
Elucidating the molecular details and functional consequences of the reciprocal
relationship of DA neurons and CIN potentially holds the key to understanding the mechanisms
behind LID. The phosphorylation of MAP-kinase pathway protein extracellular signal-regulated
kinase (pErk1/2; phospho-Thr202/Tyr204–ERK1/2), is involved in many transcriptional
processes and has been implicated as a marker for LID (Pavón et al. 2006; Santini et al. 2009;
Santini et al. 2007). Upon early L-Dopa dosing, pErk1/2 in the dorsal striatum is found in SPNs
and directly correlates to the degree of LIDs (Figure 1.3). However, with continuous L-Dopa
treatment a unique patterning of pErk1/2 develops. Upon long-term L-Dopa dosing, there is a
shift in pErk1/2 patterning from SPNs to CINs with increased pErk1/2 expression in CINs
correlating to increased LIDs (Ding et al. 2011). The understanding of pErk1/2 expression in
CINs is unclear, however, when pErk1/2 is pharmacologically inhibited, there is a subsequent
decrease in LID (Ding et al. 2011; Schuster et al. 2008). Another biochemical marker implicated
in enhanced LID formation is the immediate early gene c-Fos (Cenci and Konradi 2010; Ding et
al. 2007). The activity of c-Fos is increased in CINs following optogenetic “long-duration”
stimulation of CINs that is correlated to decreased LIDs (Bordia et al. 2016). These changes in
gene regulating signaling proteins can potentially alter the basal firing rate of CINs through
changes in glutamatergic input and morphology, and, thus, play a role in the formation of LIDs.
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Figure 1.3: pErk1/2 patterning in the striatum following LID (Adapted from (Ding et al.
2011))
During acute dosing of L-Dopa, pErk1/2 is expressed in SPNs and not in CINs. Upon chronic LDopa dosing and increased LID formation, expression is increased in CINs and decreased in the
SPNs. SPN: medium spiny neuron; CIN: cholinergic interneuron; LID: L-Dopa induced
dyskinesia.
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1.5 Sonic Hedgehog signaling
DA neurons release Sonic Hedgehog throughout life
In order to understand the pathophysiology underlining LID formation, it is important to
understand how DA neurons communicate. DA neurons are “multilingual”, meaning they
communicate to their targets with glutamate, GABA, and other cell signaling factors besides DA
throughout life (Chuhma et al. 2018; Trudeau et al. 2014). It therefore follows that all these
factors are also lost during DA neuron degeneration in PD. One such signaling factor produced
by DA neurons is the trophic factor Sonic Hedgehog (ShhDAN), which is found to be critical for
the maintenance and survival of the nigrostriatal circuit (Gonzalez-Reyes et al. 2012). Although
Shh has been extensively studied in development and patterning of the notochord and floorplate
(Briscoe and Ericson 1999; Perrimon 1995; Smith 1994), its critical role in the adult brain is just
emerging.
Shh is a 19-kDa protein of the hedgehog family that acts as an intein and cholesterol
transferase (Beachy et al. 1997; Fietz et al. 1994). Shh is involved in proliferation of neural
precursor cells (Dahmane and Ruiz-i-Altaba 1999; Ruiz i Altaba et al. 2002), neuronal
differentiation (Tanabe et al. 1995; Wang et al. 1995), axon outgrowth (Charron et al. 2003),
synapse formation, and enhanced neurotransmitter release (Yao et al. 2016), and neuroprotective
properties (Zhang et al. 2014). In PD mouse models, viral over-expression of Shh reduces the
loss of DA neurons induced by DA-toxins such as methylphenyltetrahydropyridine (MPTP) and
6-hydroxydopamine (6-OHDA) (Dass et al. 2002; Gonzalez-Reyes et al. 2012; Tsuboi and Shults
2002). Partial genetic ablation of Shh in DA neurons of mice produces progressive degeneration,
whereas those DA neurons with intact Shh survive (Dass et al. 2002; Gonzalez-Reyes et al.
2012; Tsuboi and Shults 2002). While this data points to a cell autonomous function of Shh in
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DA neuron survival, this possibility was ruled out by the ablation of the obligate necessary Shh
signal transduction component Smoothened (Smo) from DA neurons which did not phenocopy
the ablation of Shh from DA neurons (Gonzalez-Reyes et al. 2012). In mice lacking ShhDAN,
these DA neurons and their striatal targets, which, in return, provide neurotrophic support to DA
neurons via their secretion of the DA neuron trophic factor glia derived neurotrophic factor
(GDNF), progressively die as the mouse ages, showing the importance of reciprocal trophic
factor support (Gonzalez-Reyes et al. 2012; Hidalgo-Figueroa et al. 2012).
Shh receptor expression and function
Although the striatal neurons express DA, glutamate, ACh, and GABA receptors, only
CINs and FSNs express the Shh receptor Patched-1 (Ptc-1) (Gonzalez-Reyes et al. 2012; Moss
and Bolam 2008). Shh signaling is unique in that activation of the 12-transmembrane resistancenodulation-division (RND)-like transporter protein Ptc-1 releases the constitutive repression of
the 7-transmembrane G-protein coupled receptor (GCPR) smoothened (Smo; Figure 1.4) (Izzi et
al. 2011). This Ptc-1/Smo interaction has been shown to be critical for regulating appropriate Shh
pathway activity. Activation of Smo recruits Gi protein complex that reduces levels of cyclic
AMP (cAMP) (Beachy et al. 1997) and allows for either transcription independent or canonical
transcription dependent processes to occur (Bijlsma et al. 2012).
Shh has been shown to have a neuromodulatory effect on glutamatergic
neurotransmission in slice preparations (Bezard et al. 2003) and can be secreted from neurons by
high frequency burst firing (Su et al. 2017). Therefore, ShhDAN might also have acute effects on
CIN and FSN. Previously, we’ve shown that activation of the Shh pathway through Smo inhibits
the transcription of muscarinic acetylcholine autoreceptor M2 in the striatum (Gonzalez-Reyes et
al. 2012). Among the neuronal subtypes of the striatum, M2 is mainly expressed by CINs, where
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it provides negative feedback regulation of ACh release (Lim et al. 2014). Additionally, RGS4 is
enhanced in CINs, which inhibits M2 to promote ACh release. In mice with genetic ablation of
Shh from DA neurons, basal ACh release is attenuated, as well as, upregulated M2R’s
(Gonzalez-Reyes et al. 2012) . Taken together, these data suggest that ShhDAN plays a role in the
release of ACh from CINs and may provide an unexpected link between DAN degeneration and
LID development when it is lost in PD.
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Figure 1.4: Shh signaling pathway
During the off state, Shh is unbound to Ptc-1 and Smo remained repressed. During the on state,
Shh binds to Ptc-1, releasing the repression of Smo and activates downstream mechanisms. Shh:
Sonic hedgehog; Ptc-1: patched receptor-1; Smo: smoothened receptor.
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1.6 Intent of Thesis
The development of LID is not a natural symptom of PD, but instead, is a major
complication of current PD therapy. The current gold-standard PD management only attempts to
normalize levels of DA by treatment with the DA precursor L-Dopa and does not augment the
other signaling modalities of DA neurons. Hence, L-Dopa therapy must cause an imbalance of
DA and non-DA signaling modalities in medicated PD patients. Interestingly, knockdown of TH
from DA neurons showed resistance to LID formation (Ulusoy et al. 2010). This study indicates
that when other factors secreted by DA neurons remain intact L-Dopa therapy does not pose the
risk of LID formation. This suggests that the presynaptic loss of all the factors associated with
DA neurons, such as Shh, are critical in the development of LID.
Here, I provide several lines of evidence supporting the hypothesis that the loss of Shh in
DA neuron degeneration contributes to the formation of LID during DA substitution therapy and,
conversely, that augmenting Shh signaling specifically on CINs can alleviate LID. I tested the
physiological relevance of ShhDAN regarding LID, through pharmacological, genetic -presynaptic
and -postsynaptic manipulation in diverse mouse and non-human primate models. First, I tested
the Shh agonist, SAG, and Shh antagonist, cyclopamine, in two classic PD mouse models (1) the
DA neuron toxin 6-hydroxydopamine (6-OHDA) unilateral lesion within the DLS (Boix et al.
2015; Lundblad et al. 2005), and (2) a genetic model of Aphakia mice (Pitx3AK/AK) with selective
loss of DA neurons in the SNpc through deletion of the Pitx-3 gene (Ding et al. 2007). Then I
used genetic presynaptic manipulation where mice have conditional ablation of Shh from mature
DA neurons (ShhDA-/-) (Gonzalez-Reyes et al. 2012). The genetic postsynaptic manipulation
approach consisted of (1) ablating Smo from CINs (SmoCIN-/-) and (2) constitutively activating
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Smo on CINs (SmoM2+/-CIN). Furthermore, in collaboration with Dr. Erwan Bezard, we
corroborated the basic tenet of my hypothesis in MPTP treated macaques.
The findings described in this thesis reveal that reduced ShhDAN signaling strength
relative to DA signaling onto CIN of the DLS facilitates LID, while augmenting Shh signaling
attenuates the formation of LID, as well as, the expression of established LID. My data suggests
that ShhDAN is a critical modulator of CIN activity and uncovers an un-anticipated presynaptic
mechanism that contributes to LID. Further, Shh pathway agonists inhibit LID to the same
degree as Amantadine without curtailing the anti-akinetic benefit of L-Dopa suggesting that the
Shh signaling pathway constitutes a valid target for the development for LID inhibiting
pharmacology.

21

Part I: Reduced Sonic Hedgehog by DA neuron
degeneration contributes to LID formation that can be
alleviated by replacing both DA and Sonic Hedgehog
signaling factors
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2. Chapter 2: Smo agonists attenuate LID in neurotoxic and genetic
models of PD
2.1 Chronic Smo inhibition augments, while Smo activation attenuates LIDs
DA neurons utilize several signaling molecules, in addition to DA, to communicate with
their targets, which all must diminish with DA neuron degeneration. Using a genetic tracer allele
for Shh confirmed that Shh was reduced in parallel to DA neuron loss in 6-OHDA DA-toxin
unilateral lesion model (Figure 2.1 A - C) and genetic aphakia mice lacking the pitx3 gene (AK-/; Figure 2.1 D, E). Hence, the lack of Shh signaling in L-Dopa therapy might be a critical
determinant of LID formation and/or expression in the well-established models of LID.
In the 6-OHDA model of LID, the unilateral, striatal injections of the toxin cause greater
than 70% degeneration of nigral DA neurons ipsilaterally resulting in an ipsilateral turning bias
(Figure 2.2 A, B). Acute and chronic L-Dopa dosing shifts the turning bias from ipsilateral to
contralateral, indicative of the beneficial anti-akinetic effect of L-Dopa, and co-injection with the
Smo agonist, SAG, did not affect the L-Dopa induced shift in rotational bias (Figure 2.2 B).
Thus, SAG administration does not curtail the effectiveness of L-Dopa. Chronic exposure to LDopa in 6-OHDA injected mice results in the appearance of classically defined asymmetric
abnormal involuntary movements (AIMs; Figure 2.3 A). Daily injections of L-Dopa (14 days, 5
mg/kg L-Dopa) with the Smo antagonist cyclopamine (5 mg/kg) results in an almost doubling of
AIM scores on day 4 and 14 compared to L-Dopa alone (Figure 2.4 A, B). Conversely, coinjection of L-Dopa with SAG (0.8, 2.5, or 7 mg/kg) results in dose dependent, and over time
gradual attenuation of AIMs from no effect at the lowest dose on day 4 to a more than 3 fold
reduction in AIMs with the highest dose of SAG on day 14 compared to L-Dopa alone (Figure
2.4 B).
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In AK-/- mice, the absence of the transcription factor Pitx3 results in the bilateral, partial
loss of dopaminergic innervation of the dorsal striatum (Figure 2.1 D) and PD-like motor
deficits that are responsive to L-Dopa therapy. Daily injection of AK-/- mice with 25 mg/kg LDopa results in LID. Observed previously, AK-/- mice need more days and a higher dose of LDopa to establish LIDs than 6-OHDA mice, this may be due to compensational mechanisms in
the genetic model (Ding et al. 2007). As in the 6-OHDA model, daily co-injections of L-Dopa
(25 mg/kg) with cyclopamine (5 mg/kg) results in a doubling of AIM scores by day 26 compared
to L-Dopa only injected controls (Figure 2.4 A, C). In contrast, daily co-injections of L-Dopa
(25 mg/kg) with SAG (20 mg/kg) results in an almost 75% reduction of AIM score compared to
L-Dopa only injected controls (Figure 2.4 C).
Modulation of Smo activity in either model could potentiate or curtail the anti-akinetic
effect of L-Dopa and thereby indirectly effect the display of AIMs. However, daily injections of
cyclopamine or SAG with L-Dopa compared to daily injections of L-Dopa alone did not affect
spontaneous locomotor activity in response to L-Dopa in 6-OHDA treated animals or AK-/- mice
suggesting that the observed modulation of LID is not a reflection of an underlying regulation of
motor activity level (Figure 2.4 D).
In the 6-OHDA mice, ceasing SAG treatment on day 15 while continuing daily L-Dopa
injections resulted in a reappearance of AIMs on day 16, indicating the attenuation of SAG is
rapidly reversible (Figure 2.5 A). Escalating the L-Dopa dose from 5 mg/kg to 20 mg/kg caused
a concentration dependent increase in the severity of AIMs revealing that the reinstated AIMs
remain sensitive to the concentration of L-Dopa dose. Reinstatement of SAG and L-Dopa cotreatment (days 39, 43, 47, 51) as a within subject SAG escalation caused a dose-dependent
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attenuation of AIMs. Together, these findings show a bidirectional effect of stimulation and
inhibition of Smo on LID formation in well-established models of LID.
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Figure 2.1: Shh levels are reduced with DA neuron degeneration in classic models of PD
(A) Schematic showing DLS injection sites (2 ul x 2) of the DA neurotoxin 6-OHDA. (B) 10 x
tile scan image of the midbrain following 6-OHDA injections showing SNpc dopaminergic
neuron loss on the lesion side compared to the non-lesioned side. (C) Zoomed in 20 x images of
SNpc for the non-lesion (top) and lesion side (bottom). TH, tyrosine hyndroylase for DA neurons
(red), Shh-lacZ (green), and DAPI (purple) were stained. Scale bar = 50 µm. (D) 10 x tile scan
images showing one hemisphere of the midbrain for AK+/-; ShhL/L control mice and AK-/-; ShhL/L
mutant mice with loss of DA neurons from the SNpc. (E) Zoomed in 20 x images of SNpc for
the AK+/-; ShhL/L (top) and AK-/-; ShhL/L (bottom) mice. TH (red), Shh-lacZ (green), and DAPI
(purple) were stained. Scale bar = 50 µm.
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Figure 2.2: Dosing with L-Dopa and SAG has similar anti-parkinsonian properties in the 6OHDA toxin model
(A) Immunohistochemistry showing unilateral loss of TH (red) indicative of a DA neuron lesion
6-OHDA model. (B) Quantification of rotational bias calculated as contra- to ipsi- lateral turn
ratio. Mice that turn equally to both sides is represented by the dotted line at 0.5. Classically
defined, 6-OHDA mice without L-Dopa (baseline: BL) turn ipsilateral to the lesion and when on
L-Dopa mice turn contralateral to the lesion, indicative of the beneficial anti-akinetic effect of LDopa. Long-term dosing with both L-Dopa (5 mg/kg) and SAG (7 mg/kg) did not alter
contralateral turning compared to controls (n = 8 - 9). RM 2-way ANOVA time effect: F (2,50) =
20.19 p<0.0001. Post hoc Bonferroni’s test: ** P < 0.01; *** P < 0.001 for BL vs. day 1 or day
13. n.s. indicates P > 0.05. Graphs plotted as mean +/- SEM.
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Figure 2.3: Scoring criteria of abnormal involuntary movements (adapted from
(Sebastianutto et al. 2016))
Represented images showing the four types of AIMs: 1) locomotion movement: contralateral
rotations, 2) axial movement: dystonic posturing, and severe twisting of the head or neck, 3) limb
movement: rapid, jerky movements of the front or hind limbs, and 4) orofacial movement:
abnormal chewing, licking, grooming, or sticking out of the tongue. The four types of AIMs
were scored on a severity scale of 0 - 4, with 0 exhibiting no abnormality and 4 showing
uninterruptable continuous dyskinetic movement.
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Figure 2.4: Chronic Smo inhibition facilitates while chronic Smo stimulation attenuates
LID in a neurotoxic and a genetic model of PD
(A) Experimental design of chronic drug (cyclopamine: cyclo, or SAG) and L-Dopa daily
regimen for 6-OHDA (top) or AK-/- (bottom) PD mouse models. (B) AIM score of 6-OHDA mice
with either vehicle (n = 6), cyclo (5 mg/kg; n = 6), or SAG (7 mg/kg; n = 9). RM 2-way ANOVA
treatment effect: F (4,28) = 12.24, p<0.0001. Post hoc Bonferroni’s test: * P<0.05, ** P<0.01
treatment vs. control. (C) AIM time of AK-/- with either vehicle (n = 8), cyclo (5 mg/kg; n = 7),
or SAG (20 mg/kg; n = 8). 1-way ANOVA F (2,20) = 20.46 p<0.0001. Post hoc Bonferroni’s test:
* P<0.05, ** P<0.01 treatment vs. control. (D) Fold change of distance moved following chronic
co-treatment of L-Dopa and either cyclo or SAG in 6-OHDA (day 14; n = 8) and AK-/- (day 26; n
= 12) mice over L-Dopa and vehicle treated controls. n.s. indicates P > 0.05. All bar graphs
plotted as mean +/- SEM.

29

Figure 2.5: Smo agonist attenuation of LIDs is reversible and scales with L-Dopa dose
(A) Longitudinal AIM scoring during L-Dopa (5 mg/kg) administration with SAG (7 mg/kg) for
7 and 12 days. Followed by SAG washout during days 16 - 27 while maintaining 5 mg/kg LDopa. Subsequently, the L-Dopa dose was increased to 20 mg/kg during days 33 - 51, followed
by a within subject escalation of SAG from days 39 - 51 from 1, 5, 10, and 15 mg/kg with 3 days
of washout with only L-Dopa in between (d 7, 12 n = 9; d 16 - 51 n = 5). Paired 2-tailed
student’s t test: * P < 0.05 for treatment vs. vehicle. n.s. indicates P > 0.05. Bar graph plotted as
mean +/- SEM.
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2.2 Acute activation of Smo decreases AIMs
Clinically relevant, animals with established AIMs were challenged with a single dose of
the agonist of Smo to check for reduction in the severity of LID. LID was induced by daily
injections of L-Dopa for 14 or 20 days in 6-OHDA lesioned or AK-/- mice, respectively, and then
given a single dose of either Smo agonist or antagonist co-injected with the final dose of L-Dopa
(Figure 2.6 A). In the 6-OHDA lesioned animals, there was about a 50% attenuation of AIMs
when animals were injected with either the Smo agonists, Purmorphamine (15 mg/kg, Figure 2.6
B) or SAG (10 mg/kg, Figure 2.6 C) along with L-Dopa. The AK-/- mice were injected with
either 5 mg/kg cyclopamine, 20 mg/kg SAG, the clinical effective antidyskinetic drug
Amantadine (AM, 60 mg/kg) (Pahwa et al. 2015), or a combination of SAG (20 mg/kg) and
amantadine (60 mg/kg) with 25 mg/kg L-Dopa (Figure 2.6 D). There was no change in AIM
score following acute cyclopamine injection, but about a 50% reduction with either SAG or
Amantadine and a 82% reduction with the combination of SAG and Amantadine (Figure 2.6 D).
Acute injection of cyclopamine or SAG had no effect on spontaneous locomotor activity
compared to controls (Figure 2.6 E). However, Amantadine by itself or in combination with
SAG depresses locomotor activity three-fold compared to controls (Figure 2.4 E). These results
indicate that a single dose of SAG significantly attenuates the display of established LID to a
degree similar of that achieved by Amantadine without altering overall movement.
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Figure 2.6: Acute Smo stimulation attenuates established LIDs in a neurotoxic and a
genetic model of PD
(A) Experimental design of acute drug challenge (purmorphamine: PUR, cyclo, SAG, and/or
amantadine: AM) regimen following chronic daily L-Dopa. (B) AIM score of 6-OHDA mice
challenged with vehicle (n = 6) or PUR (15 mg/kg; n = 7). Unpaired 2-tailed student’s t test *
P<0.05 for treatment vs. control. (C) AIM score of 6-OHDA mice challenged with vehicle (n =
5) or SAG (10 mg/kg; n = 7). Unpaired 2-tailed student’s t test * P<0.05 for treatment vs.
control. (D) AIM time of AK-/- mice challenged with either vehicle (n = 13), cyclo (5 mg/kg; n =
13), SAG (20 mg/kg; n = 13), AM (60 mg/kg; n = 8) or SAG combined with AM (n = 8). 1-way
ANOVA F (4,50) = 9.79 p<0.0001, Post hoc Bonferroni’s test: * P<0.05, ** P<0.01, *** P<0.001
for treatment vs. control. (E) Fold change of distance moved on day 20 following chronic LDopa and acute treatment in AK-/- mice following 5 mg/kg cyclo (n = 9), 20 mg/kg SAG (n = 8),
60 mg/kg Amantadine (AM; n = 9), or combined AM and SAG (n = 8). Unpaired 2-tailed
student’s t test: * P < 0.05 for treatment vs. vehicle. n.s. indicates P > 0.05. All bar graphs plotted
as mean +/- SEM.
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2.3 pErk1/2 activation in CINs is attenuated by Smo activation
As mentioned earlier, activation of the MAP-kinase pathway as recognized by the
phosphorylation of Erk1/2 (pErk1/2) has emerged as a biochemical marker of LID (Ding et al.
2011; Pavón et al. 2006; Santini et al. 2009). L-Dopa injection to DA-hypersensitive animals, but
not to intact animals, increases the prevalence of pErk1/2 positive neurons in the striatum and the
pharmacological inhibition of the MAP kinase pathway attenuates LID in mice models (Ding et
al. 2011). Consistent with the behavioral data, there is a two-fold increase of pErk1/2 prevalence
in CINs of the DLS but not the DMS after co-injections of cyclopamine and L-Dopa compared to
controls in 6-OHDA lesioned animals (Figure 2.7 A - C). Conversely, there is a two-fold
decrease of the prevalence of pErk1/2 expressing CINs after SAG and L-Dopa co-injection
compared to controls in 6-OHDA lesioned animals (Figure 2.7 A - C). In AK-/- mice, there is a
1.5-fold increase in the numbers of pErk1/2 expressing CINs following cyclopamine and L-Dopa
co-injections and, conversely, an almost two-fold decrease following SAG and L-Dopa coinjections in the DLS but not the DMS (Figure 2.7 A – C). Similarly, there is a two-fold
decrease in the prevalence of pErk1/2 positive CINs following either acute Purmorphamine or
SAG in 6-OHDA treated animals and following SAG in AK-/- mice in the DLS but not in the
DMS (Figure 2.7 D). There was no change in the prevalence of pErk1/2 positive CIN in
response to acute cyclopamine injection into AK-/- mice compared to controls in the DLS or
DMS, similar to their lack of behavioral results (Figure 2.7 D). Thus, consistent with the
established increase in the numbers of pErk1/2 positive CIN in the DLS in well-studied models
of LID we find that the Smo mediated attenuation of LID is associated with a correlated
reduction in the prevalence of pErk1/2 in CIN selectively in the DLS.
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Figure 2.7: Smo inhibition enhances while Smo stimulation reduces pErk1/2 expression in
CINs following chronic L-Dopa dosing
(A) Schematic showing different compartments of the dorsolateral (DL) and dorsomedial (DM)
striatum where images were quantified. (B) Represented images of pErk1/2 (red) colocalization
(arrowhead/yellow) with ChAT (green) from animals in the chronic drug experiments in Figure
2.4. Scale bar = 50 µm. (C) Quantification of the prevalence of pErk1/2 in CINs expressed as
fold change from animals in the chronic drug experiments in Figure 2.4. Values are expressed as
fold change over vehicle treated animals (~36 CINs per condition). Unpaired 2-tailed student’s t
test * P<0.05, ** P<0.01 treatment vs. vehicle. (D) Same as above from the acute challenged
drug experiments in Figure 2.6. (~36 CINs per condition). Unpaired 2-tailed student’s t test **
P<0.01, *** P<0.001, for treatment vs. vehicle. n.s. indicates P > 0.05. All bar graphs plotted as
mean +/- SEM.
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2.4 SAG Administration reduced dyskinetic behavior in the MPTP Macaque model of PD
Most pharmacological treatments in clinical development for PD are pre-clinically tested
on methylphenyltetrahydropyridine (MPTP) treated macaque monkeys because they phenocopy
human symptoms (Bezard et al. 1997). Therefore, in a collaboration with Dr. Erwan Bezard, we
tested whether acute treatment with SAG could attenuate the display of established LID in nonhuman primates (Appendix 1 A). Four Macaques were rendered parkinsonian with repeated
injections of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine hydrochloride (MPTP; i.v.) and then
subjected to a chronic L-Dopa treatment regimen, which induced dyskinesia, a process that
overall takes 7 months. These dyskinesias can be blunted by the clinically effective antidyskinetic drug amantadine (Ko et al. 2014). Vehicle or SAG (3, 9, and 27 mg/kg) was
administered with L-Dopa injection in a within-subject drug escalation design (Appendix 1 A).
The acute injections of SAG lead to a dose dependent attenuation of established LID showing
significance at the highest dose of SAG at 27 mg/kg during the first 2 hours of drug exposure
(Appendix 1 B, C). As observed in the murine models of LID, SAG injections did not diminish
the anti-akinetic benefits of L-Dopa treatment in the Macaques (Appendix 1 D).
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2.5 The attenuation of LID by Smo stimulation scales with the concentration of L-Dopa
The opposite effect of inhibition and stimulation of Shh/Smo signaling on LID under
otherwise constant dosing of L-Dopa suggests that the severity of LID may be correlated to the
relative difference between Shh/Smo and DA signaling. Therefore, the dose-response
relationship between L-Dopa and SAG was examined. LIDs were induced in three separate
groups of AK-/- mice, receiving either 5, 10 or 30 mg/kg of L-Dopa daily leading to distinct,
concentration dependent, levels of LID severity. In a probe trial, the degree of LID attenuation
was tested using four different concentrations of SAG 0.8; 2.5; 7.5; and 15 mg/kg in each LDopa group as a within subject escalation (Figure 2.8 A, B; 3 days of SAG washout in between
each incremental SAG increase). In each L-Dopa group, the attenuation of LID by SAG was
dose-dependent (Figure 2.8 B). These results allow the calculation of the estimated
concentration of SAG that results in half-maximal (EC50) inhibition of LID in each of the three
L-Dopa groups. The analysis revealed a correlation between the dose of SAG needed to
counteract LIDs that formed in response to escalating concentrations of L-Dopa compared to
controls receiving only L-Dopa (R2 = 0.965, Figure 2.8 C). These results indicate that the
severity of LID is determined by the degree of imbalance between Shh/Smo and DA signaling,
suggesting that Shh/Smo signaling impedes DA-inhibition of CINs.
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Figure 2.8: Degree of attenuation of LID by Smo agonist scales with L-Dopa dosing
(A) Timeline of dose-response experiment showing three cohorts of AK-/- mice receiving either
chronic 5 mg/kg L-Dopa, 10 mg/kg L-Dopa, or 30 mg/kg L-Dopa and within subject escalating
doses of SAG (0.8, 2.5, 7.5, and 15 mg/kg; n = 8 for each drug condition). There were 3 days of
SAG washout with just L-Dopa dosing between each challenge dose. (B) Dose-response graph.
The effect of SAG is expressed as a ratio compared to controls with 1.0 having complete
elimination of AIMs, 0 showing the same degree of AIMs as controls and 0.5 as the halfmaximal effective concentration (EC50- dotted line) that reduces LID 50%. Linear regression
lines were plotted to best fit the data points. Stars represent significance to corresponding
controls receiving L-Dopa and vehicle only. Unpaired 2-tailed Student’s t test * P<0.05, **
P<0.01. n.s. indicates P > 0.05. Graph plotted as mean +/- SEM. (C) EC50 response graph
showing a positive linear regression (R2= 0. 965) with each escalating L-Dopa dose.
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2.6 Smo activation potentially acts upstream of M4R activation on dSPN
Considering the implication of aberrant hyperactivity of dSPNs in LIDs, the next obvious
question was: Is Smo dependent modulation of LID mediated by CIN regulation of dMSN
activity? The finding that boosting cholinergic signaling via the muscarinic M4 receptor, which
is expressed by dSPNs, strongly attenuating AIMs in the 6-OHDA model of LID (Shen et al.
2016) offered an experimental opening to test if Shh signaling acts upstream or downstream of
dSPN activity. If this thinking is correct, Smo modulatory effect on CIN activity would be
upstream of M4R effect on dSPNs, and then cyclopamine (enhances LID) simultaneously
administered with M4PAM (attenuates LIDs) can give a readout of LID to determine the
pathway sequence of events. Consistent with the previous study, M4 positive allosteric
modulator (M4PAM), VU0467154, attenuated L-Dopa induced AIMs in AK-/- mice supporting
the idea that LID in AK-/- mice are caused in part by reduced cholinergic signaling onto SPNs
(Figure 2.9 A, B). As predicted, the cyclopamine-induced increase in AIMs can be attenuated by
M4PAM to the same levels achieved by M4PAM in only L-Dopa treated AK-/- mice (Figure 2.9
B), consistent with Smo mediated modulation of LID occurring presynaptic to M4 signaling on
dSPNs. Although CINs have M4R themselves to induce auto-inhibition, cyclopamine would also
decrease CIN activity (Gonzalez-Reyes et al. 2012) and both would be presynaptic to the dSPN
effects. The attenuation observed by M4R activation of dSPNs was because M4R promotes LTD
restoring the LID-induced hyperactivity of dSPNs (Shen et al. 2016). Together, this finding point
to Smo mediated modulation of LID in AK-/- mice being upstream of the action of M4R on
dSPNs and gives new insight into the mechanisms of how ShhDAN signaling works to counteract
LIDs.
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Figure 2.9: Shh signaling reduces LIDs by acting upstream of M4R activation on dSPNs
(A) Experimental design displaying that AK-/- mice were dosed for several days with L-Dopa (25
mg/kg) or L-Dopa (25 mg/kg) and cyclo (5 mg/kg) until LIDs were established, and then
challenged with a single dose of M4PAM, an allosteric M4R agonist (cylco: cyclopamine;
M4PAM: VU0467154). (B) AIM time of AK-/- mice following daily L-Dopa with either vehicle
or cyclo and challenged with M4PAM (n = 7). Paired 2-tailed Student’s t test P<0.05, * P<0.05,
** P<0.01 for Veh vs. M4PAM. Unpaired 2-tailed Student’s t test P<0.05, * P<0.05 for Veh vs.
Cyclo. Bar graph plotted as mean +/- SEM.
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3. Chapter 3: Presynaptic ablation of ShhDAN leads to the development of
LIDs that is rescued with Smo activation
3.1 ShhDAN-/- mice develop LID in a dose dependent manner
To examine whether Shh signaling specifically originating from DA neurons rather than
from other sources in the body is the player involved in LIDs, AIMs were assessed in mice with
selective ablation of Shh from DA neurons (ShhDAN-/-; Figure 3.1 A; all mouse strains used in
this study are referenced in the methods section). As seen in the 6-OHDA and AK-/- mice, LID
behavior was developed in a dose-dependent manner upon chronic treatment with L-Dopa in a
dose dependent manner (Bastide et al. 2015; Ding et al. 2007; Lundblad et al. 2004). Daily
dosing with 10 mg/kg L-Dopa for 11 days gradually induced AIMs in ShhDAN-/- mice starting on
day 1 (Figure 3.1 B, C). AIMs were observed only in ShhDAN-/- mice and not in control animals.
Increasing L-Dopa to 25mg/kg resulted in doubling of AIMs on day 12 in ShhDAN-/- mice and
induced an almost seven-fold increase from controls suggesting that ShhDAN-/- mice develop
dose-dependent LID (Figure 3.1 B, C).

40

Figure 3.1: Genetic ablation of ShhDAN promotes the development of LIDs that are rescued
with Smo activation
(A) Shh was ablated from DA neurons using a combination of a Shh conditional allele and DatCre mouse line. (B) Experimental design for chronic L-Dopa regimen in ShhDAN+/- and ShhDAN/- mice (Baseline: BL, day: d). (C) LID induction by daily injection of 10 mg/kg L-Dopa for 11
days (RM 2-way ANOVA day x genotype: F (2,36) = 4.53, p=0.018. Post hoc Bonferroni’s test: *
P<0.05 for BL vs. d11) followed by a 25 mg/kg L-Dopa challenge on Day 12 (RM 2-way
ANOVA treatment effect: F (1,18) = 16.23, p=0.001. Post hoc Bonferroni’s test: *** P<0.001 for
d11 vs. d12; genotype effect: F (1,18) = 18.36, p=0.0004, **** P<0.0001 for control vs. mutant on
d12) in 3 - 4 month ShhDAN-/- and ShhDAN+/- mice (n = 10). (D) Experimental design for
pharmacological complementation to restore Shh pathway activity. (E) Pharmacological
complementation with 10 or 20 mg/kg SAG (n = 5) or vehicle (n = 10) in combination with LDopa after chronic 25 mg/kg L-Dopa for 20 days. 2-way ANOVA genotype effect: F (1,35) =
21.36. Post hoc Bonferroni’s test: p=0.0002, **** P<0.0001 for control vs. mutant on d 20;
genotype x treatment effect: F (2,35)=9.15, p=0.001. Post hoc Bonferroni’s test: *** P<0.001,
**** P<0.0001 for mutant with and without SAG on d 20 and d 21. n.s. indicates P > 0.05. All
bar graphs plotted as mean +/- SEM.
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3.2 Smo activation reduces LID in ShhDAN-/- mice
To determine whether the acute absence of Shh signaling plays a role in LID expression
in ShhDAN-/- mice, treatment with SAG was administered to see if restoring Shh signaling levels
would counteract LIDs. Using a different cohort of animals, L-Dopa was injected at 25 mg/kg
daily for 20 days inducing pronounced AIMs in ShhDAN-/- mice but not in control animals as
expected (Figure 3.1 D, E). In a probe trial, co-injection of L-Dopa with either 10 or 20 mg/kg
SAG did not show any effects in controls but reduced AIMs to control levels in ShhDAN-/- mice
(Figure 3.1 D, E). These results indicate that the long-term reduction of ShhDAN renders the
brain susceptible to the formation of LID-like motor activity that can be attenuated by the acute
postsynaptic activation of Shh signaling.

3.3 pErk1/2 activation in CINs is attenuated with SAG
Next, ShhDAN-/- mice were investigated to see if they would express biochemical markers
of LID in response to repeated L-Dopa injection and established LIDs. Consistent with the
behavioral data, the pattern of pErk1/2 expression in the striatum shows cell type specific
dynamics. There was a 50% increase in the prevalence of CINs with detectable pErk1/2 30 min
after L-Dopa (25 mg/kg) injection only in the DLS of ShhDAN-/- mice compared to control
animals just receiving L-Dopa (25 mg/kg; Figure 3.2 A - C). A single co-injection of 20 mg/kg
SAG with L-Dopa 30 min prior to brain harvest on day 21 normalized the prevalence of
pErk1/2+ CINs in the DLS to control levels (Figure 3.2 A - C). There was no difference in the
prevalence of pErk1/2+ CINs of the DMS in L-Dopa injected ShhDAN-/- mice compared to
controls, nor did SAG co-injection with L-Dopa decrease the prevalence of pErk1/2+ CIN in the
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DMS (Figure 3.2 B, C). No changes were detected in the prevalence of pErk1/2+ FSN, the only
other neuronal subtype in the striatum that expresses the Shh receptor Ptc-1 (Gonzalez-Reyes et
al. 2012), in L-Dopa treated ShhDAN-/- mice and controls (Figure 3.2 D). Collectively these
results indicate that ShhDAN-/- mice display LID-like behavior upon chronic L-Dopa
administration that results in expression of the classical biochemical LID markers pErk1/2 in the
DLS and implicates ShhDAN as a regulator of the MAP Kinase pathway in CINs.
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Figure 3.2: ShhDAN-/- mice have increased pErk1/2 expression in CINs following chronic LDopa dosing in the DLS
(A) Represented images of mice from the complementary experiment in Figure 3.1, pErk1/2
(red) colocalization (arrows) in CIN (ChAT, green) following 25 mg/kg L-Dopa with and
without 20 mg/kg SAG in DLS (Scale bar = 50 µm). (B) Same as above for the DMS. (C)
Percent of pErk1/2+ CINs from images in A - B (n = 8 - 12, 35-38 CINs each). RM 3-way
ANOVA genotype effect: F (1,105) = 7.09, p=0.009. Post hoc Bonferroni’s test: **** P<0.0001 for
control vs. mutant; treatment effect: F (1,105) = 9.79, p=0.002. Post hoc Bonferroni’s test: ***
P<0.001 for mutant with and without SAG; and area x genotype effect: F (1,98) = 11.21, p=0.001.
Post hoc Bonferroni’s test: ** P<0.01 for mutant DLS vs. mutant DMS. (D) Percentage of
pErk1/2 (red) among Parv+ FSNs (parvalbumin, green) following chronic L-Dopa in the DLS
and DMS areas (n = 8, ~36 parv+ cells each). n.s. indicates P > 0.05. All bar graphs plotted as
mean +/- SEM.
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3.4 Shh signaling across the striatum seems to be patterned and not homogenous
Consistent with the marked spatial selectivity of the regulation of MAP kinase pathway
by ShhDAN, there was enhanced Shh signaling found in the DLS. Using a gene-expression tracer
allele for Gli3, which is a mediator of Shh signaling and is itself up regulated by Shh signaling,
revealed a pronounced high lateral to low medial gradient across the DLS (Figure 3.3 A).
Conditional labeling of neuropil of Shh expressing neurons by the Shh-Cre dependent activation
of myristylated GFP showed a complex pattern with the highest density of Shh carrying neurites
in the DLS of the anterior and posterior striatum compared to the DMS (Figure 3.3 B, C). These
differences between the DLS and DMS are consistent with habitual learned behavior, the
prevalence of DA neuron degeneration in PD, CIN loss in aged ShhDAN-/- mice, and pErk1/2
expression in CINs (Figure 3.3 D). Together, these results give evidence of the spatial selective
patterning of Shh signaling in the striatum and further implicates the link between ShhDAN
signaling in the DLS and PD-like pathologies.
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Figure 3.3: ShhDAN signaling in the striatum has a patterned bias towards the DLS
(A) Using a gene-expression tracer allele for the Shh signaling transcription factor, Gli3,
revealed a gradient across the striatum with high lateral and low medial expression. (B) Images
showing the expression pattern of myristylated GFP in the anterior and posterior striatum of Shh
carrying neuropil. Conditional neuropil labeling of neurons that express Shh driven by Shh-Cre
expression of myristylated GFP. Images shown as a heat map in a 16-member pseudocolor
palette to depict the intensity of GFP fluorescence. (C) Quantification of the relative intensity of
myristylated GFP between the DLS and DMS in both the anterior and posterior part of the
striatum. Paired 2-tailed student’s t test * P<0.05, ** P<0.001 for DLS vs DMS (n = 8). (D)
Scheme showing the prevalence of behaviors and pathologies restricted to the DLS and not
observed in the DMS.
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3.5 The prevalence of c-Fos in LIDs is attenuated with Smo agonist
Immediate early genes like c-Fos are strongly induced in response to L-Dopa injection in
rodent and primate models of PD (Pavón et al. 2006). Likewise, the optogenetic inactivation of
neuronal assemblies in the DLS that previously activated c-Fos expression in response to L-Dopa
injection, attenuates LID (Girasole et al. 2018). Consistent, there is a six-fold increase in the
prevalence of c-Fos+ cells in the DLS in response to chronic L-Dopa injection in ShhDAN-/- mice
compared to controls (Figure 3.4 A, B). Co-injection of 20 mg/kg SAG with L-Dopa 30 min
prior to brain harvest normalized the activation of c-Fos to control levels (Figure 3.4 A, B).
Interestingly, these c-Fos+ neurons are not CIN+ or FSN+ and must be SPNs, suggesting an
indirect role of ShhDAN on overall activity of the SPN pathways.
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Figure 3.4: Smo activation reduces overall c-Fos expression following chronic L-Dopa
dosing in mice lacking ShhDAN
(A) Represented images of c-Fos+ cells (red) in the DLS following chronic L-Dopa dosing in
control and ShhDAN-/- mice from Figure 3.1 (Scale bar = 50 µm). (B) Quantification showing the
number of total c-Fos+ cells following 25 mg/kg L-Dopa or 25 mg/kg L-Dopa and 20 mg/kg
SAG. 2-way ANOVA genotype effect: F (1,80) = 38.10, p=<0.0001. Post hoc Bonferroni’s test:
**** P<0.0001 for control vs. mutant; treatment x genotype effect: F (1,80) = 44.90, p<0.0001.
Post hoc Bonferroni’s test: **** P<0.0001 for mutant with and without SAG (n = 8, ~445 cells
per 700 µm x 700 µm area of the DLS). n.s. indicates P > 0.05. All bar graphs plotted as mean
+/- SEM.
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4. Chapter 4: Post-synaptic stimulation of Smo receptor on CINs
reduces LID
4.1 Smo ablation on CINs leads to the development of LIDs
To examine whether ShhDAN signaling occurs through CINs, LID-like behaviors were
assessed in mice with selective ablation of Smo directly from CINs (SmoCIN-/-; Figure 4.1 A).
Mice were chronically dosed with 25 mg/kg L-Dopa and quantified for LID development
(Figure 4.1 B). Continuous L-Dopa (25 mg/kg) dosing for 20 days revealed induction of AIMs
in SmoCIN-/- mice (Figure 4.1 C). Interestingly, control animals with one normal allele of Smo
on CINs (SmoCIN+/-) showed slightly increased AIMs compared to their baseline levels but was
significantly lower than SmoCIN-/- mice (Figure 4.1 C). This suggests an allele dependent
relationship and suggests dose-dependent signaling through normal CIN. Examining overall
locomotor activity of SmoCIN-/- mice reveals a reduction in baseline levels compared to controls
(Figure 4.1 D). This reduction in movement suggests the importance of Shh/Smo signaling in
movement and phenocopies to reduced locomotor activity seen in ShhDAN-/- mice (GonzalezReyes et al. 2012). These differences were eliminated following 20 days of L-Dopa dosing,
suggesting that chronic L-Dopa restored locomotor deficits to control levels.
Consistent with the behavioral data and earlier results, the pattern of pErk1/2 expression
showed increased pErk1/2 expression in CINs following 20 days of chronic L-Dopa (25 mg/kg)
in SmoCIN-/- mice compared to controls (Figure 4.1 E, F). This increase in the prevalence of
pErk1/2 expression in CINs is restricted to the DLS and not observed in the DMS, consistent
with earlier results from cyclopamine experiments (Figure 2.7 B, C) and in ShhDAN-/- mice
(Figure 3.2 A - C). Additionally, the activation of c-Fos expression was increased in SmoCIN-/mice compared to controls following 20 days of L-Dopa dosing, correlating to their development
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of LIDs (Figure 4.1 G). These findings point to ShhDAN signaling acting through Smo directly
on CINs.
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Figure 4.1: Genetic ablation of Smo selectively from CINs contributes to the development
of LIDs
(A) Construct and scheme of postsynaptic Smo ablation from CINs using a combination of the
Smo conditional allele and ChAT-IRES-Cre mouse line. (B) Experimental design for chronic
daily L-Dopa (25 mg/kg) regimen in SmoCIN+/- and SmoCIN-/- mice (Baseline: BL, day: d). (C)
Quantification of LID induction by daily injection of 25 mg/kg L-Dopa for 20 days (RM 2-way
ANOVA day x genotype effect: F (1,11) 4.95, p=0.048. Post hoc Bonferroni’s test: ** P<0.01 for
control vs. mutant on d20; and day effect: F (1,11) = 52.61, p<0.0001. Post hoc Bonferroni’s test: *
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P<0.05 for control BL vs. d20 and **** P<0.0001 mutant BL vs. d20) in 10 - 11 month
SmoCIN+/- and SmoCIN-/- mice (n = 6 – 7). (D) Overall distance moved shows baseline reduction
in activity for SmoCIN-/- mice. RM 2-way ANOVA genotype effect: F (1,11) =5.19 p=0.044. Post
hoc Bonferroni’s test: * P<0.05 for control vs. mutant BL. L-Dopa dosing for 20 days showed no
change in activity between SmoCIN+/- and SmoCIN-/- mice. n.s. indicates P > 0.05. (E)
Representative images of pErk1/2 (red) colocalization (yellow, white arrows) in CIN (ChAT,
green) following 25 mg/kg L-Dopa in the DLS and DMS (Scale bar = 50 µm). (F) Quantification
of percent of pErk1/2+ CINs (n = 6 - 7, 35-38 CINs each). RM 2-way ANOVA area x genotype
effect: F (1,135) = 7.95, p=0.006. Post hoc Bonferroni’s test: ** P<0.01 for control vs. mutant DLS.
n.s. indicates P > 0.05. (G) Images (left; Scale bar = 50 µm) and quantification (right) of the
overall number of c-Fos+ cells (red) in the DLS following 25 mg/kg L-Dopa (n = 6 - 7, ~445
cells per 700 µm x 700 µm area). Unpaired student’s t-test ** P<0.01 for control vs. mutant. All
bar graphs plotted as mean +/- SEM.
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4.2 Constitutively active Smoothened receptor on CINs ameliorates LIDs
The next complementary experiment investigated the gain of function of Smo using a
constitutively active form of Smo called SmoM2 on CINs, independent of Shh source or other
Smo+ cells, such as FSN(Figure 4.2 A; SmoM2+/- AK-/- chat-cre mice). SmoM2 is fused with an
eYFP protein and is expressed only in those cells that are recombined (Figure 4.2 B, showing
expression of SmoM2 in CINs). Upon chronic dosing with 25 mg/kg L-Dopa, LIDs emerge in
control AK-/- chat-cre mice by day 12 but not in SmoM2+/- AK-/- chat-cre mice (Figure 4.2 C, D).
Hence, these mice show an opposite phenotype compared to ShhDAN-/- and SmoCIN-/- mice.
Additionally, SmoM2+/- mice without the presences of a Cre promoter were assessed to
determine if the SmoM2 allele disrupted AIM induction. There were no differences observed in
AIM formation between both controls (SmoM2+/- mice or AK-/- chat-cre mice) for all 20 days of
dosing (data not shown). Locomotor activity was unchanged in SmoM2+/- AK-/- chat-cre mice
compared to controls during baseline and all days of L-Dopa dosing revealing that the observed
resistance of LID formation is not a reflection of an underlying reduction of motor activity
(Figure 4.2 E).
The expression of pErk1/2 in CINs was evident in control mice by day 20 but was
reduced in SmoM2+/- AK-/- chat-cre mice, mimicking their AIM behavior (Figure 4.2 F, G).
Interestingly, pErk1/2 was reduced in both the DLS and DMS. This suggests that regulation of
Erk1/2 by Smo signaling can occur in all CINs. Thus, the observation of a selective increase of
pErk1/2 in the DLS in ShhDAN-/- animals is consistent with the idea that Shh signaling
predominantly occurs on CIN of the DLS in the undisturbed brain.
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Figure 4.2: Constitutively active form of SmoM2 in CINs provides resistance to LID
development
(A) Construct and scheme of mice with postsynaptic constitutively active version of SmoM2 on
CINs using a combination of a SmoM2-YFP conditional allele and ChAT-IRES-Cre mouse line
in the AK-/- mice. (B) Images of the DLS showing recombination of constitutively active version
SmoM2 specifically in CINs using eYFP (green) co-labeled with ChAT (red, white arrows) that
is not seen in AK-/-ChAT-Cre control mice. (C) Experimental design for chronic daily L-Dopa (25
mg/kg) regimen for 20 days (day: d). (D) LID quantification by daily injection of 25 mg/kg LDopa for 20 days in 2 - 4 month control AK-/- ChAT-Cre and mutant SmoM2+/-AK-/-ChAT-Cre mice (n =
6). RM 2-way ANOVA time x genotype effect: F (5,50) =7.91, p=<0.0001. Post hoc Bonferroni’s
test: * P<0.05, **** P<0.0001 for control vs. mutant. (E) Overall distance moved was
unchanged between control and experimental mice during both baseline and over 20 days of
daily L-Dopa dosing. (F) Representative images of pErk1/2 (red) colocalization (yellow, white
arrows) in CIN (ChAT, green) following 25 mg/kg L-Dopa in the DLS and DMS (Scale bar = 50
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µm). (G) Percent of pErk1/2+ CINs (n = 8 - 12, 35 - 38 CINs each). RM 2-way ANOVA
genotype effect: F (1,68) = 27.42, p=<0.0001. Post hoc Bonferroni’s test: *** P<0.001, ****
P<0.0001 for control vs. mutant. n.s. indicates P > 0.05. All bar graphs plotted as mean +/- SEM.
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5. Chapter 5: Potential mechanisms: Lack of Smo activation reduces
CIN activity by dampened cortical glutamatergic input
5.1 Lack of ShhDAN attenuates while Smo agonist rescues basal p-rpS6240/244 levels of CINs
Reduced CIN activity might be a contributing factor in LID formation and expression
considering the evidence that increased nicotine use, boosting signaling by the muscarinic ACh
receptor M4, and optogenetic activation of CINs attenuate LID in mouse models (Perez et al.
2018). Therefore, the role of ShhDAN on CIN activity was explored to understand its function in
LIDs. In order to allow comparative measurements of cholinergic activity across populations of
CINs, p-rpS6240/244 immunoreactivity was used. p-rpS6240/244 is part of the m-Torc pathway and is
a widely used neuronal activity marker for CIN, which has been shown to follow the spiking
pattern of CINs under basal and stimulated conditions (Bertran-Gonzalez et al. 2012; Matamales
et al. 2016; Matamales et al. 2016). Analysis of CIN activity through p-rpS6240/244 activity has
been used in studies investigating reinforcement learning, aging, and catalepsy induced
behaviors (Bertran-Gonzalez et al. 2012; Kharkwal et al. 2016; Matamales et al. 2016). To
account for across subject variability, NeuN immunoreactive marker was used as an internal
control to normalize housekeeping levels between subjects. There was a 37% reduction in prpS6240/244 reactivity in CINs of ShhDAN-/- mice compared to controls in the DLS (Figure 5.1 Araw images showing immunostaining; heat map images in Figure 5.2 A and quantification in
Figure 5.2 B, presynaptic side). Consistent with this, cholinergic tone, measured by in vivo
dialysis of ACh release, was reduced 8-fold in ShhDAN-/- mice (Gonzalez-Reyes et al. 2012).
Remarkably, acute injection of one dose of SAG (20 mg/kg) into ShhDAN-/- mice normalizes prpS6240/244 levels (Figure 5.2 A, B, presynaptic side). Injection of L-Dopa (25 mg/kg) shows
similar degree of activity in CIN of ShhDAN-/- mice but acute injection of SAG (20 mg/kg)
56

counteracted CIN activity in the presence of L-Dopa and normalizes levels in ShhDAN-/- mice to
control basal levels (Figure 5.2 A, B, presynaptic side). These results suggest that reduced Shh
signaling emanating from DA neurons might contribute to the formation and expression of LID
by dampening cholinergic activity in the DLS.
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Figure 5.1: Activity Marker p-rpS6240/244 in CINs
(A) Large 20x raw images showing p-rpS6240/244 co-localized in CINs for basal levels of
ShhDAN+/- mice (top), ShhDAN-/- mice (bottom; Scale bar = 50 um). Smaller panels show zoomed
in image of square (Scale bar = 10 um) with markers for p-rpS6240/244 (red), ChAT (green), NeuN
(blue) and a heat map of p-rpS6 showing a 16 member pseudocolor palette to depict the intensity
of p-rpS6240/244 fluorescence. Left scheme shows the DL area within the striatum where the
images were taken from.
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Figure 5.2: Lack of ShhDAN signaling reduces activity marker p-rpS6240/244 in CINs that is
restored with Smo activation directly
(A) Representative high-magnification confocal images of p-rpS6240/244 in CINs of DL striatum
as a heat map (Scale bar = 10 um). The corresponding smaller image shows ChAT (red) and
DAPI (blue) double stain. A region of interest (ROI) is shown around the ChAT staining in the
white dotted line. Each CIN has its own ROI and is quantified based on the mean gray value
intensity (m.g.v.) per cell of p-rpS6240/244 staining normalized to NeuN staining, to account for
between subject differences, in individual somata. A 16-member pseudocolor palette depicts the
intensity of p-rpS6240/244 fluorescence. Left side represents images of mice with genetic presynaptic manipulations and saline, SAG, or L-Dopa dosing, while the right side represents
images of mice with genetic post-synaptic manipulations and saline or SAG dosing. (B)
Quantification of p-rpS6240/244 intensity of CINs. Each dot represents one neuron, and red lines
indicate the mean ± SEM. In order on the pre-synaptic side, there’s ShhDAN+/- mice (white),
ShhDAN-/- mice (red), ShhDAN-/- mice with 20 mg/kg SAG (blue), ShhDAN+/- mice with 25 mg/kg
L-Dopa (grey) and ShhDAN+/- mice with 25 mg/kg L-Dopa and 20 mg/kg SAG (cyan). In order
on the post-synaptic side, there’s SmoCIN+/+ mice (white), SmoCIN-/- mice (orange), SmoCIN-/mice with 20 mg/kg SAG (blue), and SmoM2+/-ChAT-cre mice (cyan). Kruskal-Wallis
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nonparametric 1-way ANOVA followed by Dunn’s post-test shows **** P<0.0001 for controls
vs. mutants, or mutants with and without treatment, n.s. indicates P > 0.05. (n = 3-4, 60-100 cells
per n). (C) Scheme showing possible mechanism of Shh signaling counteracting DA inhibition
of CINs that lead to balanced control of SPNs and restored motor output.
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5.2 Genetic ablation of Smo on CINs attenuates p-rpS6240/244 that is not rescued with Smo
agonist
Examining the postsynaptic manipulation of Smo on CIN activity revealed reduced
activity in SmoCIN-/- mice consistent with results from the ligand ablation experiments (Figure
5.2 A, B). Importantly, acute injection of SAG (20 mg/kg) did not restore p-rpS6240/244 levels as
seen in ShhDAN-/- mice (Figure 5.2 A, B, postsynaptic side). This finding established that SAG
acts through Smo on CINs rather than through indirect mechanisms to regulate CIN activity.
Conversely, SmoM2+/- expression in CINs showed similar levels of CIN activity compared to
controls suggesting that baseline levels of Shh signaling results in maximal p-rpS6240/244 levels in
CINs (Figure 5.2 A, B, postsynaptic side).
Additional evidence for the acute regulation of CIN activity by Shh signaling comes from
viral injection of AAV9-eGFP-cre into the DLS of SmoL/L mice (Figure 5.3 A). To eliminate
compensational effects of genetic ablation of Smo on CINs from birth, viral injections allowed
the study of induced ablation of Smo in the adult. This also allowed for a within-subject control,
comparing the contralateral side to the ipsilateral side, as well as, within the ipsilateral side
GFP+ recombined CINs vs. GFP- CINs. A drawback to viral injections is that recombination is
not cell specific for CINs and results could stem from indirect mechanisms. However, consistent
with the genetic ablation findings, p-rpS6240/244 levels were reduced in ipsilateral GFP+ CINs
compared to both controls (Figure 5.3 B, C). The ipsilateral GFP- CINs were slightly reduced
compared to the contralateral side suggesting feedback and crosstalk mechanisms, including
lateral inhibition, between CINs within the ipsilateral side (Figure 5.3 C).
Together, both genetic and viral ablation of Smo on CINs results point to the conclusion
that ShhDAN acting to increase or restore CIN activity by the activation of Smo specifically
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located on CINs and that mechanisms might act to counteract L-Dopa inhibition of CINs that
leads to balanced regulation of both SPN pathways on motor output.
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Figure 5.3: Acute viral ablation of Smo reduces neuronal activity marker p-rpS6240/244 in
CINs validating genetic findings
(A) Schematic of AAV9-Cre GFP viral injection into the DLS. Dotted box represents area
imaged and quantified. (B) Representative high-magnification confocal images of p-rpS6240/244 in
CINs of DLS as a heat map (Scale bar = 10 um). The corresponding smaller image shows ChAT
(red) and Dapi (blue) double stain. Underneath shows the same image with ChAT (red) and viral
induced GFP (cyan) indicating recombination of the SmoL/L allele. Each CIN has its own ROI
and is quantified based on the mean gray value intensity (m.g.v.) per cell of p-rpS6240/244 staining
normalized to NeuN staining, to account for between subject differences, in individual somata. A
16-member pseudocolor palette depicts the intensity of p-rpS6240/244 fluorescence. (C)
Quantification of p-rpS6240/244 intensity of CINs. Each dot represents one neuron, and red lines
indicate the mean ± SEM. The contralateral (contra) CINs (white), ipsilateral (ipsi) cre+ CINs
(red), and ipsilateral cre- CINs (grey) are compared (n = 3, 60 - 80 cells per n). Kruskal-Wallis
nonparametric 1-way ANOVA followed by Dunn’s post-test shows **** P<0.0001 for contra vs.
ipsi, or * P<0.05 for ipsi GFP+ vs. ipsi GFP-, n.s. indicates P > 0.05.
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5.3 ShhDAN regulates number of cortical glutamatergic synapses on CINs
These changes in basal firing rate of CINs, through reduced ShhDAN levels, can reflect
alterations in glutamatergic input and morphology, and, thus, contribute to the formation of
“aberrant learning” observed in LIDs. This “aberrant learning” posits that L-Dopa dosing mimics
“phasic-like” DA release and disrupts normal spike-time dependent plasticity leading to
unwanted strengthening or stripping of random synapses that result in involuntary movements or
dyskinesia (Beeler et al. 2010; Zhai et al. 2018). Consistent with this, there is increased activity
of dSPN, which is associated with an increase in the numbers, and strength of vGluT1 synapses
associated with the development of LIDs. Since CINs of the DLS are thought to be important
regulators of SPNs but also targets of learning related synaptic plasticity (Aoki et al. 2015;
Bradfield et al. 2013; Matamales et al. 2016; Zhang et al. 2013; Zhang et al. 2018), ShhDAN was
tested as a critical component for the glutamatergic synaptic rearrangement of CINs.
CINs in the DLS receive glutamatergic input from the cortex (marked selectively by
expression of the vesicular glutamate transporter 1, vGluT1) and the thalamus (marked
selectively by vGluT2; Figure 5.4 A). The number and size of vGluT1 and vGluT2 boutons on
soma proximal dendrites that are in juxtaposition with a postsynaptic density, recognized by
PSD95 to mark electrically active synapses (Goyal and Chaudhury 2013; Romorini et al. 2004),
was quantified (Figure 5.4 B, C). ShhDAN-/- mice display synapse type, structure, and striatal
domain specific deficits compared to controls. The numbers of vGluT1, but not vGluT2,
terminals on CIN in the DLS were reduced (Figure 5.4 C), and only the smallest class of
vGluT1 boutons were affected (Figure 5.4 D). The number of glutamatergic terminals has been
shown to reflect learning (Cheng et al. 2011) and reduced numbers of these synapses might
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indicate disturbed learning caused by altered glutamatergic drive of striatal CIN in ShhDAN-/mice.
Together, these results suggest a scenario in which the lack of Shh signaling from DA
neurons in disease or during L-Dopa therapy results in disturbed glutamatergic drive of CINs,
which in turn result in reduced CIN activity. These findings begin to give potential insight into
the underlying cause of aberrant CIN activity in LIDs by ShhDAN acting as a dynamic modulator
of glutamatergic synapses.
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Figure 5.4: Lack of ShhDAN reduces number of cortical synapses on CINs in the DLS
(A) Cortical (vGluT1: blue) and thalamic (vGluT2: magenta) input into the striatum can be
distinguished by their respective glutamate transporter isoforms. Synapses were analyzed in the
DLS and DMS (boxes). (B) Confocal images (Z-stack 20 µm thick at 63x; scale bar = 20 µm) of
vGluT1 (blue) labeled terminals on CIN soma and primary dendrites (ChAT, green) adjacent to
PSD95 (red, white arrows) for ShhDAN+/+ and ShhDAN-/- mice. Bottom images show enlargement
of white dotted box in overview above (scale bar = 5 µm). (C) Quantification of number of
vGlut1 and vGlut2 synapses on CINs with juxtaposition of postsynaptic density marked by
PSD95, revealing a deficit of cortical synapses in ShhDAN-/- mice compared to ShhDAN+/+ mice
(n = 4, 6 CINs per each area, 120 – 165 synapses per 90 µm x 90 µm area). Unpaired 2-tailed
student’s t test ** P<0.01, for mutant vs. control. n.s. indicates P > 0.05. (D) Size histograms of
vGlut1 boutons adjacent to PSD95 reactivity in CIN of the DLS and DMS striatum of ShhDA+/+
and ShhDAN-/- mice (n= 4, 6 CINs per each, 120 – 165 synapses per 90 µm x 90 µm area).
Unpaired 2-tailed student’s t test * P<0.05. vGluT2 analysis not shown. All graphs plotted as
mean +/- SEM (Bar graphs: red lines; Line graphs: shaded area).
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6. Chapter 6: Long-term optical stimulation of DAN result in LID-like
motor activity that is rescued with Smo activation
6.1 Prolonged stimulation of DAN increase rotation number that is blocked by Smo activation
High frequency stimulation of hippocampal neurons elicits Shh release (Su et al. 2017).
Guided by these studies we expressed Dat-Cre dependent channelrhodopsin (ChR2) selectively
in mesencephalic DA neurons of the ventral lateral midbrain and implanted an optical fiber
terminating above the SNpc (Figure 6.1 A). Selective ChR2-eYFP expression in TH positive
DA neurons was confirmed by postmortem analysis (Figure 6.1 B). TH fiber density in the
striatum was not altered by ChR2 expression and/or 20 days of daily 1-hour optical stimulation
sessions (Figure 6.1 C). Interestingly, unilateral high frequency stimulation (20mW/473nm; 5s
of 60hz 10ms pulses) evoked contralateral rotations that were time-locked with stimulation
(Figure 6.1 D). Intensity of rotational activity was increased in a linear fashion during one-hour
long stimulation sessions when comparing the first 10 minutes to the last 10 minutes.
A gradual escalation of the intensity of the locomotion response is commonly observed
upon injection of dopaminergic psychostimulants, DA agonists and L-Dopa and is thought to be
caused by behavioral “priming” or progressive sensitization towards repeated dopaminergic
signaling. Since we propose that ShhDAN signaling counteracts DA inhibition on CINs, we tested
whether dynamic changes in ShhDAN signaling, with Shh levels exhausted by the end of the hour,
could contribute to the gradual increase in rotational response to unilateral photostimulation of
DA neurons. Consistent with greater Shh signaling at the beginning and diminished Shh
signaling at the end of photostimulation, we find that blocking Shh signaling by injection of the
Smo inhibitor cyclopamine (5 mg/kg) elicited a maximal rotational response immediately at the
beginning of stimulation rather than only after one hour as seen in controls (Figure 6.2 A).
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Injection of cyclopamine did not alter locomotion by itself in absence of stimulation (Figure 6.2
B) suggesting that the activation of ShhDAN/Smo becomes relevant only upon concomitant DA
signaling. This data points to the possibility that cylcopamine further decreases CIN activity and
increases rotation to a similar degree during the first 10 mins as the last 10 mins in controls
(Figure 6.2 C). Conversely, activating Shh signaling by injection of the Smo agonist SAG (20
mg/kg) blocked the gradual increase in rotational behavior seen in controls (Figure 6.2 D). SAG
did not alter locomotor behavior during baseline before stimulation similar to cyclopamine
(Figure 6.2 E). This data points to SAG enhancement of CIN activity throughout the one-hour
stimulation resulting in increased control from CINs on DA-induced rotational output (Figure
6.2 F).
Together, these observations suggest that the gradual increase in locomotion is caused by
progressively diminished Smo activation during the one-hour stimulation sessions. A
parsimonious explanation for gradually reduced Smo activity in this paradigm is the possibility
that releasable ShhDAN stores exhaust in the course of forced DA neuron stimulation which in
turn would result in the progressive relief of repression of locomotion by progressively reduced
CIN activity. Thus, forced DA neuron stimulation might produce over time a situation of
reduced ShhDAN signaling relative to DA signaling onto CIN, which, in the the 6-OHDA lesioned
animals, the AK-/- mice, ShhDAN-/- mice, and, SmoCIN-/- mice facilitate LID formation and
expression.
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Figure 6.1: Optical stimulation of DA neurons increases rotation in a time dependent
manner
(A) Construct and experimental design showing injection of Cre dependent AAV5 expressing
ChR2-eYFP fusion protein in Dat-Cre mice into the SNpc. Photostimulation of the SNpc DA
neurons lasted one-hour using a 473 nM laser for 5 seconds every 30 seconds. (B) Colocalization of ChR2 (green- viral induced eYFP) with TH (red) in the SNpc. (C) Represented
images (left) and quantification (right) showing that both unilateral expression of ChR2 and
prolonged stimulation does not alter TH fiber density in the ipsilateral striatum compared to the
contralateral hemisphere (n = 8; n.s. indicates P > 0.05). (D) Quantification of contralateral
rotations during periods of DA neuron stimulation (blue ticks) and non-stimulation in the first
and last 10 minutes of one-hour period (n = 8). RM 2-way ANOVA stimulation: F (1,7) = 67.33
p<0.0001. Post hoc Bonferroni’s test: * P<0.05, ** P<0.01 for stimulation vs. non-stimulation;
time: F (1,7) = 22.56 p=0.002. Post hoc Bonferroni’s test: *** P<0.001 for 0 - 10 vs. 50 - 60
minute time points. All bar graphs plotted as mean +/- SEM.
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Figure 6.2: Reduced ShhDAN augments rotational behavior in optical stimulation of DA
neurons
(A) Number of contralateral rotations during stimulation in 10-minute bins over the course of
one-hour of stimulation in animals injected with vehicle or 5 mg/kg cyclo (n = 5). RM 2-way
ANOVA treatment effect: F (1,8) = 7.40 p=0.026. Post hoc Bonferroni’s test: ** P<0.01 for
vehicle vs. cyclo; time effect: F (4,32) = 5.69 p=0.001. Post hoc Bonferroni’s test: *** P<0.001 for
vehicle 10-20 vs. 50-60. n.s. indicates P > 0.05. (B) Baseline locomotion shows no change
between mice treated with vehicle or 5 mg/kg cyclo in open field arena during the 10 minutes
before optogenetic stimulation (n = 7). (C) Potential scheme suggesting cyclo action on ShhDAN
signaling by inhibiting CINs and promoting the dSPN pathway to increase rotation. (D)
Contralateral rotations over one-hour following vehicle or 20 mg/kg SAG (n = 7). RM 2-way
ANOVA time effect: F (4,44) = 6.96 p=0.0002. Post hoc Bonferroni’s test: ** P<0.01 for vehicle
10 - 20 vs. 50 - 60. n.s. indicates P > 0.05. (E) Baseline locomotion shows no change between
mice treated with vehicle or 20 mg/kg SAG in open field arena during the 10 minutes before
optogenetic stimulation (n = 7). (F) Possible schematic suggesting SAG actions on ShhDAN
signaling to increase CIN activity and restore balance of the SPN pathways on motor output. All
bar graphs plotted as mean +/- SEM.
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6.2 Long-term DA neuron stimulation produce AIM-like behavior that is reduced by Smo
agonist
Next, we tested whether long duration optogenetic stimulation would lead to LID-like
dyskinesia. To this end, LID-like movements were identified and quantified during 10-minute
time bins following the one-hour forced stimulation sessions (Figure 6.3 A). As described
earlier for scoring LID in the unilateral 6-OHDA model, stereotypical and contra-lateral
rotations, axial, limb, and orofacial movements were measured. Remarkably, the first hour of
pulsatile, forced stimulation induced LID-like rotational, axial and contra-lateral AIMs timelocked with stimulation in the last 10 minutes, but not in the first 10 minutes (Figure 6.3 B).
Because of the qualitative and quantitative similarity to the motor activity observed in the
unilateral 6-OHDA paradigm, this behavior was termed optogenetic-induced dyskinesia (OID).
Daily repeated one hour stimulation sessions resulted in an escalation of the OID response: on
day 9 mice exhibited (1) orofacial (tongue protrusions) movements in addition to abnormal axial
and limb movements observed on day 1 and (2) AIM-like behavior was noted during the first 10
minutes of the stimulation; this behavior further increased gradually during the remainder of the
session (Figure 6.3 B). OID on day 9 was of greater intensity compared to the OID seen during
the last 10 minutes of the stimulation session on day 1, indicating that repeated stimulation leads
to progressive and long lasting sensitization to forced firing.
If OID would emerge due to gradual exhaustion of ShhDAN then postsynaptic activation
of Smo signaling during the one-hour stimulation should be attenuated OID. Saline injection 15
min prior to forced stimulation on day 10 did not alter the display and profile of OID compared
to day 9 (Figure 6.3 C). On day 11, animals were injected with SAG (20 mg/kg) 15 min before
stimulation. As observed before, AIM-like behavior time-locked with forced stimulation (Figure
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6.3 C). Remarkably, SAG treatment led to a significant attenuation of AIMs during the first and
last 10 minutes compared to day 10 (Figure 6.3 C). The greatest reduction of AIM-like activity
is among abnormal axial- (twisting of the body, red sections of the bars in Figure 6.3 B, C, D),
abnormal limb- (green sections of bars in Figure 6.3 B) and orofacial- movements (yellow
sections of bars in Figure 6.3 B). Rotational behavior (blue sections of bars in Figure 6.3 B) was
not significantly reduced by SAG. OID was also scored on a timescale, quantifying the total
duration of time an animal spent displaying AIM-like behaviors and shows a highly similar
stimulation dependent display of AIMs (data not shown) compared to the more specific AIM
scale scoring (Figure 6.3 B, C). These results show that forced firing of DA neurons results in
progressive AIM-like activity within minutes of onset of pulsatile stimulation that escalate in
magnitude by repeated daily session that can be attenuated partially by concomitant Smo
activation.
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Figure 6.3: Long-term optical stimulation of DA neurons results in LID-like behavior
(A) Experimental paradigm for Opto-induced dyskinesia (OID). (B) OIDs mimicked AIM-like
behavior and were scored as such during the first 10 and last 10 mins for day 1 and 9 (n = 8).
AIM scores were quantified during off stimulation and on stimulation (blue ticks) and broken
down into rotation (blue), axial (red), limb (green), and orofacial (yellow) under the same criteria
as 6-OHDA AIM scoring. RM 3-way ANOVA stimulation effect: F (1,14) = 56.11 p<0.0001. Post
hoc Bonferroni’s test: **** P<0.0001 for stimulation vs. non-stimulation; day x stimulation
effect: F (1,14) = 15.6 p=0.002. Post hoc Bonferroni’s test: ** P<0.01 for stimulation during d1 vs.
d9 at 50-60, *** P<0.001 for stimulation during d1 vs. d9 at 0-10. (C) AIM scores following day
10: saline (n = 6) and day 11: SAG (20 mg/kg; n = 6). RM 3-way ANOVA stimulation effect: F
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= 124.2 p<0.0001. Post hoc Bonferroni’s test: **** P<0.0001 for d10 stimulation vs. nonstimulation, * P<0.05, *** P<0.001 for d11 stimulation vs. non-stimulation; day x stimulation
effect: F (1,12) = 13.56 p=0.003. Post hoc Bonferroni’s test: ** P<0.01 for stimulation d10 vs. d11.
(D) Video still image of mouse posture during stimulation showing axial AIM on day 10 and
non-axial on day 11 following SAG treatment. (E) Immuno-strain of c-Fos (red) expression in
the stimulated vs. non-stimulated DLS in saline and 20 mg/kg SAG treated animals (Scale bar=
50 um). (F) Quantification of c-Fos+ cells (red). RM 2-way ANOVA treatment effect: F (1,27) =
41.41 p<0.0001. Post hoc Bonferroni’s test: **** P<0.0001 for saline treated group stimulation
d10 vs. SAG treated group stimulation d11; stimulation effect: F (1,27) = 114.3 p<0.0001. Post hoc
Bonferroni’s test: *** P<0.001, **** P<0.0001 for stimulation vs. non-stimulation for d10 and
d11 (saline: n = 2, SAG: n = 6 ~445 cells per 700 um x 700 um area). (G) Images and (H)
quantification of CIN soma mean p-rpS6240/244 gray intensity normalized to NeuN in the DLS
following one-hour stimulation on day 10 (saline n = 2, 80-100 cells per each) or day 11 (SAG n
= 6, 40-60 cells per each). Each dot represents one neuron and mean/SEM indicated by red line.
Paired 2-tailed Student’s t test ** P<0.01 for stim- vs. unstim- side, ****P<0.0001 for saline vs.
SAG. n.s. indicates P > 0.05. All bar graphs plotted as mean +/- SEM.
(1,12)
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6.3 Prolonged stimulation of DAN increases c-Fos activation and reduces p-rpS6 in CINs
As shown before, c-Fos expression is induced by L-Dopa and optogenetic inhibition of
neuronal assembles in the hypo-dopaminergic striatum that expressed c-Fos in response to a
previous dose of L-Dopa blocks LID (Girasole et al. 2018). Consistent, we find increased
numbers of c-Fos expressing cells in the stimulation ipsilateral striatum compared to the
contralateral striatum in the vehicle group (Figure 6.3 E, F). Importantly, we find that SAG
decreased the total number of c-Fos activated cells in the stimulated striatum when given 15
minutes prior to onset of pulsatile stimulation (Figure 6.3 E, F).
The attenuation of LID-like behavior in response to Smo activation is correlated with an
increase in p-rpS6240/244 expression in CIN of the DLS in the ShhDAN-/- paradigm (Figure 4.2 A,
B). Consistent with the inhibition of CINs in response to optogenetic stimulation of DA neurons,
there is decreased p-rpS6240/244 reactivity in CIN of the stimulation ipsilateral DLS compared to
the contralateral unstimulated control side (Figure 6.3 G, H). Stimulation in the presence of
SAG restores p-rpS6240/244 levels in CINs of the stimulated DLS compared to saline treated
controls (Figure 6.3 G, H).
Together, these experiments indicate that prolonged firing of DA neurons results in
reduced ShhDAN/Smo signaling, dampening CIN activity, and causing LID-like motor activity
within minutes, which then further intensifies in response to daily stimulation sessions.
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7. Chapter 7: Part I Discussion
The findings described here point to diminished ShhDAN being one critical factor in LID.
Reduced ShhDAN levels and/or diminished Shh signaling relative to DA levels facilitate while
increased Shh signaling attenuates LID formation and expression suggesting a novel therapeutic
approach for the treatment and avoidance of LID in PD patients. These findings support the idea
that Shh/Smo signaling are key mediator of CIN function in the DLS. There are three important
points that these studies strongly suggest: (1) Shh, along with DA, must be considered to be a
physical component of CIN modulation that emanates from DA neurons, (2) the relative balance
of DA and ShhDAN signaling is a critical determinant of CIN activity, and (3) Smo pharmacology
can normalize PD related dysfunction of CIN upstream of ACh signaling.

7.1 Deficits in ShhDAN/Smo signaling onto DLS CIN is critical in causing LIDs
A fundamental unresolved issue in understanding the mechanisms leading to the
appearance and expression of LID is whether and how this phenomenon is related to the
underlying pathology of PD, namely DA neuron degeneration (Borgkvist et al. 2018). We tested
the possibility that reduced ShhDAN/Smo signaling could be a significant cause of LID formation
and expression as: (1) progressive DA neuron degeneration must lead to reduced ShhDAN in
addition to the loss of DA in the brain, and (2) DA substitution therapy without augmenting
Shh/Smo signaling must result in a distortion of the relative strength of Shh and DA signaling.
Consistent with these expectations we found that reducing Shh/Smo signaling in any of four
ways – (1) inhibiting Smo by the antagonist Cyclopamine in either the AK-/- or the 6-OHDA
model of LID, (2) ablating Shh from DA neurons, (3) ablating Smo from CINs, and (4)
exhausting DA neuron of stored Shh via optogenetic stimulation of DA neurons- facilitated or
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increased LID or LID-like OID. Conversely, boosting Smo signaling with two different and
selective agonists, SAG or Purmorphamine, attenuated established LID or LID-like OID in (1)
6-OHDA mice, (2) AK-/- mice, (3) L-Dopa treated parkinsonian Macaques, (4) ShhDAN-/- mice,
(5) SmoCIN-/- mice, and (6) mice with exhausted Shh stores in DA neurons. Consistent and
remarkable, the conditional genetic expression of the constitutively active form of SmoM2 in
CINs in the AK-/- animal background, which is prone to produce LIDs, creates LID-resistant
mice. The acute or long-term systemic dosing with Smo agonists did not curtail the
symptomatic benefit of L-Dopa treatment. While the attenuation of LID by Smo agonists in the
mouse paradigms was almost complete, the anti-dyskinetic effect in the primate model was
modest. However, the temporal profile of drug action suggests that matching the
pharmacokinetics of Smo agonist with that of L-Dopa could result in enhanced attenuation of
LID in primates as well.
There is overwhelming evidence that implicates altered physiology and neuronal activity
of CINs in DLS in LID in PD models. For example, (1) repeated dosing with L-Dopa, and
correlation with progressively increased LID expression, results in increased pErk1/2
prevalence in CIN of the DL striatum (Ding et al. 2011), (2) boosting ACh signaling mediated
by the muscarinic ACh receptor, M4 (Shen et al. 2015) and, (3) long duration, optogenetic
stimulation of CIN ameliorates LID (Bordia et al. 2016). Consistent with these reports and
mirroring the behavior in the 6-OHDA, AK-/-, ShhDAN-/-, and SmoCIN-/- paradigms we found that
ablation of Shh from DA neurons or the ablation of Smo in CINs resulted in dampened neuronal
activity of CIN, and an increase in the prevalence of CIN with detectable pErk1/2 in the DLS
but not the DMS. Conversely, stimulation of Smo resulted in increased CIN activity, which was
not observed when the Smo receptor is ablated from CINs, and a decrease in the numbers of
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CIN with pErk1/2 expression selectively in the DLS. It is noteworthy that mice with OID do not
display increased pErk1/2 despite their CINs showing reduction in CIN neuronal activity. While
pErk1/2 is a well-established marker for DA hypersensitivity in the striatum (Gerfen et al. 2002)
our observations suggest that DA hypersensitivity is not sufficient for LID development per se.
Consistent, there was no evidence that mice with OID develop DA hypersensitivity in contrast
to 6-OHDA, AK-/-, ShhDAN-/- , and SmoCIN-/- mice. This observation might be explained by a
physiological stress response in CINs correlating to MAP-kinase activation due to L-Dopa
therapy that is alleviated with Shh signaling (Dai et al. 2012; Darling and Cook 2014; Zhang
and Liu 2002).
Among all the DA neuron projection targets and constituent neuronal subtypes of the
striatum, only CIN and FS neurons express detectable levels of the Shh receptor Ptc-1
(Gonzalez-Reyes et al. 2012) suggesting that modulation of neuronal activity and MAP Kinase
activity in CIN by Shh signaling is direct. In 6-OHDA, AK-/-, ShhDAN-/-, and SmoCIN-/- mice, we
find that those CINs that express pErk1/2 in mice displaying LIDs reside in the striatal domain
of greatest density of Shh carrying neuropil. These observations reveal a remarkable overlap of
the cytohistological and neurochemical pathology in PD and LID with patterned Shh signaling
in the striatum that selectively effects CINs.
How could ShhDAN/Smo effects on CIN be connected to LID relevant plasticity of
striatal output neurons? A critical feature of LID pathophysiology is the aberrant DA dependent
LTP of glutamatergic synapses on dSPN (Zhai et al. 2018). It was found that ACh signaling via
M4 mAChR can counteract DA dependent LTP and instead promote LTD of glutamatergic
synapses in dSPN (Shen et al. 2015). Consistent, boosting M4 mAChR signaling with positive
allosteric modulators (PAM) alleviates LID (Shen et al. 2015). We find that the facilitation of
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LID in response to the Smo inhibitor, cyclopamine, was normalized by co-injection of the
M4PAM (VU0467154). Thus, the LID promoting reduction of CIN activity by diminished
ShhDAN signaling can lead to reduced M4 mAChR signaling. This reduced M4 activity leads to
diminished LTD of glutamatergic synapses on dSPN. Hence, our experiments provide a novel
and unexpected mechanism by which DA neuron degeneration can underlie aberrant
glutamatergic synapse plasticity on dSPNs through diminished ShhDAN signaling on CINs.

7.2 ShhDAN counter DA-mediated inhibition of CIN residing in the DLS by multiple mechanisms
A central and persistent question in understanding basal ganglia function in the control
and PD brain is how dopaminergic signaling controls CIN function (Barbeau 1962; Zhang and
Cragg 2017). DA blunts ACh release from CIN through (1) Gαi coupled D2 receptors and
GABA signaling promoting D5 receptors (Yan et al. 1997; Yan and Surmeier 1997) and by (2)
eliciting excitatory withdrawal by modulating GABAergic and glutamatergic input onto CIN by
presynaptic mechanisms (Zhang et al. 2018). In turn, ACh release, acting via nicotinic
receptors present in DA nerve terminals, facilitates DA release (Threlfell et al. 2012). While the
rapid desensitization of nicotinic receptors (Giniatullin et al. 2005) and the induction of LTP of
glutamatergic synapses onto CIN by DR5 signaling (Oswald et al. 2015) might reduce the DA
mediated inhibition on CIN, together these mechanisms seem to provide inescapable negative
control of CIN by DA. In contrast, how CIN activity recovers from DA induced “pauses” of
firing is not well understood. Interestingly, previous studies implicate DA and glutamate in the
recovery, or “rebound”, of CIN activity after a DA induced pause, by optogenetic stimulation of
dopaminergic afferents in vivo (Chuhma et al. 2018; Straub et al. 2014). It is tempting to
speculate that another unidentified signaling factor might be ShhDAN, since the present findings
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suggest that ShhDAN is released by burst firing of DA neurons and that ShhDAN increases
cholinergic activity marker p-rpS6240/244 and normalizes L-Dopa induced dampening of CIN
activity (Figure 7.1 A, B). How then could ShhDAN curtail DA driven inhibition of CIN?
The present studies offer several mechanistic insights: First, in all of these paradigms the
acute effect of Smo -agonist or -antagonist treatment is only seen upon activation of DA
signaling. This suggests that Smo signaling must impinge on a component of D2/D5 receptor
signaling after pathway activation by DA. Shh signaling activates the GPCR Smo by inhibiting
the transmembrane transporter Ptc-1 whose unidentified cargo blocks Smo from coupling to the
G-proteins Gαi or Rho, and/or from activating the Gli class of transcription factors (Riobo et al.
2006) Second, ShhDAN/Smo signaling is likely to act in a stoichiometric manner on the D2/D5
receptor pathways since the half maximal effective dose of the Smo agonist that counteract LID,
is dose-dependent with the L-Dopa dose used to induce LID. Interestingly, both, D2R and Smo
couple to Gαi. Coupling to the same signaling effector could provides a mechanism by which
delayed activation of Smo by ShhDAN relative to D2R activation by DA could terminate DA
signaling by recruiting limited pools of Gαi away from D2Rs by activated Smo. Third, the
ablation of Shh from DA neurons causes a profound loss of small glutamatergic synapses that
originate from the cortex on CIN and provide excitatory input to CINs. Since DA can also
inhibit CIN through presynaptic processes that block glutamatergic drive (Zhang et al. 2018),
these findings leave open the possibility that ShhDAN could counteract the DA-induced
inhibition of CIN by stabilizing glutamatergic synapses on CIN long term.
On first sight, these data and the finding that boosting muscarinic (Shen et al. 2016) or
nicotinic signaling can ameliorate LIDs (Bordia et al. 2016) are at direct odds with the wellestablished increase in cholinergic tone compared to dopaminergic tone in PD (Barbeau 1962;
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McGeer et al. 1961; McKinley et al. 2019). Why does the elevated cholinergic tone of the PD
brain not protect from LID? Recent findings demonstrate that DAN degeneration leads to an
absolute reduction of both, DA and ACh (McKinley et al. 2019) a result also consistent with the
earlier finding that ShhDAN-/- mice reveal CIN degeneration and a profound reduction in
cholinergic tone (Gonzalez-Reyes et al. 2012). Hence, there appear three possibilities why the
relative increase in ACh tone in the PD brain does not protect from LID: (1) Some modes of
cholinergic signaling may facilitate LID. In support, brief pulses of muscarinic mediated
cholinergic signaling increases LID (Bordia et al. 2016) and the ablation of CIN reduces LID
(Won et al. 2014). (2) L-Dopa dosing shifts the balance of ACh and DA towards higher DA
than ACh. (3) ACh levels only protect from LID if they are at or above normal levels. My
studies support the latter possibility and, importantly, offer an un-anticipated, additional but
critical mechanism by which DA and ACh homeostasis is maintained in the striatum: First,
acute ShhDAN/Smo signaling counteracts DA signaling mediated inhibition of CIN but does not
alter CIN activity independent of DA. Thus, ShhDAN-/- mice, exhibit reduced cholinergic tone
(Gonzalez-Reyes et al. 2012). Second, if the mechanism of action of ShhDAN/Smo signaling in
CIN is dependent on activated DA effectors as discussed above, then the reduced levels of DA
signaling in the PD brain will make the concomitant diminished ShhDAN irrelevant. Thus, the
net effect of DA neuron degeneration is a relief of repression from DA leading to a rise in ACh.
Third, diminished levels of ShhDAN/Smo signaling become relevant upon L-Dopa dependent
activation of D2/D5R signaling that will provide a substrate through which ShhDAN/Smo
signaling can interfere with DA signaling dependent inhibition of CIN. In essence my data is
compatible with the idea that Shh signaling only effect CINs that are concomitantly exposed to
DA, which could explain both the relative increase in ACh tone in the PD brain in the absence
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of ShhDAN, as well as, the inhibition of LID via stimulating CIN activity by counteracting LDopa dependent inhibition of CIN.
Overall, my results suggest the following model by which diminished ShhDAN/Smo
signaling facilitates LIDs. In the normal brain, there is coordinated balance between DA and
Shh signaling on CIN activity. This leads to coordination between DA and ACh levels in the
striatum that is essential for undisturbed behavior (Figure 7.2 A). PD creates a progressive
dampening of DA neuron input. This slow reduction may allow cells to adapt accordingly,
however, long-term loss of DA neurons induce corresponding changes to striatal neurons in this
circuit. In PD, ACh levels fall in parallel to DA levels but not to the same extent, which causes
an imbalance between the ratios of each with ACh above DA (McKinley et al 2019). This
imbalance results in motor impairments. Then L-Dopa therapy floods the system with
uncoupled DA without the administration of Shh signaling to counteract DA-induced inhibition
on CINs (Figure 7.2 B). This enhances striatal DA concentrations and shifts the balance in the
opposite direction resulting in high DA and low ACh. This relative difference between striatal
DA and ACh concentrations determine the degree of LID. There may still be an increase in
ACh levels upon L-Dopa dosing compared to the PD-state, but it is not enough to
counterbalance DA levels (McKinley et al 2019). My present work shows that coadministration of Smo agonist and L-Dopa restores the balance of DA to Shh signaling on CINs
and may do this by counteracting D2R mediated inhibition of CINs (Figure 7.2 C). This
increases striatal ACh concentrations to counterbalance high DA levels and leads to a reduction
in LIDs. In summary, ShhDAN mediates DA neuron control of CIN activity in healthy and in
parkinsonian states. Further, the pharmacological augmentation of ShhDAN/Smo signaling in PD
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patients could ameliorate formation of LID in response to DA substitution therapy by
modulating CIN activity.
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Figure 7.1: Bidirectional effect of Smo on DA-induced inhibition of CIN activity
(A) Potential scheme showing that DA/ L-Dopa activation causes “pause” or decrease in ACh
release of CINs. The lack of Smo activation to counteract this inhibition leads to increased LIDs.
(B) Upon Smo activation, DA-induced inhibition is repressed, which leads to increases ACh
release. This increase in CIN activity decreases LIDs.
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Figure 7.2: Proposed model for Shh signaling mediated attenuation of LIDs
(A) In the normal brain, ShhDAN mediated Smo signaling gates DA mediated D2R signaling with
a bidirectional effect on CIN activity. The balance of DA and Shh signaling on CINs produces
controlled striatal output of ACh and DA concentrations for normal motor output. (B) In the
absence of ShhDAN, L-Dopa enhances D2R mediated inhibition of CINs. L-Dopa therapy alone
creates an imbalance of DA and Shh signaling with high DA and low Shh. This results in striatal
output imbalance of ACh and DA concentrations with more DA than ACh that leads to increased
LIDs. (C) Co-administration of Smo agonist and L-Dopa counteracts D2R mediated inhibition of
CINs, restoring the balance of DA and Shh signaling on CINs. This increases striatal ACh
concentrations to counterbalance high DA levels and leads to a reduction in LIDs.
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Part II: Cortical source of Sonic Hedgehog from
glutamatergic input to the DLS does not reveal the
same phenotype as ShhDAN in LIDs
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8. Chapter 8: Motor cortex source of Shh does not potentiate LID
formation
The cortex is critical for action selection and decision making in motor function.
Glutamatergic input from the cortex molds synaptic strength and is involved in plasticity and
learning. The teaching signaling from the cortico-striatal loop acts on CINs and is involved in
cognitive flexibility through interactions with DA (Bamford and Bamford 2019; Wang et al.
2013). Many cortical nuclei target the striatum to crystalize a planned behavior that demands
constant updating. There are six layers within the cortex that comprise a number of cell types and
are organized in distinctive columns (Boraud et al. 2018). The output of each column allows for
behavioral tuning within motor and cognitive areas. Accordingly, cortical influence over
behavior is another aspect of striatal motor learning that may be dysregulated in PD and LID
states.

8.1 Sonic Hedgehog from cortical neurons communicate with the DLS
The results thus far implicate ShhDAN as an important regulator of neuroplasticity in the
DLS during normal and disease states (Su et al. 2017; Yao et al. 2016; Zhang et al. 2014), but
ShhDAN is only one of several potential sources of striatal Shh. Cortical pyramidal tract (PT)
neurons either express Ptc-1, the Shh signaling receptor, or Shh (ShhPT) itself (Figure 8.1 A).
Specifically, there is a population of Motor cortex (M1/2) PT neurons that project Shh
exclusively to the DLS (Figure 8.1 B – C). Therefore, it posits that ShhPT could represent an
additional source of Shh signaling that contributes to trophic support and neuromodulation of
CINs in the DLS in a similar manner as ShhDAN. It is further hypothesized that the loss of Shh
originating from multiple sources potentiates the severity of LID formation.
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Within the cortex, there seems to be cells that either receive and/or express Shh signaling
(Figure 8.1 A). Examining cortical Ptc-1 mRNA levels, shows expression of positive cells in all
layers of cortex, and Shh-nLacZ expression reveals positive Shh expressing neurons within layer
V. In a more sophisticated analysis, the use of the viral mapping tool AAV9-CAG-FLEXtdTomato into Shh-Cre+ mice was used (Figure 8.1 B, C). Recombination of tdTomato occurs
only in those neurons expressing Shh and can be used to visually map connections between
different brain regions. Here, separate mice were injected at two different sites, one in the DLS
and the other into the M1/2 cortex. The DLS injection revealed distinct connections to the M1/2
cortex, however, the viral spread overlapped with the DMS and cannot be differentiated (Figure
8.1 B). Therefore, the M1/2 cortex injection site was used to determine specific projections to the
striatum (Figure 8.1 C). This injection revealed M1/2 cortical projections specifically to the
DLS and not to the DMS. Together, these mapping experiments uncover direct connections
between Shh expressing neurons in the cortical-striatal pathway, exclusively to the DLS, the area
involved in PD and learning pathologies (Figure 3.3 D).
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Figure 8.1: Glutamatergic neurons from the Motor cortex 1/2 express Shh to the DLS
(A) Scheme of the anatomy of the motor cortex (M1/2: motor cortex 1 and motor cortex 2) in
proximity to the striatum. Images representing the M1/2 cortex showing the Shh receptor Ptc-1
mRNA expression in all layers (left) and Shh-nLacZ expression in layer V (right) of the
glutamatergic pyramidal tract (ShhPT) neurons. (B) Viral injection of AAV9-CAG-FLEXtdTomato into Shh-Cre+ mice uncover recombination of tdTomato in only those neurons
expressing Shh. Injection into the DLS showed direct neuronal connections to the M1/2 cortical
PT neurons. Right: zoomed in image of the M1/2 from the white box. (C) Injection of AAV9CAG-FLEX-tdTomato into the M1/2 cortex of Shh-Cre+ mice revealed Shh carrying projections
only to the DLS and not the DMS. Right top: zoomed in image (top white box) of the tdTomato+
expressing neurons (red) from the M1/2 cortex. Right bottom: zoomed in image (bottom white
box) of the targeted DLS (red) from these tdTomato+ expressing neurons from the M1/2 cortex.
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8.2 ShhPT is upregulated in AK-/- PD mouse model
Shown previously, expression levels of Shh by DA neurons were variable in the
undisturbed brain and were in part regulated by negative feedback from CIN since ShhDAN
expression can be induced 10-fold by physiological cell stress in CINs or axonal injury
(Gonzalez-Reyes et al. 2012). These observations point to the possibility that Shh expression
among multiple sources within the CIN centered connectome could be coordinated by feedback
signals from CIN in such a way that lowered expression by any one particular source is
compensated by other sources. We therefore hypothesized that Shh expression across the CIN
centered connectome is homeostaticially regulated and that CINs act as sensors for ambient
levels of Shh expression.
Therefore, compensatory mechanisms were explored by looking at expression levels of
Shh in the corresponding intact area of AK-/- mice. Since AK-/- mice have loss of the nigrostriatal
pathway and thus, have reduced ShhDAN input, Shh levels were examined in the intact cortical
area using rt-PCR. All measures indicate comparable levels in AK-/- mice compared to AK+/mice for midbrain SNpc, cortex, and Amygdala (Figure 8.2 A). Shh expression levels were
slightly upregulated in SNpc and cortex compared to AK+/- controls. The increase in Shh
expression in the SNpc, despite the loss of the nigrostriatal projection, can be from compensation
of the intact VTA DA neuron and/or the lack of negative feedback loop results in the increase of
surviving Shh+ neurons in the SNpc (Figure 8.2 B). This increase of Shh expression in the SNpc
is consistent with previous findings in 6-OHDA lesioned mice, AF64a (toxin for CINs) injected
mice, and ShhDAN-/- mice (Gonzalez-Reyes et al. 2012). These results point to the key players
involved in the feedback loop between DA neurons and CINs, because ablation of either DA
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neurons, CINs, or ShhDAN causes dysregulation of this loop. The results here suggests that ShhPT
also plays a role and there is crosstalk between the two circuits.
Shh levels in the amygdala was measured as a control because this area is Shh+ but is
outside of the nigrostriatal and corticostriatal circuit. Consistent, there was no change in Shh
expression levels in the amygdala from AK-/- mice compared to controls (Figure 8.2 A).
Quantification of TH expression levels showed extensive reduction in the SNpc because this is
the area of DA loss in the AK-/- mice. Together, these findings point to a potential compensatory
mechanism and indicates some cross talk between the two converging sources of striatal Shh.
When one source is lost, the other source may increases expression to compensate. Therefore, if
these sources communicate to each other, then the loss of both sources should enhance the
display and expression of LIDs.
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Figure 8.2: ShhPT is upregulated following loss of SNpc DA neuron connections
(A) Fold change of gene expression for either Shh (left- SNpc, Cortex, or Amygdala) or TH
(right- SNpc) of AK-/- mice compared to AK+/- controls (n = 10). Shh levels from the amygdala
and TH levels from the SNpc was used as within subject controls. Unpaired 2-tailed nonparametric Mann-Whitney test ** P<0.01, **** P<0.0001, for AK-/- vs. AK+/- mice. n.s. indicates
P > 0.05. Bar graph plotted as mean +/- SEM. (B) Scheme depicting the loss of ShhDAN source
leads to the upregulation of ShhPT expression, indicating crosstalk between the two sources. Shh
increase in the SNpc could be due to VTA DA neuron compensation and/or loss of the negative
feedback loop from CINs.
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8.3 Viral ablation of Sonic Hedgehog from motor cortical PT neurons does not alter LIDs
To test for the role of ShhPT in LID development, Shh was ablated from the Motor cortex
(M1/2) using the AAV5-eGFP-Cre virus of AK-/-; ShhL/L mice (Figure 8.3 A- B). The Motor
cortex was targeted because of the direct projections to the DLS (Figure 8.1 C), its involvement
in the expression of behaviors, and this area is the major interface between the CNS and the
musculoskeletal system (Alexander and Crutcher 1990). Animals were injected twice bilaterally
to infect both M1 and M2 cortexes. GFP labeling showed viral infection in the M1/2. Control
mice received AAV5-eGFP virus to account for viral infection. Mice were rested for 4 weeks to
allow for appropriate recombination and then dosed daily with 25 mg/kg L-Dopa (Figure 8.3 C).
There was no change in AIMs between Cre+ or Cre- virally injected animals for day 1, 4, and 11
(Figure 8.3 D). These results point to Shh from M1/2 not being involved in the development of
LIDs. However, some limitations for this experiment include the differences between viral
spread and infection between animals. The varying loss of ShhPT in the M1/2 could account for
the lack of difference in LID development. Alternatively, these results point to the M1/2 not
being involved in LID but may point to involvement of other cortical areas besides the motor
cortex, such as the Orbito-frontal cortex (OFC), the Prefrontal cortex (PFC), or the anterior
Cingular cortex (ACC). Additional experiments are needed, either injection of AAV5-eGFP-Cre
into these other cortical areas or the use of ShhL/L Emx-Cre (ShhPT-/-) mice, which have loss of
Shh from all cortical PT neurons. These mice will not have the issue of viral spread and would
be an ideal option to look at all ShhPT expressing neurons to the DLS.
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Figure 8.3: Shh ablation from the motor cortex has no effect on LIDs
(A) Scheme of AAV5-eGFP-Cre injection into motor cortex 1 and motor cortex 2 (M1/2). (B)
Representative images showing viral infection (green) into the M1/2 cortex. Left: 10x tile scan.
Right: zoomed in image of white box. (C) Timeline of chronic 25 mg/kg L-Dopa dosing 4 weeks
after viral injection of either Cre+ or Cre- virus for 11 consecutive days of AK-/-; ShhL/L mice. (D)
AIM analysis showing no difference between Cre+ and control injected mice at day 1, 4, or 11
following daily dosing with L-Dopa. n.s. indicates P > 0.05. Bar graph plotted as mean +/- SEM.
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8.4 ShhPT ablation does not attenuate CIN survival rate
Previous findings showed a 50% loss of total number of CINs in the DLS when Shh is
ablated from DA neurons (Gonzalez-Reyes et al. 2012). Therefore, both ShhDAN and ShhPT
sources may contribute 50% of Shh input each to the striatum and/or there may be two neuron
populations that are sensitive to the different sources of Shh. To explore if ShhPT communicates
to CINs in the same fashion as ShhDAN does, CINs of ShhPT-/- mice were assessed to see if ShhPT
impinges on their survival rate. However, there was no difference in CIN numbers (ChAT+ cells)
of ShhPT-/- mice compared to controls at 2 months of age (Figure 8.4 A, B). Older mice (15
months) did not reveal any differences as well. These findings suggest that ShhPT is not
necessary for the survival of CINs as seen with ShhDAN. The lack of increase in LIDs of M1/2
Shh ablated mice and the lack of change in CIN survival rate indicates that ShhPT is not critical
for the development of LID, and instead, lends greater impact to the importance of the ShhDAN
source in LIDs.
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Figure 8.4: ShhPT has no effect on CIN survival rate
(A) Images of CINs (ChAT: black) in the DLS following ablation of Shh from PT neurons
(ShhPT-/- mice) and controls (ShhPT+/- mice) at 15 months of age. Dotted box represents DLS
area where CINs were counted. (B) Quantification of CIN number in the DLS of either 2 month
or 15 month old ShhPT-/- mice compared to controls (n= 2 – 4; Six striatal areas were counted for
each that spanned the anterior-posterior striatum).
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8.5 ShhPT ablation increases CIN activity and may target FSN
To determine if ShhPT alters CIN activity, p-rpS6240/244 levels were assessed in ShhPT-/mice. Unexpectedly, there was an increase in p-rpS6240/244 levels in CINs of ShhPT-/- mice
compared to controls (Figure 8.5 A - B). This result is the opposite of findings seen in ShhDAN-/mice in CINs. Therefore, it posits that ShhPT does not act directly on CINs and explains why
there is no reduction in CIN survival rate when ShhPT is ablated. ShhPT can potentially be
released to specific neurons within the DLS that act to inhibit CINs resulting in their increase in
activity when ShhPT is ablated. Thus, perhaps ShhPT input acts on the other Ptc-1+ neurons in the
DLS, FSNs, which have been known to regulate SPN activity and may indirectly, through lateral
inhibition, alter CINs (Klug et al. 2018; Koós and Tepper 2002; O'Hare et al. 2017; Owen et al.
2018). The crosstalk between CINs and FSN could explain this increase in CIN p-rpS6240/244
levels if ShhPT-/- mice have reduced FSN activity (Figure 8.5 C). Additional experiments are
needed to examine the survival rate and activity levels of FSN in ShhPT-/- mice. This finding
suggests the possibility that ShhDAN target CINs while ShhPT target FSN, and are important for
their survival and maintenance, respectively.
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Figure 8.5: Lack of ShhPT increases CIN activity and may potentially regulate FSNs
(A) Heat map images and (B) quantification of CIN soma mean p-rpS6240/244 gray intensity
normalized to NeuN in the ShhPT-/- mice and controls (saline n = 2 - 4, 80-100 cells per each).
Each dot represents one neuron and mean/SEM is represented as red line. Unpaired 2-tailed
Student’s t test ****P<0.0001 for mutant vs. control. (C) Scheme of potential distribution of Shh
source: ShhDAN projecting Shh to CINs and ShhPT projecting Shh to FSN, the other Ptc-1+
neurons, in the DLS (left). Then when ShhPT is ablated FSN inhibition of CIN is disrupted
(right).
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9. Chapter 9: Part II Discussion
Considering the evidence that ShhDAN is critical to avoid LIDs, other sources of Shh
might be necessary as well. However, when looking at ShhPT or more specifically ShhPT from the
Motor cortical areas M1/2, the evidence does not suggest a role from this source in CIN survival
or in the development of LIDs. These findings point even more to the importance of ShhDAN and
that not all sources of Shh play a role in CIN maintenance and LID formation.
Although ShhPT directly communicates with DLS and ShhPT increases Shh expression
levels when the nigrostriatal ShhDAN source is lost, there does not seem to be a direct role of the
Motor cortex in LID development. One possible explanation may be due to the possibility that
LIDs are habitual-aberrantly learned behaviors, and habitual behaviors are thought to reflect a
switch from cortical controlled behavior to automated subcortical control (Boraud et al. 2018;
Wilkinson et al. 2009). Thus, ShhPT from the cortex may not participate in the automated process
of LIDs. However, the possibility of the involvement of other areas of the cortex in LID
formation cannot be ruled out, since all areas express Shh and ShhPT might regulate FSNs.
Indeed, there is emerging evidence showing the involvement of FSN in LIDs (Alberico et al.
2017; Girasole et al. 2018; Gittis et al. 2011). Therefore, investigating LID development in
ShhPT-/- mice with 6-OHDA lesion would be the next logical step. ShhPT-/- mice have ablation of
Shh in all cortical areas. The indirectly and opposite regulation of CIN activity from ShhPT,
showing an increase in activity when ShhPT is ablated, demonstrates the complexity of this
system and perhaps may dysregulate both CINs and FSN when both Shh sources are ablated.
Furthermore, ShhPT does not play a role in the survival of CINs and does not dampen
CIN activity, suggesting that ShhPT does not modulate CINs directly, as seen with ShhDAN. The
above evidence shows the importance of ShhDAN instead of ShhPT because: (1) acute
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cyclopamine in PD mouse models would exacerbate LIDs, (2) there would be increased LIDs in
SmoCIN-/- mice (receptor ablation on CINs removing all potential sources) compared to ShhDAN-/mice (ligand ablation from one source), and (3) there would be a loss of 50% CINs in ShhPT-/mice. Moreover, the pathology of PD points to the importance of ShhDAN, because these DA
neurons are the neurons that degenerate, and LIDs develop because of the lack of Shh signaling
during L-Dopa therapy. Thus, the role of ShhPT may potentially be involved in LIDs but not to
the same extent as ShhDAN because ShhDAN is the presynaptic mechanism that contributes to the
development of LIDs.
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10. Chapter 10: Conclusion
In conclusion, the assembly of evidence provided here show that ShhDAN signaling
regulates CIN activity to normalize action selection and abnormal movement of the DLS.
Following L-Dopa therapy, stimulation of Shh signaling restores hyperactivity of dSPNs and
allows CINs to reset the balance of both SPN pathways in motor output. ShhDAN regulates CIN
by providing trophic support, counteracting DA-inhibition, and sculpting cortical glutamatergic
synapses within the DLS that are involved in normal and aberrant motor learning. The exact role
of ShhPT in the DLS needs to be explored further, but evidence begins to show that ShhPT does
not regulate CINs directly and possibly regulates FSN instead. Collectively, these results provide
novel insight into the development of LIDs by the neurodegeneration of DA neurons reducing
ShhDAN levels, which are critical for the regulation of CINs. Whereas, ShhPT from the Motor
cortex does not appear to influence LIDs, thus giving more weight to the importance of the
ShhDAN as the source in LID development. These findings have direct translational implications.
The development of LID is not a natural occurrence of the disease but only a side effect
that emerges during the treatment with L-Dopa. These results show the benefit of considering
other signaling factors produced by DA neurons in addition to DA. Shh signaling therapy with LDopa can provide relief to patients suffering from LIDs. The finding that the SAG dose scales
with the dose of L-Dopa can provide reliable guidance to physicians in accurately reducing LIDs
in patients by precisely restoring the balance of DA and Shh signaling within the DLS.
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11. Chapter 11: Future directions
The studies described here open a number of possibilities for future directions. The
obvious next step would be to see if SAG therapy is effective in the clinical setting. However,
considering the potential oncogenic properties of SAG, downstream targets of Smo signaling in
CINs may be a better option. Deep sequencing of CIN profiles in the absence of Shh or presence
of SAG may give insight into which mechanisms to explore further. These analyses may give
rise to potential pharmacological target(s) that may achieve similar results as stimulation of
Shh/Smo signaling.
I show robust evidence for the role of ShhDAN in LID development in the diseased state,
therefore, the role of ShhDAN must be important in the normal non-diseased learning and should
be explored further. Investigating the role of ShhDAN and SmoCIN in reinforcement learning tasks
such as T-maze could give insight into the basic role of Shh signaling in the adult brain.
Preliminary evidence shows that ShhDAN-/- mice cannot override the habitually learned behavior
in the T-maze following devaluation and points to ShhDAN as a critical component in flexible
learning capabilities. This together with the reduction of vGluT 1 terminals on CINs in ShhDAN-/mice, points to Shh, along with DA, acting as a physical component of the “teaching signal” that
emanates from DA neurons. Investigating the exact role of Shh in plasticity in these learning
tasks will open many doors. If SmoCIN-/- mice have similar unbreakable habitual patterns then
ShhDAN’s potential role as a “teaching signal” acting directly through CINs is consistent with my
results described here.
Additionally, the role of D2R on CINs has not been explored in the context of LID. It
will be interesting if D2R ablation on CINs leads to a reduction in LID because of the lack of
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“pause” in CIN activity. To explore if Smo and D2R interact, SAG should have no effect on
mice lacking the D2R on CINs.
As described earlier, to exclude the role of Shh from cortical sources, assessing LID in
ShhPT-/- mice would address this issue. In order to induce AIMs, a 6-OHDA lesion would have
to be administered and animals dosed with chronic L-Dopa. These animals would show
increased LID development compared to controls because of the dysregulation of both CINs and
FSNs. This approach would address the question as to the role of ShhPT in LID establishment.
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12. Methods
Reagent or Resource
Antibodies
Rabbit anti-TH
Chicken anti-B Galactosidase
Goat anti-chat
Goat anti-parv
Rabbit anti-p-p44/42 MAPK
(Erk1/2)
Rabbit anti-cfosB
Rabbit anti-p-(Ser/Thr) PKA
substrate
GP anti-vGlut1

GP anti-vGlut2
Rabbit anti-PSD95
Rabbit anti-p-rpS6 (ser240/244)
Mouse anti-NeuN
Alexa Fluor 488- Donkey AntiGoat IgG
Alexa Fluor Cy3- Donkey AntiGoat IgG
Alexa Fluor Cy3- Donkey AntiRabbit IgG
Alexa Fluor 594- Donkey AntiRabbit IgG
Alexa Fluor Cy5- Donkey AntiMouse IgG
Alexa Fluor Cy5- Donkey AntiGP IgG
Alexa Fluor Cy5- Donkey AntiChicken IgG

Source

Identifier

Millipore
Millipore
Millipore
Swant
Cell Signaling
Technology

657012
AB986
AB144P
PVG-213
9101

Cell Signaling
Technology
Cell Signaling
Technology
Dr. Thomas Jessell
from Columbia
Laboratory
Millipore
Invitrogen
Cell Signaling
Technology
Chemicon
international
Jackson
ImmunoResearch
Jackson
ImmunoResearch
Jackson
ImmunoResearch
Jackson
ImmunoResearch
Jackson
ImmunoResearch
Jackson
ImmunoResearch
Jackson
ImmunoResearch

2250
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9621

AB2251-1
51-6900
5364
MAB377
705-545-147
705-165-147
711-165-152
711-585-152
715-175-150
706-175-148
703-175-155

Virus Strains
AAV5-EF1α-DIO-ChR2-eYFP

AAV9-CMV.HI-eGFP-CreWPRE-SV40
AAV9-CMV-PI-EGFP-WPREbGH
AAV5-CamKII-eGFP-Cre
AAV5-CamKIIa-eGFP
AAV9-CAG-FLEX-tdTomato

University of North
Carolina Vector Core

James M. Wilson

Deisseroth:
https://www.med.unc.edu/
genetherapy/vectorcore/in-stockaav-vectors/deisseroth/
RRID: Addgene_105545

James M. Wilson

RRID: Addgene_105530

University of North
Carolina Vector Core
University of North
Carolina Vector Core
University of North
Carolina Vector Core

AV6450B

Chemicals, Peptides, and Recombinant Proteins
6-Hydroxydopamine
Sigma-Aldrich
hydrobromide
Smoothened Agonist (SAG)
Carbosynth Limited
SAG-HCl
Carbosynth Limited
Cyclopamine
Carbosynth Limited
VECTASHIELD Antifade
Vector Laboratories
Mounting Medium
Neg-50
Thermo Scientific
C&B-Metabond
Parkell
Benserazide hydrochloride
Sigma-Aldrich
L-3,4-Dihydroxyphenylalanine
Sigma-Aldrich
methyl ester hydrochloride
Hydroxypropyl-β-cyclodextrin
(HPCD)
Amantadine hydrochloride
Ascorbic acid
Bupivacaine (Murcaine)
M4PAM (VU0467154)
Purmorphamine

AV4621B
Boyden:
https://www.med.unc.edu/genether
apy/vectorcore/in-stock-aavvectors/boyden/
H4381
FS27779
FS76762
FC20718
Cat# H-1000, RRID: AB_2336789
6506M
S380
B7283
D1507

Sigma-Aldrich

H107

Sigma-Aldrich
Sigma-Aldrich
Sigma-Aldrich
StressMarq
Biosciences
ABCam

A1260
A92902
B5274
SIH-184
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Ab120933

Experimental Models: Organisms/Strains
Mouse: WT: C57BL/6J
The Jackson
Laboratory
L/L
Mouse: Shh-nLZ
The Jackson
Laboratory
L/L
Mouse: Shh-nLZ /Dat-Cre
The Jackson
Slc6a3tm1(cre)Xz/JMouse: Shh- Laboratory
nLZL/L
Mouse: R26-myrGFP
The Jackson
Laboratory
Mouse: Shh-GFP-Cre
The Jackson
Laboratory
Mouse: Pitx3ak/ak
Dr. Un Jung Kang
from Columbia
University
L/L
Mouse: Smo
The Jackson
Laboratory
+/Mouse: R26SmoM2
The Jackson
Laboratory
Mouse: ChAT-Ires-Cre
The Jackson
Laboratory
Mouse: Gli3-nLacz
Ulloa and Briscoe,
2007
Mouse: Emx1-IRES-Cre
The Jackson
Laboratory
Non-human primates: Macaca
Xierxin, Beijing, PR
Fascularis
of China
Software and Algorithms
ImageJ
NIH
EthoVision 10 XT

Noldus

Prism 8.2.1

Graphpad
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JAX:000664
JAX:000664
JAX: 020080

JAX: 007576
JAX: 005622

JAX: 004526
JAX: 005130
JAX: 006410

JAX: 005628

https://imagej.nih.gov/ij/; RRID:
SCR_003070
http://www.noldus.com/animalbehaviorresearch/products/ethovision-xt;
RRID: SCR_000441
https://www.graphpad.com/scienti
fic-software/prism/

EXPERIMENTAL MODELS AND SUBJECT DETAILS
Animals
6-OHDA experiments
Wild-type C57/Bl6 mice weighing 22-28 g (2 months old) were purchased from Jackson
Laboratory for the 6-OHDA lesion experiments. L-Dopa treatment began at 6-10 weeks of age.
All mice were maintained on a 12 h light/dark cycle, with ad libitum food and water. Animal use
and procedures were in accordance with the National Institutes of Health guidelines and
approved by CCNY’s Institutional Animal Care and Use Committees (IACUC).

Genetically modified mice experiments
Homozygous ak/ak mice (Abbreviated as AK-/-) were generously provided by Dr. Un Jung
Kang (Columbia University; (Ding et al. 2007; Hwang et al. 2003)). The generation of the ShhnLZL/L/Dat-IRES-Cre (Abbreviated as ShhDAN-/-) mouse strain was described previously
(Gonzalez-Reyes et al. 2012). Homozygous Pitx3All genetic conditional mice used in
experiments were purchased from Jackson’s Laboratory (reference numbers listed above) and
further bred in house. Animals were dosed with L-Dopa at 22-32 g weight and roughly 3-10
months old (specified in main text). SmoCIN-/- mice were made using conditional SmoL/L mice
bred with ChAT-IRES-Cre (Rossi et al. 2011). SmoM2+/-ChAT-cre AK-/- mice were made using
conditional SmoM2-YFPL/+ mice (Jeong et al. 2004; Xie et al. 1998) bred with ChAT-IRES-cre
and AK-/- mice. Recombination was checked using eYFP. For the neuropil carrying Shh
experiment, Shh-cre eGFP mice (Harfe et al. 2004) were bred with Rosa26mTmG (Muzumdar et
al. 2007). Gli3-nLacZ mice were used for expression experiments (Bai et al. 2004). Emx1-IRESCre mice were bred with ShhL/L mice to ablate Shh from the cortex (ShhPT-/- mice). All mice
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were maintained on a 12 h light/dark cycle, with ad libitum food and water. Animal use and
procedures were in accordance with the National Institutes of Health guidelines and approved by
CCNY’s Institutional Animal Care and Use Committees (IACUC).

Non-human primate experiments
The non-human primate experiments were performed in accordance with the European
Union directive of September 22, 2010 (2010/63/EU) on the protection of animals used for
scientific purposes in an AAALAC-accredited facility following acceptance of study design by
the Institute of Lab Animal Science (Chinese Academy of Science, Beijing, China). The four
Macaca fascicularis male monkeys (Xierxin, Beijing, PR of China) were housed in individual
cages allowing visual contacts and interactions with other monkeys in adjacent cages. Food and
water were available ad libitum. Animal care was supervised daily by veterinarians skilled in the
healthcare and maintenance of NHPs.

METHOD DETAILS
Drugs
In mice, all pharmacological agents were administered intraperitoneal (i.p.). Animals
were treated daily in a volume of 10 mL/kg of body weight with a combination of L-Dopa (5-25
mg/kg) and the peripheral L-amino acid decarboxylase antagonist, benserazide (12.5-20 mg/kg)
diluted in 0.9% sterile saline (referred to as just “L-Dopa” and specified doses described in main
text). Sonic Hedgehog agonist (SAG; 0.8-20 mg/kg) and antagonist (Cyclopamine; 2.5-5 mg/kg)
were dissolved in DMSO and brought into solution with 45% HPCD in 0.9% sterile saline for 6OHDA and AK-/- AIM studies. SAG-HCl was diluted in 0.9% sterile saline and used for the
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ShhDAN-/- and SmoCIN-/- mice studies. Both cyclopamine and SAG were administered 15 minutes
before L-Dopa injections. Amantadine was dissolved in 0.9% sterile saline and given 100
minutes prior to L-Dopa administration. M4PAM was dissolved in 0.9% sterile saline and given
at the same time as L-Dopa. Purmorphamine was dissolved in a cocktail of Polyethylene glycol
(PEG) and ethanol in PBS and given 15 minutes before L-Dopa dosing. Control mice were
treated with a mixture of carrier (DMSO, HPCD etc.) in similar proportions to the treatment
drugs.

Mouse unilateral 6-OHDA model
According to the well-established method, we applied the unilateral 6-OHDA injection
into the dorsolateral striatum (Francardo et al. 2011). Mice were anesthetized with a mixture of
ketamine (80 mg/kg) and xylazine (12 mg/kg) administered i.p. and the surgical field was
prepared with betadine. Bupivacaine (Marcaine), a local anesthetic, was subcutaneously (s.c.)
injected near the incision site. Bregma was visualized with 3% hydrogen peroxide There were
two unilateral injections (2 x 2ul each) of 6-OHDA into the left striatum using the following
coordinates based on the mouse brain atlas of Paxinos and Franklin (2001): Anteroposterior (AP)
+1.0 mm; Lateral (ML), + 2.1 mm; Dorsoventral (DV), -2.9 mm; and AP +0.3 mm; L +2.4 mm;
DV -2.9 mm. 6-OHDA-HCl (3.0 mg/ml) was dissolved in a solution containing 0.2 g/L ascorbic
acid and 9 g/L NaCl and injected via a Hamilton syringe with a 33-gauge needle attached to a
micro-syringe pump at a slow rate of 0.4 ul/min and left in place for 3 minutes and then retracted
slowly. Following surgery, animals were injected with 5% sucrose (10 ml/kg, s.c.) and saline (10
ml/kg, i.p.) and recovered on a heating pad. To avoid dehydration and significant weight loss,
hydrogel pouches and hi-fat chow were given to the mice ad lib. Behavioral testing and drug
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treatment began three weeks following surgery. Lesion assessments were quantified by
ipsilateral paw-use bias in the cylinder test and verified histologically, post-mortem, by
quantification of tyrosine hydroxylase (TH) fiber density at the end of experiments. Only animals
with 70% or more of TH depletion were included in the analyses.

Asymmetric forelimb-cylinder test
The cylinder test was used to assess the anti-akinetic effects of L-Dopa for the 6-OHDA
lesioned mice by measuring forelimb paw placement. Mice were placed in a glass cylinder
(10cm wide x 14cm high) 30 minutes post L-Dopa injection to be analyzed for 4 minutes. Two
mirrors were placed in the back to see mice from all angles. The limb use asymmetry score was
quantified as a ratio of contralateral to the lesion paw use over the total number of wall contacts
with both paws (Lundblad et al. 2002).

Open field test
In the open field test (OFT), whole body movements were measured using Noldus
Ethovision XT video tracking system. The animals head, body, and tail positions were tracked in
a transparent Plexiglas 4-chamber box apparatus (50 x 50 cm for each chamber). Freely
locomotive movements were measures as distanced moved through the chamber following
baseline (no drug) and 45 minutes following drug administration. Contralateral to the lesion
turning behavior was monitored as a percentage over ipsilateral turning. All OFT lasted 5
minutes to assess both the anti-akinetic effects of L-Dopa in concert with treatment drugs and to
determine the potential sedative effects.
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Abnormal involuntary movements
Abnormal involuntary movement (AIMs) scoring was rated on the established behavioral
rating scales (Cenci and Lundblad 2007; Lundblad et al. 2002). Briefly, there are four types of
AIMs: 1) abnormal rotational locomotion, 2) axial AIMs, showing dystonic posturing, and
severe twisting of the head or neck, 3) limb movements, with rapid, jerky movements of the front
or hind limbs, and 4) orofacial movements of abnormal chewing, licking, grooming, or sticking
out of the tongue. The four types of AIMs were scored on a severity scale of 0-4, with 0
exhibiting no abnormality and 4 showing uninterruptable dyskinetic movement. 1-2 blinded
experimenters rated AIMs. AIM scores were assessed by a blind observer to the treatment group,
35 minutes post treatment injection and 20 min post L-Dopa injection. Animals were single
caged during AIM assessments. Scores for each animal were recorded every 20 minutes, for 1
min each, over 2 hours. The total sum of AIM score throughout 2 hours was calculated as the
“Total AIM” score.

AK-/- forelimb and 3-paw dyskinesia
Animals were recorded in a clear plastic cylinder (16 cm in diameter and 25 cm in height)
30 minutes following L-Dopa injection. Mirrors were placed behind the cylinder to allow for
ventral views of the behavior. Each trial was five minutes with a 30-second habituation period
followed by behavioral scoring. The duration of abnormal paw movement was quantified for
each trial similar to previously described (Ding et al. 2007) and included sliding and shaking of
the forelimb paws on the cylinder, and “three-paw” dyskinesia (two forelimbs and one
hindlimb). “Four-paw” dyskinesia was observed in extreme dyskinetic cases.
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Primate MPTP model
Model preparation
The 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) intoxication protocol ,
chronic L-Dopa treatment and the clinical assessments was conducted in four male macaques
(Macaca fascicularis, Xierxin, Beijing, PR of China), as previously published. The macaques
were first rendered parkinsonian with MPTP-hydrochloride (0.2mg/kg, i.v., Sigma) dissolved in
saline. Then daily (at 9 am) assessment of parkinsonism in home cages for 30 min by two
blinded observers was done using a validated rating scale assessing tremor, general level of
activity, body posture (flexion of spine), vocalization, freezing and frequency of arm movements
and rigidity (for each upper limb). Once parkinsonism was stable, levodopa (Madopar, Roche,
Levodopa/carbidopa, ratio 4:1) was administered twice daily for 4-5 months at an individuallytailored dose designed to produce a full reversal of the parkinsonian condition (p.o. by gavage).
Over this period, animals developed severe and reproducible dyskinesia, presenting choreic–
athetoid (characterized by constant writhing and jerking motions), dystonic and sometimes
ballistic movements (large-amplitude flinging, flailing movements), as seen in long-term LDopa-treated PD patients. O, 45% HPCD in 0.9% saline and administered i.v.. Within subject
escalation was performed with washout period of three days.
Immediately after drug administration, we transferred the monkeys to an observation
cage (dimensions - 1.1m x 1.5m x 1.1m) as per guidelines. The total duration of observation was
240 min post-gas exposure. We performed a battery of behavioural observations as previously
described. Experts blinded to the treatment observed 10-min video recordings taken every 30
min throughout the duration of the experiment and scored the severity of the parkinsonian
condition using the parkinsonian disability score. The parkinsonian disability score is a
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combination of four different scores: (i) the range of movement score, (ii) bradykinesia score,
(iii) posture score, and (iv) tremor score. These four scores are combined using formula: (4 range of movement) + bradykinesia + postural abnormality + tremor. We rated the severity of
dyskinesia using the Dyskinesia Disability Scale: 0, dyskinesia absent; 1, mild, fleeting, and rare
dyskinetic postures and movements; 2, moderate, more prominent abnormal movements, but not
interfering significantly with normal behaviour; 3, marked, frequent and, at times, continuous
dyskinesia intruding on the normal repertoire of activity; or, 4, severe, virtually continuous
dyskinetic activity replacing normal behaviour and disabling to the animal.

Statistical analysis
Statistical analyses were carried out using Graphpad Prism (version 8). Time course of
parkinsonian disability and dyskinesia scores was analysed in 30 min time bins over the 4 hours
observation period. The median of the total scores of disability, dyskinesia, chorea and dystonia
at 0-2 hours following treatment was analysed. The parkinsonian and dyskinesia scores were
statistically compared between different conditions using a Friedman’s test followed by Dunn’s
multiple comparison test.

Optogenetic manipulations
Implant construction and implantation
Implants and patch cables were constructed and polished as previously described (Sparta
et al. 2012). Mice were anesthetized with isoflourene and the surgical field was prepared with
betadine. Bupivacaine was injected in the scalp prior to incision. Bregma was visualized with 3%
hydrogen peroxide and a craitonomy was made over the injection site. The AAV5-EF1a-DIO-
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hChR2(H134R)-eYFP-WPRE virus (UNC Vector Core, titer) was injected at AP -3.2 mm, ML
+1.5 mm, DV -4.3 mm by pressure injection with a pulled glass pipette and allowed to dwell for
10 minutes. A ferrule implant was placed at AP -3.2 mm, ML +1.5 mm, DV -4.2 mm, secured
with metabond, and protected with a dust cap (Thor Labs). Following surgery, mice were given
0.05 mg/kg buprenex and recovered on a heating pad. At least one month was allowed for viral
expression.

Optogenetic stimulation paradigms
One trial of stimulation consisted of a ten-minute habituation period followed by an hour
of intermittent stimulation. Simulation consisted of five seconds of stimulation at the beginning a
seven second Ethovision module at 60Hz with 10ms pulses with a laser power of 20mW from
the tip of the implant. After 30s passed the next stimulation commenced. Stimulation was
controlled via a TTL pulse from Ethovision’s software to a Doric four channel pulse generator
controlling a 710nm Laserglow DPPS laser. All sessions were recorded and analyzed with
Ethovision. Pharmacological agents were given 30 minutes prior to the beginning of the trial.

Optogenetic-induced dyskinesia
For optogenetic-induced dyskinesia (OID) experiments, stimulation occurred in a 5L
glass cylinder and consisted of one hour of intermittent stimulation as previously described.
Stimulation occurred daily for the duration of the experiments. A second camera (Casio EXFH100) recorded behavior from the side of the cylinder during the first and last ten minutes of
the trial. OIDs were assessed on rotation, limb, orofacial, and axial movements using the exact
scoring scale with the 6-OHDA lesion paradigm (Cenci and Lundblad 2007). OIDs were scored
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during both stimulation and non-stimulation periods and contributed to the total AIM score
independently. Pharmacological agents were given 15 minutes prior to the beginning of the trial.

Viral injections
AAV9-eGFP-Cre injection into the DLS
Using the same surgical protocol and coordinates for 6-OHDA lesion injection mice (2x
2ul injections at AP +1.0 mm; ML, + 2.1 mm; DV -2.9 mm; and AP +0.3 mm; ML +2.4 mm;
DV -2.9 mm), AAV9-CMV.HI-eGFP-Cre-WPRE-SV40 was injected unilaterally into SmoL/L
mice for acute recombination in the adult brain. GFP was used to differentiate between cells
affected with the virus and those not. The contralateral side was used as a within-subject control.

AAV5-eGFP-Cre injection into the M1/M2 cortex
Two injections (1 ul each on both hemispheres) were made into the motor cortex of AK-/-;
ShhL/L mice. M1: AP +0.8 mm; ML +/-0.8 mm; DV -1.0 mm; M2: AP +1.8 mm; ML +/-1.5 mm;
DV -1.0 mm. AAV5-eGFP-Cre was used to ablate Shh from areas infected (GFP+ cells). AAV5eGFP was used as a control virus. Animals were rested for 4 weeks for recombination and then
tested for LIDs.

AAV9-flex-tdtomato injection into the M1/M2 cortex
Two injections (0.5 ul each, unilaterally) were made into the motor cortex of Shh-Cre
mice. M1: AP +1.6 mm; ML +1.9 mm; DV -1.5 mm; M2: AP +1.6 mm; ML +0.8 mm; DV -1.5
mm. AAV9-flex-tdtomato was used to map Shh expressing neuron connections. Two injections
(0.5 ul each, unilaterally) were made into the DLS. AP +1.0 mm; ML +2.2 mm; DV -2.9 mm;
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AP +0.2 mm; ML +2.5 mm; DV -2.9 mm. Animals were rested for 3 weeks for recombination
and then perfused for immunohistochemistry.

Sample preparation and Immunohistochemistry
Animals were anesthetized with pentobarbital (10mg/ml) 30 minutes after last injection
and transcardially perfused with 50 ml of 4% paraformaldehyde (PFA) in 0.2M Phosphate buffer
PH 7.2. The brains were extracted and fixed overnight in 4% PFA and 48 hours in 30% sterile
sucrose. Brains were mounted using OTC mounting agent and sliced with a cryostat at 40 uM.
Slices were incubated with antibodies using the protocol described previously (Alcacer et al.
2012). Sections were mounted using vectashield (Vector Laboratories Inc.).
Confocal microscopy was performed using a Zeiss LMS 810 laser-scanning confocal
microscope using the same diameters for all the sections from one experiment. Counting was
performed manually in 375 x 375 µm confocal images taken in the dorsolateral and dorsomedial
striatum in blind conditions to the mouse treatment and/or genotype. TH immunofluorescence
intensity was quantified in the striatum with MacBiophotonics Image J, and the data represented
mean gray levels above background value in 375 x 375 µm confocal images. Co-stained and
single stained cells were manually counted in FIJI/ImageJ software (NIH) from the primary and
secondary antibodies used in the list above. Prevalence of pErk1/2 positive CINs was quantified
in a percentage of pErk1/2+ CIN out of total number of CIN in one plane (375 x 375 µm) in
three striatal slices: anterior (AP: 1.34 mm), middle (AP: 0.74 mm), and posterior (AP: 0.14 mm)
per animal. The criteria and settings were identical between experimental and control tissue for
each experiment. myrGFP stained neuropil analysis was done by transforming full striatal
sections into heat maps in Image J then creating a region of interest (ROI) around the
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dorsolateral and dorsomedial striatum (represented in extended Fig. 7). Heat map images reveal
the intensity level of myrGFP comparing anterior and posterior striatal sections.

p-rpS6240/244 Analysis
The mean grey value of p-rpS6240/244 intensity was measured in FIJI/ImageJ software
(NIH) using a freehand ROI area around the CIN somata similar to the protocol described by
(Bertran-Gonzalez et al. 2012). NeuN intensity of the same cell was used as a control for
fluorescence viability between subjects and numbers were plotted as a ratio of p-rpS6240/244
intensity over NeuN intensity of CINs. A 16 pseudocolor palette highlights the intensity of prpS6240/244 fluorescence. Heat map images are shown to emphasize the intensity levels and taken
within the dorsolateral striatum. About 200-300 CINs were quantified per each condition.

Glutamatergic Analysis
Glutamatergic terminals were quantified selectively on CIN only by quantifying vGluT1
or vGluT2 puncta that abutted within 0.5um a postsynaptic density recognized by post synaptic
density (PSD95) antibody co-stained with the cholinergic antibody ChAT. Z-stacks were taken at
about 20um thick. Terminals were analyzed on 6 CINs in both the dorsolateral and dorsomedial
of ShhDA-/- mice and controls at high resolution (63x oil). vGluT+ terminals were counted in
ImageJ using ROI and mask analysis of particles between the sizes of 0.1 to 5 microns. Only
those vGluT+ puncta fitting the criteria of being directly around the soma and primary dendrites
of CINs and juxta positioned to PSD95 immunoreactivity co-stained with ChAT were counted.
vGluT1 and vGluT2 were analyzed on adjacent coronal sections.
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Quantification of gene expression
Total RNA from cortex, amygdala, and lateral vMB containing the entire SN (may
include some VTA) was isolated (RNeasy Mini Kit; Qiagen) and reverse transcribed using
oligo(dT) primers and the SuperScript First-Strand Synthesis System (Invitrogen), according to
the manufacturers’ protocols. Relative changes in gene expression were quantified by rtPCR
using TaqMan gene expression assays (Applied Biosystems) and calculated by the ΔΔCt method.

Statistics
Multiple comparisons were analyzed using 2-way, 3-way, or repeated measures (RM)
ANOVA with GraphPad Prism 8.0 software, followed by post hoc Bonferroni’s test for specific
comparisons. For 2-group comparisons, 2-tailed paired or unpaired Student’s t test was used.
Nonparametric statistics were used to verify all main effects using Statistical analysis for MPTP
primate study was carried out using a parametric one-way repeated measure analysis of variance
(ANOVA) followed by Dunnett’s multiple comparison test or Mann-Whitney test when
appropriate.
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13. Appendix

Appendix 1: SAG Administration reduces dyskinetic behavior in the MPTP Macaque
model of PD (Collaboration with Dr. Erwan Bezard)
(A) Drug regimen of methylphenyltetrahydropyridine (MPTP) injected Macaques following
establishment of LID and challenged with vehicle or SAG (3, 9, and 27 mg/kg) administered
intravenously (i.v.) concomitantly to oral L-Dopa in a within-subject drug escalation design. (B)
Quantification of dyskinesia score binned for the first 2 hours of vehicle or SAG (3, 9, and
27 mg/kg) administration. Friedman’s nonparametric RM 1-way ANOVA followed by Dunn’s
post-test p=0.037 *P< 0.05 plotted as mean +/- SEM (n = 4). (C) Time course of behavioral
scores of dyskinesia over 4 hours for vehicle or SAG (3, 9, and 27 mg/kg). Error bars excluded
for clarity. (n = 4). (D) Time course of disability score of primates during L-Dopa treatment with
either vehicle or SAG (3, 9, and 27 mg/kg) over 4 hours. Parkinson’s Disease (PD) scoring
consists of a range of movements including bradykinesia, postural abnormality, and tremor
giving a maximum global parkinsonian disability score of 10.

119

References
Acquas, E. and G. Di Chiara (1999). "Dopamine D1 receptor-mediated control of striatal
acetylcholine release by endogenous dopamine." European Journal of Pharmacology 383(2):
121-127.
Acquas, E., P. Marrocu, A. Pisanu, C. Cadoni, G. Zernig, A. Saria and G. Di Chiara (2001).
"Intravenous administration of ecstasy (3,4-methylendioxymethamphetamine) enhances cortical
and striatal acetylcholine release in vivo." European Journal of Pharmacology 418(3): 207-211.
Alberico, S. L., Y.-C. Kim, T. Lence and N. S. Narayanan (2017). "Axial levodopa-induced
dyskinesias and neuronal activity in the dorsal striatum." Neuroscience 343: 240-249.
Albin, R. L., A. B. Young and J. B. Penney (1989). "The functional anatomy of basal ganglia
disorders." Trends in Neurosciences 12(10): 366-375.
Alcacer, C., E. Santini, E. Valjent, F. Gaven, J.-A. Girault and D. Hervé (2012). "Gαolf Mutation
Allows Parsing the Role of cAMP-Dependent and Extracellular Signal-Regulated KinaseDependent Signaling in L-3,4-Dihydroxyphenylalanine-Induced Dyskinesia." The Journal of
Neuroscience 32(17): 5900-5910.
Alexander, G. E. and M. D. Crutcher (1990). "Functional architecture of basal ganglia circuits:
neural substrates of parallel processing." Trends in Neurosciences 13(7): 266-271.
Alexander, G. E., M. R. DeLong and P. L. Strick (1986). "Parallel Organization of Functionally
Segregated Circuits Linking Basal Ganglia and Cortex." Annual Review of Neuroscience 9(1):
357-381.
Antonini, A., P. Vontobel, M. Psylla, I. Günther, P. R. Maguire, J. Missimer and K. L. Leenders
(1995). "Complementary Positron Emission Tomographic Studies of the Striatal Dopaminergic
System in Parkinson's Disease." JAMA Neurology 52(12): 1183-1190.
Aoki, S., A. W. Liu, A. Zucca, S. Zucca and J. R. Wickens (2015). Role of Striatal Cholinergic
Interneurons in Set-Shifting in the Rat. The Journal of Neuroscience. 35: 9424.
Aosaki, T., M. Kimura and A. M. Graybiel (1995). "Temporal and spatial characteristics of
tonically active neurons of the primate's striatum." Journal of Neurophysiology 73(3): 1234.

120

Apicella, P., E. Scarnati, T. Ljungberg and W. Schultz (1992). "Neuronal activity in monkey
striatum related to the expectation of predictable environmental events." Journal of
Neurophysiology 68(3): 945-960.
Bai, C. B., D. Stephen and A. L. Joyner (2004). "All Mouse Ventral Spinal Cord Patterning by
Hedgehog Is Gli Dependent and Involves an Activator Function of Gli3." Developmental Cell
6(1): 103-115.
Bamford, I. J. and N. S. Bamford (2019). "The Striatum’s Role in Executing Rational and
Irrational Economic Behaviors." The Neuroscientist 25(5): 475-490.
Barbeau, A. (1962). "The pathogenesis of Parkinson's disease: a new hypothesis." Can Med
Assoc J 87: 802-807.
Bastide, M. F., W. G. Meissner, B. Picconi, S. Fasano, P.-O. Fernagut, M. Feyder, V. Francardo,
C. Alcacer, Y. Ding, R. Brambilla, G. Fisone, A. Jon Stoessl, M. Bourdenx, M. Engeln, S.
Navailles, P. De Deurwaerdère, W. K. D. Ko, N. Simola, M. Morelli, L. Groc, M.-C. Rodriguez,
E. V. Gurevich, M. Quik, M. Morari, M. Mellone, F. Gardoni, E. Tronci, D. Guehl, F. Tison, A.
R. Crossman, U. J. Kang, K. Steece-Collier, S. Fox, M. Carta, M. Angela Cenci and E. Bézard
(2015). "Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's
disease." Progress in Neurobiology 132(Supplement C): 96-168.
Bastide, M. F., W. G. Meissner, B. Picconi, S. Fasano, P. O. Fernagut, M. Feyder, V. Francardo,
C. Alcacer, Y. Ding, R. Brambilla, G. Fisone, A. Jon Stoessl, M. Bourdenx, M. Engeln, S.
Navailles, P. De Deurwaerdere, W. K. Ko, N. Simola, M. Morelli, L. Groc, M. C. Rodriguez, E.
V. Gurevich, M. Quik, M. Morari, M. Mellone, F. Gardoni, E. Tronci, D. Guehl, F. Tison, A. R.
Crossman, U. J. Kang, K. Steece-Collier, S. Fox, M. Carta, M. Angela Cenci and E. Bezard
(2015). "Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's
disease." Progress in neurobiology 132: 96-168.
Bayer, H. M. and P. W. Glimcher (2005). "Midbrain Dopamine Neurons Encode a Quantitative
Reward Prediction Error Signal." Neuron 47(1): 129-141.
Beachy, P. A., M. K. Cooper, K. E. Young, D. P. von Kessler, W.-J. Park, T. M. T. Hall, D. J.
Leahy and J. A. Porter (1997). "Multiple Roles of Cholesterol in Hedgehog Protein Biogenesis
and Signaling." Cold Spring Harbor Symposia on Quantitative Biology 62: 191-204.
Beeler, J. A., Z. F. H. Cao, M. A. Kheirbek, Y. Ding, J. Koranda, M. Murakami, U. J. Kang and
X. Zhuang (2010). "Dopamine-Dependent Motor Learning Insight into Levodopa’s LongDuration Response." Annals of neurology 67(5): 639-647.
121

Beeler, Jeff A., Michael J. Frank, J. McDaid, E. Alexander, S. Turkson, M. Sol Bernandez,
Daniel S. McGehee and X. Zhuang (2012). "A Role for Dopamine-Mediated Learning in the
Pathophysiology and Treatment of Parkinson’s Disease." Cell Reports 2(6): 1747-1761.
Bertran-Gonzalez, J., B. C. Chieng, V. Laurent, E. Valjent and B. W. Balleine (2012). "Striatal
Cholinergic Interneurons Display Activity-Related Phosphorylation of Ribosomal Protein S6."
PLOS ONE 7(12): e53195.
Bezard, E., J. Baufreton, G. Owens, A. R. Crossman, H. Dudek, A. Taupignon and J. M.
Brotchie (2003). "Sonic hedgehog is a neuromodulator in the adult subthalamic nucleus." The
FASEB Journal 17(15): 2337-2338.
Bezard, E., C. Imbert, X. Deloire, B. Bioulac and C. E. Gross (1997). "A chronic MPTP model
reproducing the slow evolution of Parkinson's disease: evolution of motor symptoms in the
monkey." Brain Research 766(1): 107-112.
Bi, G.-q. and M.-m. Poo (1998). "Synaptic Modifications in Cultured Hippocampal Neurons:
Dependence on Spike Timing, Synaptic Strength, and Postsynaptic Cell Type." The Journal of
Neuroscience 18(24): 10464.
Bijlsma, M. F., H. Damhofer and H. Roelink (2012). "Hedgehog-Stimulated Chemotaxis Is
Mediated by Smoothened Located Outside the Primary Cilium." Science Signaling 5(238): ra60.
Boix, J., T. Padel and G. Paul (2015). "A partial lesion model of Parkinson's disease in mice –
Characterization of a 6-OHDA-induced medial forebrain bundle lesion." Behavioural Brain
Research 284(Supplement C): 196-206.
Boraud, T., A. Leblois and N. P. Rougier (2018). "A natural history of skills." Progress in
Neurobiology 171: 114-124.
Bordia, T., X. A. Perez, J. Heiss, D. Zhang and M. Quik (2016). "Optogenetic activation of
striatal cholinergic interneurons regulates L-dopa-induced dyskinesias." Neurobiol Dis 91: 4758.
Bordia, T., X. A. Perez, J. Heiss, D. Zhang and M. Quik (2016). "Optogenetic activation of
striatal cholinergic interneurons regulates L-dopa-induced dyskinesias." Neurobiology of disease
91: 47-58.

122

Borgkvist, A., O. J. Lieberman and D. Sulzer (2018). "Synaptic plasticity may underlie l-DOPA
induced dyskinesia." Curr Opin Neurobiol 48: 71-78.
Bradfield, Laura A., J. Bertran-Gonzalez, B. Chieng and Bernard W. Balleine (2013). "The
Thalamostriatal Pathway and Cholinergic Control of Goal-Directed Action: Interlacing New with
Existing Learning in the Striatum." Neuron 79(1): 153-166.
Briscoe, J. and J. Ericson (1999). "The specification of neuronal identity by graded sonic
hedgehog signalling." Seminars in Cell & Developmental Biology 10(3): 353-362.
Calabresi, P., B. Picconi, A. Tozzi, V. Ghiglieri and M. Di Filippo (2014). "Direct and indirect
pathways of basal ganglia: a critical reappraisal." Nature Neuroscience 17(8): 1022-1030.
Cenci, M. A. and C. Konradi (2010). "Maladaptive striatal plasticity in L-DOPA-induced
dyskinesia." Progress in brain research 183: 209-233.
Cenci, M. A. and M. Lundblad (2006). "Post- versus presynaptic plasticity in L-DOPA-induced
dyskinesia." Journal of Neurochemistry 99(2): 381-392.
Cenci, M. A. and M. Lundblad (2007). "Ratings of L-DOPA-Induced Dyskinesia in the
Unilateral 6-OHDA Lesion Model of Parkinson's Disease in Rats and Mice." Current Protocols
in Neuroscience 41(1): 9.25.21-29.25.23.
Charron, F., E. Stein, J. Jeong, A. P. McMahon and M. Tessier-Lavigne (2003). "The
Morphogen Sonic Hedgehog Is an Axonal Chemoattractant that Collaborates with Netrin-1 in
Midline Axon Guidance." Cell 113(1): 11-23.
Chatham, Christopher H., Michael J. Frank and D. Badre (2014). "Corticostriatal Output Gating
during Selection from Working Memory." Neuron 81(4): 930-942.
Cheng, X.-R., Y. Yang, W.-X. Zhou and Y.-X. Zhang (2011). "Expression of VGLUTs
contributes to degeneration and acquisition of learning and memory." Neurobiology of Learning
and Memory 95(3): 361-375.
Chuhma, N., S. Mingote, H. Moore and S. Rayport (2014). "Dopamine neurons control striatal
cholinergic neurons via regionally heterogeneous dopamine and glutamate signaling." Neuron
81(4): 901-912.

123

Chuhma, N., S. Mingote, L. Yetnikoff, A. Kalmbach, T. Ma, S. Ztaou, A.-C. Sienna, S. Tepler,
J.-F. Poulin, M. Ansorge, R. Awatramani, U. J. Kang and S. Rayport (2018). "Dopamine neuron
glutamate cotransmission evokes a delayed excitation in lateral dorsal striatal cholinergic
interneurons." eLife 7: e39786.
Dahmane, N. and A. Ruiz-i-Altaba (1999). "Sonic hedgehog regulates the growth and patterning
of the cerebellum." Development 126(14): 3089.
Dai, R., Y. Xia, L. Mao, Y. Mei, Y. Xue and B. Hu (2012). "Involvement of PI3K/Akt pathway
in the neuroprotective effect of sonic hedgehog on cortical neurons under oxidative stress."
Journal of Huazhong University of Science and Technology [Medical Sciences] 32(6): 856-860.
Damsma, G., C.-S. Tham, G. S. Robertson and H. C. Fibiger (1990). "Dopamine D1 receptor
stimulation increases striatal acetylcholine release in the rat." European Journal of Pharmacology
186(2): 335-338.
Dani, J. A. (2015). Chapter One - Neuronal Nicotinic Acetylcholine Receptor Structure and
Function and Response to Nicotine. International Review of Neurobiology. M. De Biasi,
Academic Press. 124: 3-19.
Darling, N. J. and S. J. Cook (2014). "The role of MAPK signalling pathways in the response to
endoplasmic reticulum stress." Biochimica et Biophysica Acta (BBA) - Molecular Cell Research
1843(10): 2150-2163.
Dass, B., M. M. Iravani, M. J. Jackson, T. M. Engber, A. Galdes and P. Jenner (2002).
"Behavioural and immunohistochemical changes following supranigral administration of sonic
hedgehog in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated common marmosets."
Neuroscience 114(1): 99-109.
Dauer, W. and S. Przedborski (2003). "Parkinson's Disease: Mechanisms and Models." Neuron
39(6): 889-909.
Daw, N. D., Y. Niv and P. Dayan (2005). "Uncertainty-based competition between prefrontal
and dorsolateral striatal systems for behavioral control." Nature Neuroscience 8(12): 1704-1711.
Dickinson, A. and L. Weiskrantz (1985). "Actions and habits: the development of behavioural
autonomy." Philosophical Transactions of the Royal Society of London. B, Biological Sciences
308(1135): 67-78.

124

Ding, J., J. N. Guzman, T. Tkatch, S. Chen, J. A. Goldberg, P. J. Ebert, P. Levitt, C. J. Wilson,
H. E. Hamm and D. J. Surmeier (2006). "RGS4-dependent attenuation of M4 autoreceptor
function in striatal cholinergic interneurons following dopamine depletion." Nat Neurosci 9(6):
832-842.
Ding, Y., J. Restrepo, L. Won, D.-Y. Hwang, K.-S. Kim and U. J. Kang (2007). "Chronic 3,4Dihydroxyphenylalanine Treatment Induces Dyskinesia in Aphakia Mice, a Novel Genetic
Model of Parkinson’s Disease." Neurobiology of disease 27(1): 11-23.
Ding, Y., L. Won, J. P. Britt, S. A. Lim, D. S. McGehee and U. J. Kang (2011). "Enhanced
striatal cholinergic neuronal activity mediates L-DOPA-induced dyskinesia in parkinsonian
mice." Proceedings of the National Academy of Sciences of the United States of America
108(2): 840-845.
Ding, Y., L. Won, J. P. Britt, S. A. O. Lim, D. S. McGehee and U. J. Kang (2011). "Enhanced
striatal cholinergic neuronal activity mediates l-DOPA–induced dyskinesia in parkinsonian
mice." Proceedings of the National Academy of Sciences of the United States of America
108(2): 840-845.
Drenan, R. M., S. R. Grady, A. D. Steele, S. McKinney, N. E. Patzlaff, J. M. McIntosh, M. J.
Marks, J. M. Miwa and H. A. Lester (2010). "Cholinergic Modulation of Locomotion and
Striatal Dopamine Release Is Mediated by α6α4* Nicotinic Acetylcholine Receptors." The
Journal of Neuroscience 30(29): 9877-9889.
Durif, F., D. Deffond, G. Dordain and M. Tournilhac (1994). "Apomorphine and diphasic
dyskinesia." Clinical Neuropharmacology 17(1): 99-102.
Duvoisin, R. C. (1967). "Cholinergic-Anticholinergic Antagonism in Parkinsonism." JAMA
Neurology 17(2): 124-136.
Eriksson, T., A.-K. Granérus, A. Linde and A. Carlsson (1988). "'On‐off' phenomenon in
Parkinson's disease." Relationship between dopa and other large neutral amino acids in plasma
38(8): 1245-1245.
Espay, A. J., F. Morgante, A. Merola, A. Fasano, L. Marsili, S. H. Fox, E. Bezard, B. Picconi, P.
Calabresi and A. E. Lang (2018). "Levodopa-induced dyskinesia in Parkinson disease: Current
and evolving concepts." Annals of Neurology 84(6): 797-811.
Fabbrini, G., J. M. Brotchie, F. Grandas, M. Nomoto and C. G. Goetz (2007). "Levodopainduced dyskinesias." Movement Disorders 22(10): 1379-1389.
125

Fietz, M. J., J.-P. Concordet, R. Barbosa, R. Johnson, S. Krauss, A. P. McMahon, C. Tabin and
P. W. Ingham (1994). "The hedgehog gene family in Drosophila and vertebrate development."
Development 1994(Supplement): 43.
Fiorillo, C. D., P. N. Tobler and W. Schultz (2003). "Discrete Coding of Reward Probability and
Uncertainty by Dopamine Neurons." Science 299(5614): 1898.
Fox, S. H., R. Katzenschlager, S.-Y. Lim, B. Ravina, K. Seppi, M. Coelho, W. Poewe, O.
Rascol, C. G. Goetz and C. Sampaio (2011). "The Movement Disorder Society Evidence-Based
Medicine Review Update: Treatments for the motor symptoms of Parkinson's disease."
Movement Disorders 26(S3): S2-S41.
Francardo, V., A. Recchia, N. Popovic, D. Andersson, H. Nissbrandt and M. A. Cenci (2011).
"Impact of the lesion procedure on the profiles of motor impairment and molecular
responsiveness to L-DOPA in the 6-hydroxydopamine mouse model of Parkinson's disease."
Neurobiology of Disease 42(3): 327-340.
Gerfen, C. R., S. Miyachi, R. Paletzki and P. Brown (2002). "D1 dopamine receptor
supersensitivity in the dopamine-depleted striatum results from a switch in the regulation of
ERK1/2/MAP kinase." J Neurosci 22(12): 5042-5054.
Giniatullin, R., A. Nistri and J. L. Yakel (2005). "Desensitization of nicotinic ACh receptors:
shaping cholinergic signaling." Trends Neurosci 28(7): 371-378.
Girasole, A. E., M. Y. Lum, D. Nathaniel, C. J. Bair-Marshall, C. J. Guenthner, L. Luo, A. C.
Kreitzer and A. B. Nelson (2018). "A Subpopulation of Striatal Neurons Mediates LevodopaInduced Dyskinesia." Neuron 97(4): 787-795.e786.
Girasole, A. E., M. Y. Lum, D. Nathaniel, C. J. Bair-Marshall, C. J. Guenthner, L. Luo, A. C.
Kreitzer and A. B. Nelson (2018). "A Subpopulation of Striatal Neurons Mediates LevodopaInduced Dyskinesia." Neuron 97(4): 787-795 e786.
Gittis, A. H., D. K. Leventhal, B. A. Fensterheim, J. R. Pettibone, J. D. Berke and A. C. Kreitzer
(2011). "Selective inhibition of striatal fast-spiking interneurons causes dyskinesias." The
Journal of neuroscience : the official journal of the Society for Neuroscience 31(44): 1572715731.
Gonzalez-Reyes, L. E., M. Verbitsky, J. Blesa, V. Jackson-Lewis, D. Paredes, K. Tillack, S.
Phani, E. R. Kramer, S. Przedborski and A. H. Kottmann (2012). "Sonic hedgehog maintains
126

cellular and neurochemical homeostasis in the adult nigrostriatal circuit." Neuron 75(2): 306319.
Gonzalez-Reyes, L. E., M. Verbitsky, J. Blesa, V. Jackson-Lewis, D. Paredes, K. Tillack, S.
Phani, E. R. Kramer, S. Przedborski and A. H. Kottmann (2012). "Sonic Hedgehog Maintains
Cellular and Neurochemical Homeostasis in the Adult Nigrostriatal Circuit." Neuron 75(2): 306319.
Gotti, C., S. Guiducci, V. Tedesco, S. Corbioli, L. Zanetti, M. Moretti, A. Zanardi, R. Rimondini,
M. Mugnaini, F. Clementi, C. Chiamulera and M. Zoli (2010). "Nicotinic Acetylcholine
Receptors in the Mesolimbic Pathway: Primary Role of Ventral Tegmental Area α6β2*
Receptors in Mediating Systemic Nicotine Effects on Dopamine Release, Locomotion, and
Reinforcement." The Journal of Neuroscience 30(15): 5311-5325.
Goyal, R. K. and A. Chaudhury (2013). "Structure activity relationship of synaptic and
junctional neurotransmission." Autonomic neuroscience : basic & clinical 176(0): 11-31.
Graybiel, A. M. (1998). "The Basal Ganglia and Chunking of Action Repertoires." Neurobiology
of Learning and Memory 70(1): 119-136.
Graybiel, A. M. (2008). "Habits, Rituals, and the Evaluative Brain." Annual Review of
Neuroscience 31(1): 359-387.
Graybiel, A. M., T. Aosaki, A. W. Flaherty and M. Kimura (1994). "The basal ganglia and
adaptive motor control." Science 265(5180): 1826.
Graybiel, A. M. and S. T. Grafton (2015). "The striatum: where skills and habits meet." Cold
Spring Harbor perspectives in biology 7(8): a021691-a021691.
Grilli, M., S. Zappettini, L. Raiteri and M. Marchi (2009). "Nicotinic and muscarinic cholinergic
receptors coexist on GABAergic nerve endings in the mouse striatum and interact in modulating
GABA release." Neuropharmacology 56(3): 610-614.
Haber, S. N., J. L. Fudge and N. R. McFarland (2000). "Striatonigrostriatal Pathways in Primates
Form an Ascending Spiral from the Shell to the Dorsolateral Striatum." The Journal of
Neuroscience 20(6): 2369.

127

Harfe, B. D., P. J. Scherz, S. Nissim, H. Tian, A. P. McMahon and C. J. Tabin (2004). "Evidence
for an Expansion-Based Temporal Shh Gradient in Specifying Vertebrate Digit Identities." Cell
118(4): 517-528.
Hechtner, M. C., T. Vogt, Y. Zöllner, S. Schröder, J. B. Sauer, H. Binder, S. Singer and R.
Mikolajczyk (2014). "Quality of life in Parkinson's disease patients with motor fluctuations and
dyskinesias in five European countries." Parkinsonism & Related Disorders 20(9): 969-974.
Hidalgo-Figueroa, M., S. Bonilla, F. Gutiérrez, A. Pascual and J. López-Barneo (2012). "GDNF
Is Predominantly Expressed in the PV+ Neostriatal Interneuronal Ensemble in Normal Mouse
and after Injury of the Nigrostriatal Pathway." The Journal of Neuroscience 32(3): 864.
Hunnicutt, B. J., B. C. Jongbloets, W. T. Birdsong, K. J. Gertz, H. Zhong and T. Mao (2016). "A
comprehensive excitatory input map of the striatum reveals novel functional organization." eLife
5: e19103.
Hwang, D.-Y., P. Ardayfio, U. J. Kang, E. V. Semina and K.-S. Kim (2003). "Selective loss of
dopaminergic neurons in the substantia nigra of Pitx3-deficient aphakia mice." Molecular Brain
Research 114(2): 123-131.
Ibáñez-Sandoval, O., H. S. Xenias, J. M. Tepper and T. Koós (2015). "Dopaminergic and
cholinergic modulation of striatal tyrosine hydroxylase interneurons." Neuropharmacology 95:
468-476.
Ikemoto, S. (2007). "Dopamine reward circuitry: Two projection systems from the ventral
midbrain to the nucleus accumbens–olfactory tubercle complex." Brain Research Reviews 56(1):
27-78.
Izzi, L., M. Lévesque, S. Morin, D. Laniel, B. C. Wilkes, F. Mille, R. S. Krauss, A. P. McMahon,
B. L. Allen and F. Charron (2011). "Boc and Gas1 each form distinct Shh receptor complexes
with Ptch1 and are required for Shh-mediated cell proliferation." Developmental cell 20(6): 788801.
Jeong, J., J. Mao, T. Tenzen, A. H. Kottmann and A. P. McMahon (2004). "Hedgehog signaling
in the neural crest cells regulates the patterning and growth of facial primordia." Genes &
development 18(8): 937-951.
Kaiser, S. and S. Wonnacott (2000). "α-Bungarotoxin-Sensitive Nicotinic Receptors Indirectly
Modulate Dopamine Release in Rat Striatal Slices via Glutamate Release." Molecular
Pharmacology 58(2): 312-318.
128

Kawaguchi, Y., C. J. Wilson, S. J. Augood and P. C. Emson (1995). "Striatal interneurones:
chemical, physiological and morphological characterization." Trends in Neurosciences 18(12):
527-535.
Keysers, C. and D. I. Perrett (2004). "Demystifying social cognition: a Hebbian perspective."
Trends in Cognitive Sciences 8(11): 501-507.
Kharkwal, G., K. Brami-Cherrier, J. E. Lizardi-Ortiz, A. B. Nelson, M. Ramos, D. Del Barrio, D.
Sulzer, A. C. Kreitzer and E. Borrelli (2016). "Parkinsonism driven by antipsychotics originates
from dopaminergic control of striatal cholinergic interneurons." Neuron 91(1): 67-78.
Kimura, H., P. L. McGeer, F. Peng and E. G. McGeer (1980). "Choline acetyltransferasecontaining neurons in rodent brain demonstrated by immunohistochemistry." Science 208(4447):
1057.
Klug, J. R., M. D. Engelhardt, C. N. Cadman, H. Li, J. B. Smith, S. Ayala, E. W. Williams, H.
Hoffman and X. Jin (2018). "Differential inputs to striatal cholinergic and parvalbumin
interneurons imply functional distinctions." eLife 7: e35657.
Ko, W. K., E. Pioli, Q. Li, S. McGuire, A. Dufour, T. B. Sherer, E. Bezard and M. F. Facheris
(2014). "Combined fenobam and amantadine treatment promotes robust antidyskinetic effects in
the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned primate model of Parkinson's
disease." Movement disorders : official journal of the Movement Disorder Society 29(6): 772779.
Ko, W. K. D., M.-L. Martin-Negrier, E. Bezard, A. R. Crossman and P. Ravenscroft (2014).
"RGS4 is involved in the generation of abnormal involuntary movements in the unilateral 6OHDA-lesioned rat model of Parkinson's disease." Neurobiology of disease 70(Supplement C):
138-148.
Koós, T. and J. M. Tepper (2002). "Dual Cholinergic Control of Fast-Spiking Interneurons in the
Neostriatum." The Journal of Neuroscience 22(2): 529.
Kordower, J. H., C. W. Olanow, H. B. Dodiya, Y. Chu, T. G. Beach, C. H. Adler, G. M. Halliday
and R. T. Bartus (2013). "Disease duration and the integrity of the nigrostriatal system in
Parkinson’s disease." Brain 136(8): 2419-2431.
Kravitz, A. V., B. S. Freeze, P. R. L. Parker, K. Kay, M. T. Thwin, K. Deisseroth and A. C.
Kreitzer (2010). "Regulation of parkinsonian motor behaviours by optogenetic control of basal
ganglia circuitry." Nature 466(7306): 622-626.
129

LaHue, S. C., J. L. Ostrem, N. B. Galifianakis, M. San Luciano, N. Ziman, S. Wang, C. A.
Racine, P. A. Starr, P. S. Larson and M. Katz (2017). "Parkinson's disease patient preference and
experience with various methods of DBS lead placement." Parkinsonism & Related Disorders
41: 25-30.
Lammel, S., A. Hetzel, O. Häckel, I. Jones, B. Liss and J. Roeper (2008). "Unique Properties of
Mesoprefrontal Neurons within a Dual Mesocorticolimbic Dopamine System." Neuron 57(5):
760-773.
Larson, P. S. (2014). "Deep Brain Stimulation for Movement Disorders." Neurotherapeutics
11(3): 465-474.
Lees, A. J. (1994). "Levodopa Substitution: The Gold Standard." Clinical Neuropharmacology
17: S1-S6.
Lim, S. A. O., U. J. Kang and D. S. McGehee (2014). "Striatal cholinergic interneuron regulation
and circuit effects." Frontiers in Synaptic Neuroscience 6: 22.
Livingstone, P. D. and S. Wonnacott (2009). "Nicotinic acetylcholine receptors and the
ascending dopamine pathways." Biochemical Pharmacology 78(7): 744-755.
Lundblad, M., M. Andersson, C. Winkler, D. Kirik, N. Wierup and M. A. Cenci (2002).
"Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model
of Parkinson's disease." European Journal of Neuroscience 15(1): 120-132.
Lundblad, M., B. Picconi, H. Lindgren and M. A. Cenci (2004). "A model of l-DOPA-induced
dyskinesia in 6-hydroxydopamine lesioned mice: relation to motor and cellular parameters of
nigrostriatal function." Neurobiology of Disease 16(1): 110-123.
Lundblad, M., A. Usiello, M. Carta, K. Håkansson, G. Fisone and M. A. Cenci (2005).
"Pharmacological validation of a mouse model of l-DOPA-induced dyskinesia." Experimental
Neurology 194(1): 66-75.
Maia, T. V. and M. J. Frank (2011). "From reinforcement learning models to psychiatric and
neurological disorders." Nature neuroscience 14(2): 154-162.
Mallet, N., B. Ballion, C. Le Moine and F. Gonon (2006). "Cortical Inputs and GABA
Interneurons Imbalance Projection Neurons in the Striatum of Parkinsonian Rats." The Journal of
Neuroscience 26(14): 3875-3884.
130

Marsden, C. D. and J. D. Parkes (1977). "Sucess and problems of long-term Levodopa therapy in
Parkinson's Disease." The Lancet 309(8007): 345-349.
Matamales, M., J. Gotz and J. Bertran-Gonzalez (2016). "Quantitative Imaging of Cholinergic
Interneurons Reveals a Distinctive Spatial Organization and a Functional Gradient across the
Mouse Striatum." PloS one 11(6): e0157682.
Matamales, M., Z. Skrbis, R. J. Hatch, B. W. Balleine, J. Gotz and J. Bertran-Gonzalez (2016).
"Aging-Related Dysfunction of Striatal Cholinergic Interneurons Produces Conflict in Action
Selection." Neuron 90(2): 362-373.
Matamales, M., Z. Skrbis, Robert J. Hatch, Bernard W. Balleine, J. Götz and J. Bertran-Gonzalez
(2016). "Aging-Related Dysfunction of Striatal Cholinergic Interneurons Produces Conflict in
Action Selection." Neuron 90(2): 362-373.
Maurice, N., M. Liberge, F. Jaouen, S. Ztaou, M. Hanini, J. Camon, K. Deisseroth, M. Amalric,
L. Kerkerian-Le Goff and C. Beurrier (2015). "Striatal Cholinergic Interneurons Control Motor
Behavior and Basal Ganglia Function in Experimental Parkinsonism." Cell Reports 13(4): 657666.
McGeer, P. L., J. E. Boulding, W. C. Gibson and R. G. Foulkes (1961). "Drug-induced
extrapyramidal reactions. Treatment with diphenhydramine hydrochloride and
dihydroxyphenylalanine." JAMA 177: 665-670.
McGeorge, A. J. and R. L. M. Faull (1989). "The organization of the projection from the cerebral
cortex to the striatum in the rat." Neuroscience 29(3): 503-537.
McKinley, J. W., Z. Shi, I. Kawikova, M. Hur, I. J. Bamford, S. P. Sudarsana Devi, A.
Vahedipour, M. Darvas and N. S. Bamford (2019). "Dopamine Deficiency Reduces Striatal
Cholinergic Interneuron Function in Models of Parkinson’s Disease." Neuron 103(6): 10561072.e1056.
Morales, M. and E. B. Margolis (2017). "Ventral tegmental area: cellular heterogeneity,
connectivity and behaviour." Nature Reviews Neuroscience 18: 73.
Moss, J. and J. P. Bolam (2008). "A dopaminergic axon lattice in the striatum and its relationship
with cortical and thalamic terminals." J Neurosci 28(44): 11221-11230.

131

Muzumdar, M. D., B. Tasic, K. Miyamichi, L. Li and L. Luo (2007). "A global doublefluorescent Cre reporter mouse." genesis 45(9): 593-605.
Noyce, A. J., J. P. Bestwick, L. Silveira-Moriyama, C. H. Hawkes, G. Giovannoni, A. J. Lees
and A. Schrag (2012). "Meta-analysis of early nonmotor features and risk factors for Parkinson
disease." Annals of Neurology 72(6): 893-901.
O'Hare, J. K., H. Li, N. Kim, E. Gaidis, K. Ade, J. Beck, H. Yin and N. Calakos (2017). "Striatal
fast-spiking interneurons selectively modulate circuit output and are required for habitual
behavior." eLife 6: e26231.
Oorschot, D. E. (1996). "Total number of neurons in the neostriatal, pallidal, subthalamic, and
substantia nigral nuclei of the rat basal ganglia: A stereological study using the cavalieri and
optical disector methods." Journal of Comparative Neurology 366(4): 580-599.
Oswald, M. J., J. M. Schulz, W. Kelsch, D. E. Oorschot and J. N. Reynolds (2015). "Potentiation
of NMDA receptor-mediated transmission in striatal cholinergic interneurons." Front Cell
Neurosci 9: 116.
Owen, S. F., J. D. Berke and A. C. Kreitzer (2018). "Fast-Spiking Interneurons Supply
Feedforward Control of Bursting, Calcium, and Plasticity for Efficient Learning." Cell 172(4):
683-695.e615.
Pahwa, R., C. M. Tanner, R. A. Hauser, S. H. Isaacson, P. A. Nausieda, D. D. Truong, P.
Agarwal, K. L. Hull, K. E. Lyons, R. Johnson and M. J. Stempien (2017). "ADS-5102
(Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson
Disease (EASE LID Study): A Randomized Clinical Trial." JAMA neurology 74(8): 941-949.
Pahwa, R., C. M. Tanner, R. A. Hauser, K. Sethi, S. Isaacson, D. Truong, L. Struck, A. E. Ruby,
N. L. McClure, G. T. Went and M. J. Stempien (2015). "Amantadine extended release for
levodopa-induced dyskinesia in Parkinson's disease (EASED Study)." Movement disorders :
official journal of the Movement Disorder Society 30(6): 788-795.
Parent, A. and L.-N. Hazrati (1995). "Functional anatomy of the basal ganglia. I. The corticobasal ganglia-thalamo-cortical loop." Brain Research Reviews 20(1): 91-127.
Pavese, N., M. Rivero-Bosch, S. J. Lewis, A. L. Whone and D. J. Brooks (2011). "Progression of
monoaminergic dysfunction in Parkinson's disease: A longitudinal 18F-dopa PET study."
NeuroImage 56(3): 1463-1468.
132

Pavón, N., A. B. Martín, A. Mendialdua and R. Moratalla (2006). "ERK Phosphorylation and
FosB Expression Are Associated with L-DOPA-Induced Dyskinesia in Hemiparkinsonian
Mice." Biological Psychiatry 59(1): 64-74.
Perestelo-Pérez, L., A. Rivero-Santana, J. Pérez-Ramos, P. Serrano-Pérez, J. Panetta and P.
Hilarion (2014). "Deep brain stimulation in Parkinson’s disease: meta-analysis of randomized
controlled trials." Journal of Neurology 261(11): 2051-2060.
Perez, X. A., T. Bordia and M. Quik (2018). "The striatal cholinergic system in L-dopa-induced
dyskinesias." J Neural Transm (Vienna) 125(8): 1251-1262.
Perrimon, N. (1995). "Hedgehog and beyond." Cell 80(4): 517-520.
Perrin, E. and L. Venance (2019). "Bridging the gap between striatal plasticity and learning."
Current Opinion in Neurobiology 54: 104-112.
Phelps, P. E., C. R. Houser and J. E. Vaughn (1985). "Immunocytochemical localization of
choline acetyltransferase within the rat neostriatum: A correlated light and electron microscopic
study of cholinergic neurons and synapses." Journal of Comparative Neurology 238(3): 286-307.
Poulin, J.-F., J. Zou, J. Drouin-Ouellet, K.-Youn A. Kim, F. Cicchetti and R. B. Awatramani
(2014). "Defining Midbrain Dopaminergic Neuron Diversity by Single-Cell Gene Expression
Profiling." Cell Reports 9(3): 930-943.
Quik, M., J. T. Boyd, T. Bordia and X. Perez (2018). "Potential Therapeutic Application for
Nicotinic Receptor Drugs in Movement Disorders." Nicotine & Tobacco Research 21(3): 357369.
Quik, M., C. Campos and S. R. Grady (2013). "Multiple CNS nicotinic receptors mediate Ldopa-induced dyskinesias; studies with parkinsonian nicotinic receptor knockout mice."
Biochemical pharmacology 86(8): 1153-1162.
Quik, M., A. Mallela, M. Chin, J. M. McIntosh, X. A. Perez and T. Bordia (2013). "Nicotinemediated improvement in L-dopa-induced dyskinesias in MPTP-lesioned monkeys is dependent
on dopamine nerve terminal function." Neurobiology of disease 50: 30-41.
Quik, M., A. Mallela, J. Ly and D. Zhang (2013). "Nicotine reduces established L-dopa-induced
dyskinesias in a monkey model of Parkinson’s disease." Movement disorders : official journal of
the Movement Disorder Society 28(10): 1398-1406.
133

Quik, M., M. O’Neill and X. A. Perez (2007). "Nicotine neuroprotection against nigrostriatal
damage: importance of the animal model." Trends in Pharmacological Sciences 28(5): 229-235.
Quik, M. and S. Wonnacott (2011). "α6β2* and α4β2* Nicotinic Acetylcholine Receptors As
Drug Targets for Parkinson's Disease." Pharmacological Reviews 63(4): 938-966.
Quinn, N., C. D. Marsden and J. D. Parkes (1982). "Complicated response fluctuations in
Parkinson's Diease: Response to intravenous infusion of Levodopa." The Lancet 320(8295): 412415.
Rascol, O., S. Perez-Lloret and J. J. Ferreira (2015). "New treatments for levodopa-induced
motor complications." Movement Disorders 30(11): 1451-1460.
Raz, A., A. Feingold, V. Zelanskaya, E. Vaadia and H. Bergman (1996). "Neuronal
synchronization of tonically active neurons in the striatum of normal and parkinsonian primates."
Journal of Neurophysiology 76(3): 2083.
Redgrave, P., T. J. Prescott and K. Gurney (1999). "The basal ganglia: a vertebrate solution to
the selection problem?" Neuroscience 89(4): 1009-1023.
Riobo, N. A., B. Saucy, C. Dilizio and D. R. Manning (2006). "Activation of heterotrimeric G
proteins by Smoothened." Proc Natl Acad Sci U S A 103(33): 12607-12612.
Romorini, S., G. Piccoli, M. Jiang, P. Grossano, N. Tonna, M. Passafaro, M. Zhang and C. Sala
(2004). "A Functional Role of Postsynaptic Density-95-Guanylate Kinase-Associated Protein
Complex in Regulating Shank Assembly and Stability to Synapses." The Journal of
Neuroscience 24(42): 9391.
Rossi, J., N. Balthasar, D. Olson, M. Scott, E. Berglund, C. E. Lee, M. J. Choi, D. Lauzon, B. B.
Lowell and J. K. Elmquist (2011). "Melanocortin-4 Receptors Expressed by Cholinergic
Neurons Regulate Energy Balance and Glucose Homeostasis." Cell Metabolism 13(2): 195-204.
Ruiz i Altaba, A., V. Palma and N. Dahmane (2002). "Hedgehog–GLI signaling and the growth
of the brain." Nature Reviews Neuroscience 3(1): 24-33.
Sano, H., S. Chiken, T. Hikida, K. Kobayashi and A. Nambu (2013). "Signals through the
Striatopallidal Indirect Pathway Stop Movements by Phasic Excitation in the Substantia Nigra."
The Journal of Neuroscience 33(17): 7583.

134

Santini, E., C. Alcacer, S. Cacciatore, M. Heiman, D. Hervé, P. Greengard, J.-A. Girault, E.
Valjent and G. Fisone (2009). "l-DOPA activates ERK signaling and phosphorylates histone H3
in the striatonigral medium spiny neurons of hemiparkinsonian mice." Journal of
Neurochemistry 108(3): 621-633.
Santini, E., E. Valjent, A. Usiello, M. Carta, A. Borgkvist, J.-A. Girault, D. Hervé, P. Greengard
and G. Fisone (2007). "Critical Involvement of cAMP/DARPP-32 and Extracellular SignalRegulated Protein Kinase Signaling in L-DOPA-Induced Dyskinesia." The Journal of
Neuroscience 27(26): 6995.
Schultz, W. (1992). "Activity of dopamine neurons in the behaving primate." Seminars in
Neuroscience 4(2): 129-138.
Schultz, W. (2006). "Behavioral Theories and the Neurophysiology of Reward." Annual Review
of Psychology 57(1): 87-115.
Schultz, W. (2013). "Updating dopamine reward signals." Current Opinion in Neurobiology
23(2): 229-238.
Schultz, W., P. Dayan and P. R. Montague (1997). "A Neural Substrate of Prediction and
Reward." Science 275(5306): 1593.
Schuster, S., A. Nadjar, J. T. Guo, Q. Li, C. Ittrich, B. Hengerer and E. Bezard (2008). "The 3Hydroxy-3-Methylglutaryl-CoA Reductase Inhibitor Lovastatin Reduces Severity of L-DOPAInduced Abnormal Involuntary Movements in Experimental Parkinson's Disease." The Journal of
Neuroscience 28(17): 4311.
Searles Nielsen, S., L. G. Gallagher, J. I. Lundin, W. T. Longstreth Jr., T. Smith-Weller, G. M.
Franklin, P. D. Swanson and H. Checkoway (2012). "Environmental tobacco smoke and
Parkinson's disease." Movement Disorders 27(2): 293-297.
Sebastianutto, I., N. Maslava, C. R. Hopkins and M. A. Cenci (2016). "Validation of an
improved scale for rating l-DOPA-induced dyskinesia in the mouse and effects of specific
dopamine receptor antagonists." Neurobiology of Disease 96: 156-170.
Shen, W., J. L. Plotkin, V. Francardo, W. K. Ko, Z. Xie, Q. Li, T. Fieblinger, J. Wess, R. R.
Neubig, C. W. Lindsley, P. J. Conn, P. Greengard, E. Bezard, M. A. Cenci and D. J. Surmeier
(2015). "M4 Muscarinic Receptor Signaling Ameliorates Striatal Plasticity Deficits in Models of
L-DOPA-Induced Dyskinesia." Neuron 88(4): 762-773.
135

Shen, W., J. L. Plotkin, V. Francardo, W. K. Ko, Z. Xie, Q. Li, T. Fieblinger, J. Wess, R. R.
Neubig, C. W. Lindsley, P. J. Conn, P. Greengard, E. Bezard, M. A. Cenci and D. J. Surmeier
(2016). "M4 Muscarinic Receptor Signaling Ameliorates Striatal Plasticity Deficits in Models of
L-DOPA-Induced Dyskinesia." Neuron 90(5): 1139.
Shen, W., J. L. Plotkin, V. Francardo, W. K. D. Ko, Z. Xie, Q. Li, T. Fieblinger, J. Wess, R. R.
Neubig, C. W. Lindsley, P. J. Conn, P. Greengard, E. Bezard, M. A. Cenci and D. J. Surmeier
(2015). "M4 muscarinic receptor signaling ameliorates striatal plasticity deficits in models of LDOPA-induced dyskinesia." Neuron 88(4): 762-773.
Silberberg, G. and J. P. Bolam (2015). "Local and afferent synaptic pathways in the striatal
microcircuitry." Current Opinion in Neurobiology 33: 182-187.
Smith, J. C. (1994). "Hedgehog, the floor plate, and the zone of polarizing activity." Cell 76(2):
193-196.
Song, S., K. D. Miller and L. F. Abbott (2000). "Competitive Hebbian learning through spiketiming-dependent synaptic plasticity." Nature Neuroscience 3(9): 919-926.
Sparta, D. R., A. M. Stamatakis, J. L. Phillips, N. Hovelsø, R. van Zessen and G. D. Stuber
(2012). "Construction of implantable optical fibers for long-term optogenetic manipulation of
neural circuits." Nature Protocols 7(1): 12-23.
Stoof, J. C., T. De Boer, P. Sminia and A. H. Mulder (1982). "Stimulation of D2-dopamine
receptors in rat neostriatum inhibits the release of acetylcholine and dopamine but does not affect
the release of γ-aminobutyric acid, glutamate or serotonin." European Journal of Pharmacology
84(3): 211-214.
Straub, C., N. X. Tritsch, N. A. Hagan, C. Gu and B. L. Sabatini (2014). "Multiphasic
modulation of cholinergic interneurons by nigrostriatal afferents." The Journal of neuroscience :
the official journal of the Society for Neuroscience 34(25): 8557-8569.
Su, Y., Y. Yuan, S. Feng, S. Ma and Y. Wang (2017). "High frequency stimulation induces sonic
hedgehog release from hippocampal neurons." Sci Rep 7: 43865.
Surmeier, D. J., S. M. Graves and W. Shen (2014). "Dopaminergic modulation of striatal
networks in health and Parkinson's disease." Current Opinion in Neurobiology 29: 109-117.

136

Surmeier, D. J. and A. M. Graybiel (2012). "A feud that wasn’t: acetylcholine evokes dopamine
release in the striatum." Neuron 75(1): 1-3.
Tanabe, Y., H. Roelink and T. M. Jessell (1995). "Induction of motor neurons by Sonic
hedgehog is independent of floor plate differentiation." Current Biology 5(6): 651-658.
Tanimura, A., T. Pancani, S. A. O. Lim, C. Tubert, A. E. Melendez, W. Shen and D. J. Surmeier
(2018). "Striatal cholinergic interneurons and Parkinson's disease." European Journal of
Neuroscience 47(10): 1148-1158.
Tanner, C. M., S. M. Goldman, D. A. Aston, R. Ottman, J. Ellenberg, R. Mayeux and J. W.
Langston (2002). "Smoking and Parkinson’s disease in twins." Neurology 58(4): 581-588.
Tepper, J. M., F. Tecuapetla, T. Koós and O. Ibáñez-Sandoval (2010). "Heterogeneity and
diversity of striatal GABAergic interneurons." Frontiers in neuroanatomy 4: 150-150.
Threlfell, S., M. A. Clements, T. Khodai, I. S. Pienaar, R. Exley, J. Wess and S. J. Cragg (2010).
"Striatal Muscarinic Receptors Promote Activity Dependence of Dopamine Transmission via
Distinct Receptor Subtypes on Cholinergic Interneurons in Ventral versus Dorsal Striatum." The
Journal of Neuroscience 30(9): 3398-3408.
Threlfell, S., T. Lalic, N. J. Platt, K. A. Jennings, K. Deisseroth and S. J. Cragg (2012). "Striatal
dopamine release is triggered by synchronized activity in cholinergic interneurons." Neuron
75(1): 58-64.
Tozzi, A., A. de Iure, M. Di Filippo, M. Tantucci, C. Costa, F. Borsini, V. Ghiglieri, C. Giampà,
F. R. Fusco, B. Picconi and P. Calabresi (2011). "The Distinct Role of Medium Spiny Neurons
and Cholinergic Interneurons in the D&lt;sub&gt;2&lt;/sub&gt;/A&lt;sub&gt;2A&lt;/sub&gt;
Receptor Interaction in the Striatum: Implications for Parkinson&#039;s Disease." The Journal
of Neuroscience 31(5): 1850.
Trudeau, L.-E., T. S. Hnasko, Å. Wallén-Mackenzie, M. Morales, S. Rayport and D. Sulzer
(2014). Chapter 6 - The multilingual nature of dopamine neurons. Progress in brain research. M.
Diana, G. Di Chiara and P. Spano, Elsevier. 211: 141-164.
Tsuboi, K. and C. W. Shults (2002). "Intrastriatal Injection of Sonic Hedgehog Reduces
Behavioral Impairment in a Rat Model of Parkinson's Disease." Experimental Neurology 173(1):
95-104.

137

Ulusoy, A., G. Sahin and D. Kirik (2010). "Presynaptic dopaminergic compartment determines
the susceptibility to L-DOPA–induced dyskinesia in rats." Proceedings of the National Academy
of Sciences 107(29): 13159-13164.
Ungerstedt, U. (1971). "Postsynaptic Supersensitivity after 6-Hydroxy-dopamine Induced
Degeneration of the Nigro-striatal Dopamine System." Acta Physiologica Scandinavica
82(S367): 69-93.
Wallen, A. and T. Perlmann (2003). "Transcriptional Control of Dopamine Neuron
Development." Annals of the New York Academy of Sciences 991(1): 48-60.
Wang, M. Z., P. Jin, D. A. Bumcrot, V. Marigo, A. P. McMahon, E. A. Wang, T. Woolf and K.
Pang (1995). "Induction of dopaminergic neuron phenotype in the midbrain by Sonic hedgehog
protein." Nature Medicine 1(11): 1184-1188.
Wang, W., M. Darvas, G. P. Storey, I. J. Bamford, J. T. Gibbs, R. D. Palmiter and N. S. Bamford
(2013). "Acetylcholine Encodes Long-Lasting Presynaptic Plasticity at Glutamatergic Synapses
in the Dorsal Striatum after Repeated Amphetamine Exposure." The Journal of Neuroscience
33(25): 10405.
Wickens, J. R., J. N. J. Reynolds and B. I. Hyland (2003). "Neural mechanisms of reward-related
motor learning." Current Opinion in Neurobiology 13(6): 685-690.
Wilkinson, L., Z. Khan and M. Jahanshahi (2009). "The role of the basal ganglia and its cortical
connections in sequence learning: Evidence from implicit and explicit sequence learning in
Parkinson's disease." Neuropsychologia 47(12): 2564-2573.
Wilson, C. J., H. T. Chang and S. T. Kitai (1990). "Firing patterns and synaptic potentials of
identified giant aspiny interneurons in the rat neostriatum." The Journal of Neuroscience 10(2):
508.
Wirdefeldt, K., H.-O. Adami, P. Cole, D. Trichopoulos and J. Mandel (2011). "Epidemiology
and etiology of Parkinson’s disease: a review of the evidence." European Journal of
Epidemiology 26(1): 1.
Won, L., Y. Ding, P. Singh and U. J. Kang (2014). "Striatal Cholinergic Cell Ablation
Attenuates l-DOPA Induced Dyskinesia in Parkinsonian Mice." The Journal of Neuroscience
34(8): 3090-3094.

138

Xie, J., M. Murone, S.-M. Luoh, A. Ryan, Q. Gu, C. Zhang, J. M. Bonifas, C.-W. Lam, M.
Hynes, A. Goddard, A. Rosenthal, E. H. E. Jr and F. J. de Sauvage (1998). "Activating
Smoothened mutations in sporadic basal-cell carcinoma." Nature 391(6662): 90-92.
Yagishita, S., A. Hayashi-Takagi, G. C. R. Ellis-Davies, H. Urakubo, S. Ishii and H. Kasai
(2014). "A critical time window for dopamine actions on the structural plasticity of dendritic
spines." Science 345(6204): 1616.
Yan, Z., W. J. Song and J. Surmeier (1997). "D2 dopamine receptors reduce N-type Ca2+
currents in rat neostriatal cholinergic interneurons through a membrane-delimited, proteinkinase-C-insensitive pathway." J Neurophysiol 77(2): 1003-1015.
Yan, Z. and D. J. Surmeier (1997). "D5 dopamine receptors enhance Zn2+-sensitive GABA(A)
currents in striatal cholinergic interneurons through a PKA/PP1 cascade." Neuron 19(5): 11151126.
Yao, P. J., R. S. Petralia and M. P. Mattson (2016). "Sonic Hedgehog Signaling and
Hippocampal Neuroplasticity." Trends in Neurosciences 39(12): 840-850.
Yin, H. H., B. J. Knowlton and B. W. Balleine (2004). "Lesions of dorsolateral striatum preserve
outcome expectancy but disrupt habit formation in instrumental learning." European Journal of
Neuroscience 19(1): 181-189.
Yin, H. H., S. P. Mulcare, M. R. F. Hilário, E. Clouse, T. Holloway, M. I. Davis, A. C. Hansson,
D. M. Lovinger and R. M. Costa (2009). "Dynamic reorganization of striatal circuits during the
acquisition and consolidation of a skill." Nature Neuroscience 12(3): 333-341.
Yin, H. H., S. B. Ostlund, B. J. Knowlton and B. W. Balleine (2005). "The role of the
dorsomedial striatum in instrumental conditioning." European Journal of Neuroscience 22(2):
513-523.
Zhai, S., A. Tanimura, S. M. Graves, W. Shen and D. J. Surmeier (2018). "Striatal synapses,
circuits, and Parkinson's disease." Current Opinion in Neurobiology 48(Supplement C): 9-16.
Zhang, D., A. Mallela, D. Sohn, F. I. Carroll, M. Bencherif, S. Letchworth and M. Quik (2013).
"Nicotinic Receptor Agonists Reduce l-DOPA–Induced Dyskinesias in a Monkey Model of
Parkinson's Disease." The Journal of Pharmacology and Experimental Therapeutics 347(1): 225234.

139

Zhang, W. and H. T. Liu (2002). "MAPK signal pathways in the regulation of cell proliferation
in mammalian cells." Cell Research 12(1): 9-18.
Zhang, Y., W. Dong, S. Guo, S. Zhao, S. He, L. Zhang, Y. Tang and H. Wang (2014).
"Lentivirus-mediated delivery of sonic hedgehog into the striatum stimulates neuroregeneration
in a rat model of Parkinson disease." Neurological Sciences 35(12): 1931-1940.
Zhang, Y., G. E. Meredith, N. Mendoza-Elias, D. J. Rademacher, K. Y. Tseng and K. SteeceCollier (2013). "Aberrant Restoration of Spines and their Synapses in l-DOPA-Induced
Dyskinesia: Involvement of Corticostriatal but Not Thalamostriatal Synapses." The Journal of
Neuroscience 33(28): 11655-11667.
Zhang, Y. F. and S. J. Cragg (2017). "Pauses in Striatal Cholinergic Interneurons: What is
Revealed by Their Common Themes and Variations?" Front Syst Neurosci 11: 80.
Zhang, Y. F., J. N. J. Reynolds and S. J. Cragg (2018). "Pauses in Cholinergic Interneuron
Activity Are Driven by Excitatory Input and Delayed Rectification, with Dopamine
Modulation." Neuron 98(5): 918-925 e913.
Zhou, F.-M., C. J. Wilson and J. A. Dani (2002). "Cholinergic interneuron characteristics and
nicotinic properties in the striatum." Journal of Neurobiology 53(4): 590-605.
Zhuang, X., P. Mazzoni and U. J. Kang (2013). "The role of neuroplasticity in dopaminergic
therapy for Parkinson disease." Nature Reviews Neurology 9(5): 248-256.
Zoli, M., F. Pistillo and C. Gotti (2015). "Diversity of native nicotinic receptor subtypes in
mammalian brain." Neuropharmacology 96: 302-311.

140

